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Introduction  
 
General principles of radionuclide therapy  
 
Radionuclide therapy may be defined as internal radiotherapy by means of 
unsealed sources of ionizing radiation. It typically targets particular organs or 
cells. The targeting feature of radionuclide therapy is achieved by local or 
locoregional administration of the radionuclide, by the intrinsic targeting 
properties of some radionuclides or by conjugating the radionuclide to a specific 
tracer. The radionuclides used in routine practice for therapeutic applications 
are beta-particle emitters. These β-particles consist of high energy electrons 
exerting ionizing effects in the targeted tissue. Ionizing radiation damages the 
DNA of the targeted cells and thus lethal damage may possibly be induced on a 
cellular level. 
The range of the electrons depends on the energy of the emitted β-particles of 
the applied radionuclide and for high energy β-emitters this range surpasses 
multiple cell diameters. Besides β-emissions, some radionuclides also emit 
photons or gamma (γ)-rays which are detectable by means of a γ–camera and 
hence allow for imaging the distribution of the radionuclide in the patient. 
However, photons are penetrating ionizing radiation, and as a consequence, 
treatment may entail considerable radiation protection concerns for the 
patient’s environment. 
The physical half-life determines the characteristic rate at which decay occurs 
for a particular radionuclide. The physical life of radionuclides used for internal 
radiotherapy varies widely but compared to external beam radiotherapy, 
radionuclide therapies are considered as low dose rate irradiation because the 
rate at which the radionuclides deposit their energy to the targeted cells is 
prolonged over time whereas external beam irradiation delivers a high dose in a 
very short time interval, typically a few Gy in a few minutes.   
 
Besides its merits in the management of benign disorders, such as thyroid 
disease and chronic joint inflammation, radionuclide therapy has shown its 
usefulness in oncology, for instance in the management of thyroid cancer, 
metastatic neuro-endocrine tumors, bone pain palliation and locoregional 
treatment for primary liver cancer or liver metastasis. More recently, promising 
progress was established in the field of hematology. However, radionuclide 
therapy remains a relatively unknown treatment modality for many colleagues, 
even those working in the fields of oncology. Despite the available literature 
reporting the clinical benefits of radiolabeled diphosphonates, meta-
iodobenzylguanidine, somatostatin analogues and antibodies, the application of 
these radiopharmaceuticals remains limited to few expert centers in well 
developed countries. Radioprotection concerns, limited availability and high 
costs of some radionuclides as well as compounds, such as monoclonal 
antibodies and peptides, have been drawbacks for widespread implementation 
of radionuclide based treatment strategies.  
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 Rhenium-188 for radionuclide therapy  
 
Similar to the introduction of the in-house use of the Molybdenum/Technetium 
(99Mo/99mTc)-generator in a radiopharmacy for the radiolabeling of a wide 
variety of diagnostic agents, generator derived therapeutic isotopes would 
contribute to the further development and implementation of radionuclide 
therapies. High activities of Rhenium-188 (188Re) are available from the elution 
on an on-site installable Tungsten/Rhenium (188W/188Re)-generator.  
 
188Re is of widespread interest for therapeutic applications because of its high 
energy β-emission (maximum energy 2.12 MeV). Its γ-emission of 155 keV with 
an abundance of 15% and relatively short half-life of 16.9 hours, limit 
radioprotection problems and represent a firm advantage in comparison with 
the nowadays widespread used Iodine-131 (131I) for various therapeutic 
radiopharmaceuticals (Table 1). The γ-rays emitted by 188Re allow imaging of 
the distribution of the radionuclide in the patient. If the patient is scanned at 
several timepoints, the absorbed doses to the organs may be estimated 
following quantitative analysis.  
 
In contrast to 131I the use of 188Re does not pose significant radiation protection 
problems since the energy and abundance of the γ-emissions is lower and the 
physical half-life is shorter. Hence the use of 188Re is more convenient than 131I 
for routine clinical use due to the relative ease of waste management, the 
decreased radiation burden for hospital staff and patient’s relatives and the 
shorter duration that a patient must remain in a dedicated radionuclide therapy 
suite. In addition, the flexibility of the treatment planning is improved due to 
the shorter hospitalization and on-site production of the radiopharmaceutical. 
 
TABLE 1: Physical characteristics of Iodine-131 and Rhenium-188. 
Characteristic Iodine-131 Rhenium-188 
Eγ (abundance) 364 keV (81.7%) 155 keV (15.0%) 
Eβ max (abundance) 606 keV (89.9%) 2120 keV (71.1%),  
1960 keV (25.6%) 
physical half-life 8.01 days 16.9 hours 
production fission product generator 
 
188Re is obtained on demand as carrier-free sodium perrhenate by saline elution 
of the 188W/188Re-generator system. The 188W-parent is produced by double 
neutron capture of enriched 186W-oxide targets by irradiation in a nuclear 
reactor. Following various dissolving and acidification steps, the 188W-parent is 
subsequently adsorbed on an alumia column.  188W has a physical half-life of 69 
days. Generators designed for clinical use are typically loaded with 37-55.5 GBq 
188W and provide about 18.5 GBq 188Re-perrhenate on a daily basis for at least 
8 weeks. The 188W/188Re-generator system operates similarly to the 99Mo/99mTc-
generator (1). 
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Hepatocellular carcinoma 
  
Hepatocellular carcinoma (HCC) is a malignant epithelial tumor arising from 
parenchymatous liver cells (2). It is the most prevalent primary liver cancer. In 
terms of numbers of cases, HCC is the sixth most common cancer worldwide 
with 626.000 new cases estimated for the year 2002. Because of the very poor 
prognosis, the number of deaths (598.000) is almost equal to the number of 
new cases per year. It is therefore the third most common cause of death from 
cancer. The vast majority of new cases occur in developing countries (82%). 
The areas of high incidence are sub-Saharan Africa, eastern and southeastern 
Asia, and Melanesia. The incidence is low in Latin America, southcentral Asia 
and in developed areas. Only in southern Europe is there any substantial risk. 
An overview of incidence rates of HCC in various regions of the world is given in 
Table 2. The overall sex ratio (male:female) is around 2.4 (2).  
 
TABLE 2: Age-standardized incidence rates for primary liver cancer. Data shown 
per 100.000 by sex. Table adapted from Parkin DM et al. CA Cancer J Clin 
2005;55:74-108. 
 
 Males Females 
China 37.9 14.2 
Middle Africa 27.8 13.4 
Japan 23.1 7.6 
Southern Europe 11.6 4.0 
Western Europe  6.2 1.7 
Eastern Europe 5.3 2.4 
Northern Europe 3.4 1.7 
Northern America 5.3 1.9 
 
The major risk factor for HCC is cirrhosis. All types of cirrhosis predispose to 
HCC, but the incidence is particularly high in persistent infection with hepatitis B 
(HBV) and hepatitis C (HCV), and in alcoholic liver disease. In Asia and Africa 
chronic infection by the hepatitis B virus is the main risk factor for development 
of HCC, whereas the hepatitis C virus and alcohol are relatively more important 
in the Western world and Japan (4). Although the overall incidence of HCC in 
the West is low compared to South East Asia, Sub-Saharan Africa and Japan, its 
incidence is rising (5,6). 
 
The awareness of the association between cirrhosis and HCC has resulted in the 
widespread use of surveillance schemes including ultrasound and serum alpha-
fetoprotein (AFP) measurements (7). The tumor marker AFP is a protein 
normally made by the immature liver cells in the fetus. In adults suffering 
chronic hepatitis or cirrhosis moderate levels of AFP can be seen. Blood levels 
over 400 ng/ml of AFP are suggestive for HCC. Additional, size-dependent 
examinations (8,9) are performed when confronted with a nodular lesion 
emerging in a cirrhotic liver in order to assess the presence of HCC and its 
intrahepatic spread. In nodules smaller than 2 cm, fine-needle biopsy may play 
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 a role in establishing the diagnosis of HCC. However, since high false-negative 
rates as well as tumoral seeding following fine needle biopsies have been 
reported, close follow-up by means of repeated imaging is often recommended 
whenever a potentially curative lesion is present (10,11). In nodules larger than 
2 cm, HCC diagnosis is established by the concomitant finding of two imaging 
techniques, showing a nodule larger than 2 cm with arterial 
hypervascularization, or by one positive imaging technique, showing 
hypervascularization associated with AFP concentration higher than 400 ng/ml 
(11). The best imaging techniques are spiral computed tomography (CT-scan) 
and magnetic resonance imaging (MRI) with contrast enhancement, which have 
an accuracy exceeding 80% (9). For assessment of the extent of the liver 
involvement by HCC, the sensitivity and specificity of both MRI and CT is 
markedly lower (8,9). Extrahepatic spread is ruled out by spiral CT-scan of the 
chest and by bone scintigraphy (11) . 
 
The selection of an appropriate treatment strategy for patients with HCC 
depends on careful tumor staging and assessment of the underlying liver 
disease (12). All patients without vascular invasion or extrahepatic disease 
should be evaluated for the potentially curative therapeutic options of partial 
hepatectomy or orthotopic liver transplantation. According to the so called Milan 
criteria, orthotopic liver transplantation should be considered if there is a 
solitary lesion smaller than 5 cm in diameter or fewer than 3 lesions smaller 
than 3 cm (13). Five-year survival following partial hepatectomy is on average 
25-45% and when considering highly-selected patient groups as high as 70% 
(12). Local ablative therapies such as Percutaneous Ethanol Injection (PEI), 
Radio Frequency Ablation (RFA), and Trans Arterial Chemo Embolization (TACE) 
offer palliation for patients for whom surgical approaches are contraindicated 
(11). PEI and RFA are minimally invasive and can be used on an outpatient 
basis, usually for tumor nodules smaller than 3 cm for PEI and up to 5 cm for 
RFA (14). When these therapies are used for small tumors, survival rates 
obtained from prospective cohort studies and retrospective analysis, show 
similar results as those achieved by partial hepatectomy (16-17). The precise 
role of TACE in a palliative setting as well in patients awaiting liver 
transplantation is still under debate but encouraging long term results have 
been obtained in randomized controlled trials (18). Whilst PEI, RFA and TACE 
are useful in selected patients, they are not suitable for many HCC patients with 
advanced disease. For patients presenting with involvement of regional lymph-
nodes, extra-hepatic metastases or involvement of the main portal vein, 
systemic treatment is an option (19-21). However, no strong evidence is 
provided that any systemic chemotherapy, hormonal therapy, or 
immunotherapy regimen studied to date benefits survival of HCC patients in this 
setting (22-24). External beam irradiation resulted in palliation of symptoms in 
more than half of the patients in some series but injury to the surrounding 
tissue including liver parenchyma and duodenum is risked (25-29).  
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 Radiolabeled Lipiodol for treatment of hepatocellular carcinoma  
 
Lipiodol consists of a mixture of mono-, di- and tri-iodinated ethyl esters of 
mainly linoleic, oleic and palmitic acid. It is manufactured by ethyl trans-
esterification of poppyseed oil (Laboratoire Guerbet, France) and contains 37-39 
% of iodine by weight. It has been used as a contrast material for the detection 
of HCC. When injected into the hepatic artery the oil is retained by HCCs for 
several weeks to over a year, but it is cleared from the normal liver parenchyma 
within 7 days (30,31). Several mechanisms explaining this selective retention 
have been postulated and hypotheses fall into three major categories. The first 
hypothesis mainly suggests that the  Lipiodol is retained in the blood vessels. 
This could be explained by the embolization effects of the Lipiodol droplets 
and/or the presence of abnormal tumor vessels, possibly with altered 
electrostatic charge on the endothelial surface facilitating lipid adsorption. A 
second hypothesis proposes the lodging of Lipiodol in the extra-cellular space. 
This could be explained by the presence of ‘leaky’ tumor vessels and a lack of 
macrophages or lymphatics in the tumor. A third hypothesis suggests the 
incorporation of Lipiodol in the tumoral cells. In vitro experiments with a human 
HCC cell line have shown rapid active uptake of Lipidol by HCC cells through 
pinocytosis (31). Whilst Lipiodol alone does not appear to have any significant 
anti-cancer effect, adding a radionuclide to Lipiodol has proven to be effective 
against HCC in vitro (32).  
 
131I-Lipiodol for palliative treatment of HCC 
 
Sixteen original papers have been published on the palliative use of 131I-Lipiodol 
in HCC patients. These papers reported on results obtained in 1 to 73 HCC 
patients treated with 131I-Lipiodol receiving a wide range of radioactivity (74 to 
6220 MBq) in single or multiple administrations. Using either a drop in AFP 
levels or a reduction in tumor size as response criterion, reported response 
rates varied from 17 to 92% (33-35). Palliative treatment with 131I-Lipiodol 
(n=65 patients) was compared to TACE (n=64 patients) in a prospective, 
randomized trial and survival after 6 months, 1, 2, 3 and 4 years were 
respectively 69%, 38%, 22%, 14% and 10% for the 131I-Lipiodol arm versus 
66%, 42%, 22%, 3% and 0% in the TACE-arm. Importantly, however, 
treatment tolerance was much better in the 131I-Lipiodol arm with only 3 
reported serious side-effects versus 29 in the group undergoing TACE (36). 
These results are in line with an earlier report by Bhattacharya et al. (37).  
 
While no survival benefit could be demonstrated for the whole group of 
palliative HCC patients, when focusing on HCC patients presenting with portal 
vein thrombosis a significant benefit in survival following 131I-Lipiodol treatment 
versus tamoxifen, 5-fluorouracil or anti-inflammatory medication was 
documented in a prospective randomized study by Raoul and coworkers (38).  
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 131I-Lipidol for adjuvant treatment of HCC 
 
Recurrence rates following partial liver resection are high and this is explained 
by the often multifocal nature of HCC: the remaining liver parenchyma may 
harbor metastases that are undetected by currently available imaging 
techniques and if cirrhotic, it is a seed-bed for development of de novo HCC. In 
a study by Lau et al. patients undergoing curative resection for HCC and 
recovering within 6 weeks, were randomly assigned one 1850 MBq 
administration of 131I-Lipiodol (n = 21) or no further treatment (n= 22). During 
a median follow-up of 35 months, there were significantly less recurrences 
among the patients in the adjuvant treatment (28.5%), compared with the 
control group (59%). Median disease-free survival in the treatment and control 
groups was 57 and 14 months (39). The statistical methodology used for data 
analysis by these authors, however, was criticized and a longer follow-up 
advocated by Pocock et al., also stressing the need for additional prospective 
studies (39). Non-randomized or retrospective studies by Partensky et al. and 
Raoul and coworkers tend to support the findings by Lau et al. (39,41-43). 
 
131I-Lipiodol in a neoadjuvant setting 
 
In a preliminary, prospective study by Brans et al., 10 consecutive HCC patients 
were treated by intra-arterial injection of 131I-Lipiodol into the hepatic artery 
followed by liver transplantation within 1-9 months. In 5 of the patients studied, 
an objective response was seen whereas all 10 patients were subsequently 
transplanted successfully (44). Raoul et al. studied 14 patients treated with two 
sessions of 131I-Lipiodol prior to liver transplantation and 1- and 3 year 
recurrence free survival rates of 91 and 83% were documented (42). Larger 
studies are mandatory and the long term results should be based on an 
intention to treat analysis and the true role of neoadjuvant treatment may be 
preventing drop-out in those patients who wait for long periods until 
transplantation (45).  
  
188Re labeled Lipiodol  
 
Encouraging results have been obtained using 131I-Lipiodol, but the use of the 
radionuclide 131I has hampered its routine clinical implementation. The relatively 
long physical half-life of 131I and the high energy γ-ray necessitate prolonged 
hospitalization for radioprotection purposes. Although 131I-Lipiodol therapy is 
generally well tolerated, a dose escalation study was not conducted so far as 
the administration of activities exceeding 2.22 GBq is restricted by the above 
mentioned practical issues. 188Re has favorable characteristics for radionuclide 
therapy and considering the limited success of 131I-Lipiodol for treatment of 
relatively large tumors, the switch towards a radionuclide with a higher energy 
of the beta-emission might yield improved response rates (34). The γ-emissions 
of 188Re, which are distinctly lower in energy and abundance (155 keV, 15.0%) 
than the γ-emissions from 131I (364 keV, 81.7%), allow for imaging and 
dosimetry. In contrast to 131I however, the use of 188Re does not imply 
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 significant radiation protection problems since the energy and abundance of the 
γ-emissions is lower and the physical half-life is shorter.  
 
During the past ten years, promising preclinical results using 188Re labeled 
Lipiodol for treatment of HCC have been reported (46-49). Wang et al. analyzed 
the biodistribution of 188Re-EDTB-Lipiodol after intrahepatic arterial injection in 
hepatic tumor bearing rats. The biological half-life of 188Re-EDTB-Lipiodol in 
healthy liver tissue was 34 hours versus 123 hours in hepatic tumors (46,47) 
but the radiolabeling procedure was elaborative. Jeong and coworkers from the 
Seoul National University synthesized long-chain alkyl DD (diaminedithiol) 
derivatives and animal experiments showed that with increasing length of the 
alkyl chain, tissue uptake and retention improved due to hydrophobic 
interaction with Lipiodol. Among several synthesized compounds, the Lipiodol 
solution of 188Re-HDD (4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-
decanethiol, Figure 1) had the most favorable tumor retention properties and 
dosimetric characteristics (49).  
 
FIGURE 1: Molecular structure of Lipiodol and the chelating agent HDD. The 
depiction of Lipiodol is a presumed structure. Adapted from Lee YS et al. Nucl
Med Commun 2002;23:237-242.
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 Multimodality treatment based on radiolabeled Lipiodol therapy 
 
A combination of treatment modalities could result in improvement of outcome 
without induction of severe toxicity (50). Regimens combining systemic 
chemotherapy and external beam radiotherapy were introduced into clinical 
routine for a variety of tumors. Due to the complex interactions between 
ionizing radiation and the cytotoxic drugs, the sequence of each modality is 
important. Clinical results of induction chemotherapy followed by external beam 
radiotherapy did not yield improvements in local control rates of radiotherapy 
so far. On the other hand, evidence is available that concurrent chemo-
radiotherapy results in improved local control and survival (51). The combined 
use of external beam radiotherapy and cytostatic drugs such as cisplatin, 5-
fluorouracil, gemcitabin, or topoisomerase inhibitors has shown promising 
results for treatment of non-small cell lung cancer, colorectal cancer, pancreatic 
cancer, head and neck tumors, and a variety of other tumors (52). 
 
Concerning intensification of treatment for HCC, phase I clinical studies are 
being conducted to investigate the benefit of adding systemic or intra-arterial 
chemotherapy to locoregional irradiation by 131I or 188Re labeled Lipiodol and 5-
fluorouracil and cisplatin were used with concurrent external beam irradiation 
(53-55). Of particular interest at present are Lipiodolized emulsions that remain 
in the tumor for long periods and release drugs in a sustained pattern. A wide 
variety of cytostatic drugs have been mixed successfully in Lipiodol which can 
also be radiolabeled with 131I or 188Re (56-58).   
 
Enhancement of the effects of ionizing radiation by chemotherapy, is assumed 
to be related to (1) direct enhancement of the initial radiation damage by 
incorporating drugs into DNA, (2) inhibiting cellular repair, (3) accumulating 
cells in a radiosensitive phase or eliminating radioresistant phase cells, (4) 
eliminating hypoxic cells, (5) inhibiting the accelerated repopulation of tumor 
cells (59). 
 
In the present work the radiosensitizing effects of a number of cytostatic drugs 
that have been tested in monotherapy for HCC, were investigated using an in 
vitro model for HCC. The set of drugs tested consisted of cisplatinum, 5-
fluorouracil, gemcitabin and topotecan. The first two drugs have been widely 
applied for systemic or locoregional chemotherapy in case of inoperable HCC 
(20). Gemcitabine and topotecan were introduced more recently and so far, 
only phase I or II studies evaluating its clinical use for advanced HCC are 
available (60-62). The occurrence of supra-additive effects was studied in 
respect to the type of ionizing radiation applied: a comparison was made 
between external beam irradiation and exposure to 188Re. 
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 Outline of the thesis 
 
The objective of this work was to explore various new strategies for 
radionuclide therapy of HCC.  
The first part of the clinical research consists of 3 prospective studies 
concerning the implementation of 188Re labeled Lipiodol for treatment of HCC. 
In the initial study, the biodistribution, dosimetry and safety aspects following 
the intra-arterial injection of 3.6 GBq of the new radioconjugate, 188Re-
HDD/Lipiodol, were described in detail. In patients with a well compensated 
underlying cirrhosis, increasing activities were administered and the effects on 
the liver and lung parameters were carefully monitored. In a third study, 
attention was paid to its tolerance in patients suffering HCC and moderately 
advanced cirrhosis.  
The second part of the clinical research focuses on patients treated with 
radiolabeled Lipiodol while awaiting liver transplantation. A retrospective 
analysis of the anti-tumoral effects, drop-out rate from the waiting list and 
clinical outcome was conducted.  
 
The second part of this thesis focuses on strategies for optimization of 
radionuclide therapy of HCC by combining it with cytotoxic drugs with 
radiosensitizing features. The aim of this preclinical work was to screen 
cytotoxic drugs, relevant in the treatment of HCC, for enhancement of the 
effects of irradiation in an in vitro model for HCC. In an initial study 3 
chemotherapeutic agents were tested for supra-additive effects if combined 
with external beam irradiation. In a subsequent study the occurrence of supra-
additive effects was studied in respect to the type of ionizing radiation applied: 
a comparison was made between external beam irradiation and exposure to 
188Re. 
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ABSTRACT 
 
The present study aimed to investigate the pharmacokinetics, organ dosimetry 
and toxicity following the intra-arterial administration of 188Re-4-hexadecyl-1-
2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol (188Re-HDD/Lipiodol) for 
palliative treatment of hepatocellular carcinoma (HCC). A secondary objective 
was to document the response.  
Methods: A mean activity of 3.60 GBq 188Re-HDD/Lipiodol (range: 1.86-4.14 
GBq) was administered to 11 patients (16 treatment sessions) via a 
transfemoral catheter. The pharmacokinetic and dosimetric data were collected 
by means of venous blood samples, urine collections and 4 to 5 gamma 
scintigraphies over 76 hours. Absorbed doses to the various organs were 
calculated according to the Medical Internal Radiation Dose (MIRD) formalism, 
using the MIRDDOSE© 3.1 software. The toxicity was assessed until 6 weeks 
post-administration by means of the CTC-scale. The response was evaluated on 
MRI and by monitoring of the tumor marker.  
Results: A fast blood clearance of the injected activity was observed with a 
calculated effective half-life of 7.6 (± 2.2 SD) hours in blood. The predominant 
elimination of the activity was through urinary excretion with a mean renal 
clearance of 44.1 (± 11.7 SD) % of the injected activity within the 76 hours 
after administration. Fecal elimination was negligible. The calculated whole 
body effective half-life was 14.3 (± 0.9 SD) hours. The absorbed dose to the 
liver tissue, the lungs, the kidneys and the thyroid was 4.5 ± 1.9 Gy, 4.1 ± 1.2 
Gy, 0.9 ± 0.7 Gy and 0.3 ± 0.1 Gy, respectively. Treatment was well tolerated, 
except in two patients. One Child B patient experienced a worsening of his liver 
dysfunction (hyperbilirubinaemia) and another patient experienced dyspnea and 
coughing. Response assessment on MRI showed one case of partial response, 
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 disease stabilization in 11 treatments and progressive disease in 1 treatment. In 
5 out of 8 treatment sessions with an initially elevated alpha-fetoprotein a 
reduction (range 19-90%) was observed 6 weeks later.  
Conclusion: After the intra-arterial administration of 3.60 GBq 188Re-
HDD/Lipiodol, a fast clearance of the activity appearing in the blood is observed 
and the predominant elimination is through urinary excretion. The tolerance as 
well as the preliminary response rates of the present phase I study are 
encouraging. 
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 INTRODUCTION  
 
Hepatocellular Carcinoma or HCC is the most prevalent primary liver cancer. It 
constitutes the third cause of cancer-related deaths, responsible for more than 
500 000 deaths worldwide annually (1). Although the overall incidence of HCC 
in the West is low compared to South East Asia, Sub-Saharan Africa and Japan, 
its incidence is rising (2,3). Due to the underlying carcinogenic risk factors such 
as chronic viral hepatitis and alcohol intake, the vast majority of patients 
presenting with HCC, have cirrhosis, a condition limiting the therapeutic 
possibilities. Surgery, either by means of hepatectomy or liver transplantation, 
is the mainstay of curative treatment. Overall, if the degree of liver dysfunction 
and the tumor load is taken into consideration, the vast majority of patients is 
not eligible for surgery (4).  
 
Percutaneous alcohol injection, (chemo-)embolization and radiofrequent 
ablation are among the most common treatment modalities (5). Survival 
advantages were identified with chemo-embolization in well selected patients 
(6). Other treatment modalities producing response rates exceeding 20% are 
the use of Lipiodol mixed with chemotherapeutic agents or radiolabeled with 
Iodine-131 (131I) without subsequent embolization (7). Encouraging results 
have been obtained using 131I-Lipiodol, but the use of 131I has hampered its 
routine clinical implementation (8,9). 131I has a physical half-life of 8 days and 
emits a high energetic gamma-ray (364 keV, with an abundancy of 82%) 
necessitating delayed hospitalization for radioprotection purposes. Although 
131I-Lipiodol therapy is generally well tolerated, a dose escalation study was not 
conducted so far as the administration of activities exceeding 2.22 GBq is 
restricted by the above mentioned practical issues. Rhenium-188 (188Re) has 
favorable characteristics for radionuclide therapy and considering the limited 
success of 131I-Lipiodol for treatment of relatively large tumors, the switch 
towards a radionuclide with a higher energy of the beta-emission (2120 keV 
and 1960 keV for 188Re versus 606 keV for 131I) might yield improved response 
rates (10). 188Re emits a gamma ray of 155 keV at an abundancy of 15%, 
allowing gamma-camera imaging and it has a relatively short physical half-life 
of 17 hours, limiting radiation protection problems. Additionally, the 
radionuclide is eluted from a 188W/188Re- generator, which has a long useful 
shelf-life of several months and provides a good yield of carrier-free 188Re 
routinely (11).  
 
During the past ten years, promising pre-clinical results using 188Re labeled 
Lipiodol for treatment of HCC have been reported (12-14). Only recently, 
however, were the first clinical results using 188Re-4-hexadecyl-1-2,9,9-
tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol (188Re-HDD/Lipiodol) reported 
by Sundram and coworkers (15,16).  The aim of the present study was to 
assess the biodistribution and feasibility of a locoregional administration of 3.7 
GBq of 188Re-HDD/Lipiodol in palliative HCC-patients. 
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 MATERIALS AND METHODS 
 
Synthesis and Quality Control of the Radio-conjugate 
188W/188Re-generators were purchased from the Oak Ridge National Laboratory, 
(Tennessee, USA) and the IRE (Institut des Radio-Eléments, Fleurus, Belgium). 
Lyophilised kits containing a HDD-chelator (4-hexadecyl-1-2,9,9-tetramethyl-
4,7-diaza-1,10-decanethiol) were provided by the Seoul National University 
Hospital and 188Re-HDD/Lipiodol was synthesized as described earlier by Jeong 
et al.(13). Briefly, the concentrated eluate (6 mL) from a commercially available 
188W/188Re generator containing 11.1 GBq, was heated with the HDD/SnCl2 kit 
at 100°C for 1 hour to produce 188Re-HDD complex (17). 3 mL of Lipiodol was 
added and mixed on a vortex to extract the 188Re-HDD into the Lipiodol. After 
centrifugation at 4000g the 188Re-HDD/Lipiodol fraction was separated. Finally, 
the 188Re-HDD/Lipiodol layer was washed with a 0.9% NaCl solution. Quality 
control was performed according to the method described by Jeong et al. by 
ITLC (ITLC-SG plates, Gelman Sciences, mobile phase: 0.9% NaCl and Acetone) 
(14). Radiochemical purity was in all cases higher than 95%. The total 
radiochemical yield was 53% ± 4.5 %. 
 
Patient Selection  
The diagnosis of HCC had to be established by means of CT-scan, Magnetic 
Resonance Imaging (MRI) or arteriography, eventually in conjunction with an 
elevated alpha-fetoprotein (AFP) level or biopsy. Exclusion criteria were: 
eligibility for liver resection or transplantation, pregnancy and breast feeding, 
age <18 years, Child C status according to the modified Child-Pugh score, 
Okuda III disease stage, poor general condition (Karnofsky <70%), white blood 
cell count <1500/µl and potentially toxic anticancer treatment in the preceding 
3 months. Additional contra-indications for the arteriography and isolation 
procedure were the following: serum creatinine level >2 mg/dl, prothrombin 
time <50 % of the normal value, platelet count <50 000/µl, inability of self-
care, encephalopathy and incontinence. The study was approved by the 
institutional ethic’s committee and an informed written consent was obtained 
from all patients. 
 
Administration 
Under local anesthesia, a 5 French catheter was inserted transfemorally and 
introduced into the proper hepatic artery. After obtaining a diagnostic hepatic 
arteriogram, approximately 4 ml of 188Re-HDD/Lipiodol was injected slowly into 
the proper hepatic artery under fluoroscopic control. Whenever aberrant arterial 
supply was present, the radio-conjugate was injected selectively into the right 
and left hepatic artery separately. The volume of 4 ml was divided over the 
different hepatic arteries proportional to the volume of liver parenchyma 
supplied by the respective artery. To reduce uptake of free perrhenate in the 
thyroid or gastric mucosa, patients received 0.5 gram sodium perchlorate prior 
188Re-HDD/Lipiodol administration followed by 1 gram daily until discharge.  
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 Pharmacokinetic and Dosimetric Study 
Following 188Re-HDD/Lipiodol administration patients were hospitalized in a 
dedicated radionuclide therapy room for 4 days. In all patients, whole body 
scintigraphies were acquired at 1.7 (SD 1.2) , 20.0 (SD 1.9), 27.6 (SD 1.9), 
51.7 (SD 1.8) and  75.4 (SD 1.8) hours post-administration using a triple 
headed gamma camera (IRIX®, Philips, Eindhoven, The Netherlands) equipped 
with medium energy parallel hole collimators. The imaging window was set at 
155 keV (20%). Scan speed varied from 30 to 10 cm/minute depending upon 
the time elapsed since administration. For quantification purposes a syringe 
containing a known activity of 188Re was included in the whole body scan.  
During the hospitalization period, patients collected their urine. Prior to each 
whole body scan, urinary volumes were recorded and samples taken. On these 
occasions, venous blood samples were also taken. Blood and urine samples 
were analyzed in a NaI(Tl) 3”x3”gamma well counter calibrated for 188Re (Cobra 
II, Perkin Elmer, USA). Time-activity curves were generated for blood and 
urinary activity and fitted mono-exponentially (SPSS software version 10.0, 
Chicago, USA).  
For data analysis, whole-body images were transferred to a HERMES® system 
(Nuclear Diagnostics, Sweden). Regions of interests (ROI) were drawn around 
the syringe, the total body, the liver (including tumor), the lungs and a 
background region on the first scan. ROIs were mirrored to the posterior image 
and copied to subsequent scans. The background corrected geometric mean of 
the total counts in the ROIs was used to calculate the total amount of activity in 
the total body, the liver and the lungs, using the known activity in the syringe. 
Experimental factors were determined on an anthropomorphic phantom 
(Alderson Heart/Thorax SPECT phantom) for the conversion of the syringe 
activity into organ activity. The overall uncertainty using this methodology for 
the activity calculation was less than 18%. 
Mono-exponential time activity curves were generated for the total body, the 
liver and lungs using SPSS 10.0 software. Source organ residence times were 
determined from integration of the time activity curves. Absorbed doses to the 
various organs were calculated according to the Medical Internal Radiation Dose 
(MIRD) formalism, using the MIRDDOSE© 3.1 (Oak Ridge Associated 
Universities, USA) software package (18). Using the time-activity curves of the 
blood samples, red marrow absorbed dose was calculated according to the 
methodology described by Sgouros et al. (19). 
The patient’s dose rate was regularly measured at one meter distance of the 
liver region using a survey meter.  
 
Toxicity and Response Assessment 
Laboratory testing of red and white blood cells and platelets, liver function, 
renal function and serum alpha-fetoprotein were performed short before 
treatment, on the third day and 2 and 6 weeks post-injection. Clinical 
evaluation of toxicity was performed daily during hospitalization and 2 and 6 
weeks later. Toxicity was scored by means of the Common Toxicity Criteria 
(Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. 
Division of Cancer Treatment and Diagnosis, National Cancer Institute, National 
Institutes of Health, Department of Health and Human Services, March 1998). 
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 Laboratory findings were compared by means of Wilcoxon statistical testing and 
the significance level was set at P <0.05 (SPSS version 10.0). Radiological 
response was assessed by means of the RECIST response criteria (response 
evaluation criteria in solid tumors) on MRI images acquired 6 weeks following 
treatment (20). Patients without evidence of progressive disease were eligible 
for repetitive treatment sessions with a 12 week interval. 
 
 
RESULTS 
 
Eleven patients underwent 16 treatment sessions. The mean administered 
activity per session was 3.60 GBq (range: 1.86-4.14 GBq). Eight patients were 
treated once, 1 patient twice and 2 patients thrice. Patient characteristics are 
summarized in Table 1.  
 
TABLE 1: Patient characteristics 
Risk factors: chronic hepatitis B infection (HBV), chronic hepatitis C infection 
(HCV), alcohol (ALC), hemochromatosis (HC), none (NO). Modified Child-Pugh 
score: not applicable because of absence of cirrhosis (NA). Previous treatment: 
none (NO), 131I- Lipiodol (I131), trans-arterial chemo-embolization (TACE), 
radiofrequent ablation (RFA).  
 
Nr Age 
(years) 
Sex Risk 
factor 
Modified 
Child-
Pugh 
score 
Okuda 
score 
Number 
of 
sessions 
Previous 
treatment 
(interval in weeks) 
1 71 M ALC B9 II 1 NO 
2 71 M HCV, ALC B9 II 1 I131 (16 w) 
3 71 F HCV A5 I 3 (a, b, c) I131 (14 w) 
4 69 M ALC A5 I 1 I131(16 w) 
5 58 F HCV A5 I 1 NO 
6 72 M HCV A5 I 2 (a, b) RFA (52 w) 
7 76 M HC A5 I 3 (a, b, c) NO 
8 59 M ALC A6 II 1 RFA (52 w) 
9 53 F NO NA I 1 TACE, I131 (14 w) 
10 58 M ALC A6 II 1 I131 (18 w)  
11 77 M HCV A5 I 1 I131 (16 w) 
 
 
Pharmacokinetic Data and Organ Dosimetry 
In 7 treatment sessions a minimum of 4 blood samples were taken within 76 
hours of administration. A fast blood clearance of the injected activity was 
observed, with a calculated mean effective half-life of 7.6 (± 2.2 SD) hours in 
blood. The estimated blood activity at time 0 was 77.2 (± 64.4 SD) kBq/ml. 
Urinary excretion was assessable during hospitalization in all treatments. A 
mean of 44.1 (± 11.7 SD)% of the administered activity was excreted within 76 
hours following administration. The largest fraction was excreted within the first 
21 hours (25.9 ± 6.3% SD). ITLC analysis showed that the activity in the 
urinary samples was perrhenate. Blood activity levels and cumulative urinary 
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 excretion of the injected activity are plotted as a function of time in Figure 1. 
Based on the urinary excretion levels, a mean whole body effective half live of 
14.3 (± 0.9 SD) hours was calculated using a mono-exponential fitting.  
Feces was collected on three occasions; fecal elimination proved negligible 
(mean 0.9 ± 0.2% SD of the administered activity). Scintigraphies showed 
activity in the small bowel and colon, which was faint on 4 occasions and 
significant on one occasion.  
 
FIGURE 1: Blood activity levels in percent of the injected activity per milliliter 
blood as a function of time post injection (A). Cumulative urinary excretion of 
activity in percent of the injected activity plotted as a function of time post-
injection (B). 
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The absorbed doses to the organs were calculated in all treatment sessions 
except one (session number 7c) because of technical problems (Table 2). The 
MIRDOSE red marrow absorbed dose (0.30 ± 0.08 Gy) is in good agreement 
with the red marrow dose calculation based on the methodology of Sgouros 
(0.44 ± 0.21 Gy). No thyroid activity was seen on the scintigraphies (Figure 2). 
The mean effective dose estimation was 1.0 ( ± 0.2 SD) Sv.  
The dose rate at one meter dropped below 20µSv/h within the first 24 hours 
following administration and did not exceed 5 µSv/h on day 2.  
 
TABLE 2: The absorbed doses (Gy) for the various normal organs after 
treatment with mean 3.34 (± 0.93) GBq 188Re-HDD/Lipiodol. LLI (lower large 
intestine), ULI (upper large intestine). 
 
Absorbed Dose (Gy) Target Organ 
Mean SD Range 
Liver 4.49 1.87 1.84 – 7.25 
Lungs 4.07 1.18 1.38 – 5.96 
ULI Wall 0.89 0.80 0.21 – 3.91 
Kidneys 0.89 0.71 0.24 – 2.58 
Stomach 0.30 0.08 0.14 – 0.41 
LLI Wall 0.30 0.08 0.14 – 0.42 
Thyroid 0.30 0.07 0.13 – 0.40 
Red Marrow 0.30 0.08 0.14 – 0.43 
 
FIGURE 2: Whole body scan (right: anterior image, left: posterior image) of 
patient number 4 performed 30 hours after administration of 4.12 GBq 188Re-
HDD/Lipiodol. Significant uptake is seen in the multifocal hepatocellular 
carcinoma and in the bladder. Faint uptake is observed in the lungs and no 
uptake in the thyroid nor gastric mucosa.  
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 Toxicity 
In Table 3 the adverse events are scored according to the Common Toxicity 
Criteria version 2.0. Only the events reflecting a worsening compared to the 
baseline values are tabulated. Patient number 1 received a “special request” 
liver transplantation after 5 weeks, excluding him from subsequent toxicity 
assessment and patient number 11 did not attend follow-up consultations due 
to his limited general condition.  
 
Hematology. No significant changes in blood counts were observed on 
week 2. On week 6 there was a borderline significant decrease in white blood 
cells and platelets (P-values respectively 0.048 and 0.045). Subanalysis pointed 
out that there were no significant changes at all in the blood counts if patient 
number 6 was not taken into consideration. This patient developed a transient 
grade 2 leukopenia and a grade 3 thrombocytopenia. Values for white blood 
cells and platelets before therapy and on week 6 are depicted in Figure 3 A and 
B. 
Liver Function. No clinical liver toxicity was encountered, except in 
patient number 1. This Child B patient had a pre-existing elevated bilirubin level 
and a history of spontaneous liver decompensation. He developed a fatigue 
grade 2 and an aggravation of his icterus. Overall, no significant increases were 
seen in the bilirubin, AST nor ALT levels at week 2 and 6 (Figure 3 C and D). 
There was no significant change in the modified Child-Pugh score 6 weeks 
following treatment. 
Lung Function. No acute pulmonary symptoms were reported during the 
hospitalization. Patient number 6 developed a cough after his first treatment 
session. Lung function testing did not reveal any contra-indications for further 
treatment with 188Re-HDD/Lipiodol. However, after the second session dyspnea 
and cough reoccurred and subsequent lung function testing showed a 
deterioration of the diffusion capacity (DLCO 43% of the predicted value) and 
bilateral fibrotic changes were observed on high resolution CT-scan of the 
lungs. After oral steroid treatment, spirometric changes resolved and 
symptomatic relief was rapidly achieved. Since the patient’s compliance to the 
steroid treatment was unsatisfactory in the late follow-up, symptoms reoccurred 
several months later.  
Other. No significant changes were observed in the creatinine levels 2 
and 6 weeks after the procedure. Besides the toxicity possibly related to the 
investigational agent, some adverse events were due to the catheterization: a 
small groin hematoma in 3 patients and a grade 1 allergic reaction in a patient, 
with a history of a similar reaction following 131I-Lipiodol treatment.  
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TABLE 3: Scoring of adverse events according to the Common Toxicity Criteria 
version 2.0. 
 
Session Adverse event Grade Attribution to 
investigational 
agent 
fatigue (day 2) 2 possibly 
increase in bilirubin (week 2) 3 possibly 
1 
increase in AST (day 2-week 2) 2 possibly 
3a colitis (week 2) 2 unlikely 
diarrhea (day 2) 1 unrelated 4 
tumor pain (week 2) 1 possibly 
infection with fever (week 2) 2 unlikely 
leukopenia (week 6) 2 probably 
thrombocytopenia (week 6) 2 probably 
6a 
cough (week 6) 2 possibly 
leukopenia (week 6) 1 probably 
thrombocytopenia (week 6) 3 probably 
cough, dyspnea, pulmonary fibrosis 
(week 6) 
2 possibly 
6b 
reduced carbon monoxide diffusion 
capacity  
3 possibly 
7c tumor pain (week 2) 1 possibly 
8  fatigue (week 2) 2 possibly 
fatigue (week 2) 2 probably 9 
increase in AST (week 2) 2 probably 
10 infection with fever (day 2-7) 1 unrelated 
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 FIGURE 3: White blood cell counts before therapy and at week 6 (A), platelet 
counts before therapy and at week 6 (B). The dotted lines represent sessions 
number 6a and b. Bilirubin levels before therapy and at week 2 (C), AST levels 
before therapy and at week 2 (D). 
 
 
 
Response  
Response on MRI. Patient number 10 suffered from a rapidly progressive 
multifocal tumor with grade 4 anaplastic disease on pathology. In this patient a 
partial response was obtained with a reduction of the sum of largest diameters 
by 41%. Patient number 3 suffered from progressive disease after her third 
treatment with 188Re-HDD/Lipiodol. Patients number 1 and 11 dropped out for 
response assessment 6 weeks after treatment and patient number 5 was not 
assessable because imaging was performed on different scanners. The 
remaining patients had stable disease. 
Response on AFP. Figure 4 depicts the change in serum AFP of baseline 
values at week 6. In 8 treatment sessions AFP levels were elevated prior to 
treatment. In 5 out of these treatment sessions a reduction in tumor marker 
(range 19-90%) was observed 6 weeks later.  
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 FIGURE 4: Change in serum AFP of baseline values at week 6 in 8 treatment 
sessions with an initially elevated tumor marker level. 
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DISCUSSION 
  
Taking into account the effective half-life, beta-energy and dose rate, the same 
effect on the tumor may be expected by 188Re-HDD/Lipiodol and 131I-Lipiodol 
when the administered 188Re-activity is 60% higher than the 131I-activity (21). 
This calculation is based upon iso-effect curves for different dose rates used in 
brachytherapy (22). Therefore we aimed in the present study at an 
administration of 3.7 GBq of 188Re-HDD/Lipiodol because before initiation of this 
study, a fixed activity of 2.2 GBq 131I-Lipiodol was usually applied at our 
institution. A non-selective administration in the hepatic arterial vessels was 
preferred because development of metachronous HCC in the non-treated 
segments is described in case the administration of the activity is restricted to 
the affected segments or lobe (23).  
Concerning the labeling procedure, no major technical problems were 
encountered in 15 out of 16 syntheses. The hospital stay in isolation for up to 7 
days in certain European countries in order to comply with radioprotective 
guidelines, is among the most important constraints of the use of 131I-Lipiodol. 
The patient’s dose rate measured at 1 meter dropped below the local limit of 20 
µSv/h within 24 hours following administration of 188Re-HDD/Lipiodol, allowing 
a significant shorter hospitalization. The shorter stay in the shielded therapy 
room and the use of on-site 188W/188Re-generator improved the flexibility in 
treatment planning.  
 
Since 188Re is differently attached to Lipiodol (coordinative binding with a 
chelator) compared to 131I-Lipiodol (covalent binding), differences in 
metabolism can be expected. We observed a significant accumulation of the 
radio-conjugate in the liver and lungs and, to a much smaller amount, uptake in 
the gastrointestinal tract and kidneys. The significant lung uptake is in 
agreement with the initial clinical experiences with 188Re-HDD/Lipiodol reported 
by Sundram et al. and with the previous studies on the biodistribution of 131I-
Lipiodol (15,16,24-26).  
We calculated a biologic half-life in the lungs for 188Re of 8.7 (± 4.9 SD) days 
and this result is in line with our earlier report on the biologic half-life in the 
lungs following 131I-Lipiodol therapy of 10.3 (± 5.2 SD) days (27). The relatively 
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 long biologic lung half-life in both cases suggests that the activity in the lung is 
present under a stable formulation from which diffusion to blood is minimal.  
In the present study a considerable number of patients showed faint uptake in 
other organs such as the kidneys and parts of the gastro-intestinal tract. The 
data available in the literature concerning the elimination of 131I-Lipiodol are 
scarce but all investigators agree on the predominant urinary excretion and 
negligible elimination of 131I in stool. The largest observation comprising 
measurements in 10 patients suffering from HCC yielded a median of 42% of 
the administered 131I excreted urinary within the first 8 days (24). Nakajo et al. 
obtained comparable results with a daily excretion from 4.3 up to 7.1% (25). In 
a small biodistribution study conducted by Madsen et al. in 4 patients, a lower 
daily excretion of 131I (1-3%) was observed (26). In the experiences with 188Re-
HDD/Lipiodol reported by Sundram et al. a faint visualization of the kidneys was 
described and they concluded that renal elimination was negligible. However, 
the urinary excretion was not quantified (16). According to our measurements a 
mean of 44.1% of the administered 188Re was excreted in the urine within 76 
hours. If the shorter physical half-life of 188Re is taken into account, this value 
compares favorably with the observations of Raoul et al. and Nakajo et al. 
(24,25).  
 
No visualization of the gastro-intestinal tract was described in the 
biodistribution studies using 131I-Lipiodol nor in the initial reports on 188Re-
HDD/Lipiodol (15,16,24-26). However, in our experience in 5 out of 16 
administrations transient uptake in the small or large bowel was observed, 
which was very faint in all patients but one. In the animal study conducted by 
Lee et al. intestinal uptake was observed following intravenous administration 
of 188Re labeled long chain alkyl diaminedithiol derivatives in mice and the 
intestinal activity was thought to be result of bile excretion (14). In our study 
the uptake pattern and its transient character suggested biliary excretion rather 
than gastro-intestinal wall uptake.  
 
Only few data are available on the blood activities following 131I-Lipiodol 
administration. Measurements performed by Nakajo et al. and Madsen et al. 
pointed out that less than 0.9% of the administered activity was retrieved in 
the total blood volume with a peak in blood activity after 3 days (25,26). This 
was in contrast with the activities measured in the present study, indicating an 
initially significant higher blood activity about 10% of the administered activity 
188Re-HDD/Lipiodol, with a rapid decrease over the first 3 days. Sundram et al. 
performed activity measurements in 5 patients short after the administration of 
a “scout dose” of 200 MBq 188Re-HDD/Lipiodol. The obtained activities were 
considered negligible but the biodistribution data are difficult to compare since 
most studies vary in the selectivity of administration of the radio-conjugate. 
(15,16).  
 
Absorbed doses to the liver, lungs and thyroid calculated for 1.90 ± 0.20 GBq 
131I-Lipiodol therapy, are significantly higher (7.8 ± 1.8 Gy, 6.8 ± 2.9 Gy and 7.2 
± 2.2 respectively) compared to the absorbed doses in this 188Re-HDD/Lipiodol 
study population (27). The mean effective dose of the 188Re-HDD/Lipiodol 
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 patients (1.0 ± 0.2 Sv) was significantly lower compared to 131I-Lipiodol (2.0 ± 
0.6 Sv).  
 
The initial clinical experiences using 188Re-HDD/Lipiodol have been described by 
Sundram and coworkers. In this study, about 35 out of 70 patients did not 
experience any adverse event. The most frequent adverse events consisted of 
mild anorexia, right hypochondrial discomfort and low grade fever (16). We had 
a similar observation with the occurrence of in general only mild toxicity in 9 
out of 16 treatment sessions. Patient number 1 suffered from a significant 
worsening of his liver dysfunction. Although this patient had a history of  
frequent liver decompensation and his tumor marker was steeply increasing at 
week 2, we recommend that additional data are acquired to confirm the safety 
of 188Re-HDD/Lipiodol therapy in Child B liver cirrhosis patients. No cases of 
liver failure were reported by Sundram and coworkers (15,16). However, in that 
trial the activity was administered as close to the tumor feeding artery as 
possible whereas the present study aimed to treat the whole liver and therefore 
the radio-conjugate was injected non-selectively. Sundram et al. reported 2 
cases of pleural effusion and these were attributed to radiation induced 
pneumonitis (16). In our study patient number 6 developed grade 3 lung 
toxicity 6 weeks after his second treatment. The absorbed lung doses of 
sessions 6 a en b were estimated to be respectively 4.6 Gy and 5.8 Gy, hence 
too low to explain this evolution. The timing of the occurrence of his symptoms 
and the associated bone marrow depression are suggestive for an increased 
sensitivity to ionizing radiation in this patient. No bone marrow depression was 
observed in the other patients, including the population described by Sundram 
et al. (16). Although is was not clear if the occurrence of lung fibrosis in this 
patient was related to the 188Re-HDD/Lipiodol therapy, we advocate that in the 
future particular attention is paid to patients developing pulmonary complaints. 
If radiation induced pneumonitis is detected, adequate prevention of fibrosis by 
means of steroid treatment is recommended.  
 
Besides the excellent tolerance of the treatment in the majority of patients, the 
preliminary response rates in this study were encouraging, since 6 out of 11 
patients had clear evidence of progressive disease at inclusion. 
Future research should attempt to elucidate various issues concerning the 
maximum tolerated activity and the long term effects of the treatment on the 
lung tissue. Future work should also focus on the optimization of the 
administration protocol in terms of selectivity and the use of a fixed activity in 
stead of estimating the optimal activity following the administration of a ‘scout-
dose’. In addition, efforts should be made in these studies to perform SPECT-
tumor dosimetry. As more data on the recommended activities and treatment 
intervals become available, the cost effectiveness of this treatment modality 
should be investigated. 
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 CONCLUSION 
 
A mean activity of 3.60 GBq 188Re-HDD/Lipiodol was administered to 11 
patients in 16 treatment sessions. A fast blood clearance of the injected activity 
was observed with a calculated effective half-life of 7.6 (± 2.2 SD) hours in 
blood. The predominant elimination of the activity was through urinary 
excretion with a mean renal clearance of 44.1 (± 11.7) % of the injected 
activity within the 76 hours following administration. The calculated whole body 
effective half-life was 14.3 (± 0.9 SD) hours. Treatment was well tolerated, 
except in two patients. The results of the present phase I study are 
encouraging and according to the dosimetric estimations a further dose 
escalation study is warranted.  
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ABSTRACT 
 
The present study aimed to investigate the urinary excretion, organ dosimetry 
and toxicity following the intra-arterial administration of increasing activities of 
188Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol 
(188Re-HDD/Lipiodol) for treatment of hepatocellular carcinoma (HCC) in 
patients with a well compensated cirrhosis. A secondary objective was to 
document the response. Methods: The activity levels were increased by 1.1 
GBq/step after a 6 week interval without unacceptable adverse events in at 
least 5 subsequent patients. Three gamma-scintigraphies were performed up to 
54 hours post-therapy. Absorbed doses to the various organs were calculated 
according to the MIRD-formalism, using the MIRDOSE 3.1 software. The toxicity 
was recorded until 6 weeks post-administration by means of the CTC-scale. The 
response was evaluated on magnetic resonance imaging (MRI) or computed 
tomography (CT) and by monitoring of alpha-fetoprotein (AFP). Results: Thirty-
five treatments were carried out in 28 patients. Activities from 4.8 up to 7.0 
GBq 188Re-HDD/Lipiodol were administered via a transfemoral catheter. Urinary 
excretion eliminated (mean ± SD) 41.7 ± 9.7% of the injected activity within 
46 ± 9.6 hours. The mean absorbed dose to the liver (including tumor) was 7.6 
± 2.2, 9.8 ± 4.9 and 15.2 ± 4.9 Gy for the 4.8, the 5.9 and the 7.0 GBq patient 
groups respectively, whereas the mean lung doses resulted in 5.3 ± 2.9, 6.8 ± 
3.1 and 8.9 ± 4.5 Gy. The mean whole body doses for the increasing activity 
levels resulted in 0.6, 0.7 and 0.9 Gy. Treatment was well tolerated at all 
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 activity levels, including the final level of 7.0 GBq. Further escalation of the 
administered activity was not feasible due to technical reasons, related to the 
radiolabeling procedure. Response assessment on MRI showed partial response, 
stable disease and disease progression in respectively 1, 28 and 2 assessable 
treatments. In 8 out of 17 treatment sessions with an initially elevated AFP a 
reduction ranging from 19-97% was observed 6 weeks later. Conclusion: 
Following the intra-arterial administration of 4.8 up to 7.0 GBq 188Re-
HDD/Lipiodol in patients with HCC and well compensated liver cirrhosis, no 
severe adverse events occurred. Further escalation was not feasible due to 
limitations in the radiolabeling procedure. 
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 INTRODUCTION  
 
Hepatocellular Carcinoma (HCC) is the most common type of primary liver 
cancer. HCC is among the most prevalent causes of cancer related deaths, in 
particular in South East Asia, Sub-Saharan Africa and Japan (1). In the West, its 
incidence keeps rising (2,3). The tumor often presents late and since more than 
80% of patients presenting with HCC, suffer underlying cirrhosis, therapeutic 
possibilities are limited. Surgery, by either hepatectomy or liver transplantation, 
is the mainstay of curative treatment. Overall, if the degree of liver dysfunction 
and the tumor load is taken into consideration, the vast majority of patients is 
not eligible for surgery (4). Local strategies such as percutaneous alcohol 
injection and radiofrequent ablation are often applied in case of inoperable 
patients presenting with limited tumor load (5,6). For multifocal HCC, 
transarterial chemo-embolization is generally accepted and survival advantages 
were identified in patients with well compensated cirrhosis (7). Encouraging 
results using 131I-Lipiodol have been reported, but radioprotective concerns 
regarding the use of 131I have limited its widespread implementation (8,9). The 
long physical half-life of 131I of 8 days and its high energetic gamma-ray of 364 
keV leads to delayed hospitalization for radioprotection purposes. 131I-Lipiodol 
therapy is generally well tolerated, but the use of  activities exceeding 2.22 GBq 
is restricted by the above mentioned radioprotective issues.  
 
Rhenium-188 (188Re) has favorable characteristics for radionuclide therapy and 
considering the limited success of 131I-Lipiodol for treatment of relatively large 
tumors, the switch towards a radionuclide with a higher energy of the beta-
emission (2120 keV and 1960 keV for 188Re versus 606 keV for 131I) might yield 
improved response rates (10). 188Re emits a gamma ray of 155 keV at an 
abundance of 15%, allowing gamma-camera imaging and it has a relatively 
short physical half-life of 17 hours, reducing radiation protection problems. 
Additionally, the radionuclide is eluted from a 188W/188Re-generator, which has a 
long useful shelf-life of several months and provides a good yield of carrier-free 
188Re routinely (11).  
 
The first clinical results using 188Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-
1,10-decanethiol/Lipiodol (188Re-HDD/Lipiodol) were reported by Sundram et al. 
(12,13). Whereas Sundram and coworkers applied activities varying from 1.8-
9.8 GBq, depending on the dose estimations following the administration of a 
scout dose, Lambert et al. used a fixed activity of 3.6 GBq. Tolerance was 
excellent in patients with well compensated cirrhosis (Child-Pugh class A) and 
according to the dosimetric estimations, a further escalation of the activity 
seemed feasible (14). The aim of the present study was to administer 
increasing activities of 188Re-HDD/Lipiodol and to assess the urinary elimination, 
organ dosimetry and toxicity. A secondary end point was response assessment.  
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 MATERIALS AND METHODS 
 
Synthesis and Quality Control of the Radio-conjugate 
188W/188Re-generators were purchased from the IRE (Institut des Radio-
Eléments, Fleurus, Belgium). Lyophilised kits containing a HDD-chelator 
complex (4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol) were 
provided by the Seoul National University Hospital and 188Re-HDD/Lipiodol was 
synthesized as described earlier by Jeong et al. (15,16). The concentrated 
eluate (6 mL) from a commercially available 188W/188Re-generator, was heated 
with the HDD/SnCl2 kit at 100°C for 1 hour to produce 188Re-HDD complex 
(16,17). 3 mL of Lipiodol was added and mixed on a vortex to extract the 188Re-
HDD into the Lipiodol. After centrifugation at 4000g the 188Re-HDD/Lipiodol 
fraction was separated. Finally, the 188Re-HDD/Lipiodol layer was washed with a 
0.9% NaCl solution. Quality control was performed according to the method 
described by Jeong et al. by ITLC (ITLC-SG plates, Gelman Sciences, mobile 
phase: 0.9% NaCl and Acetone) (15).   
 
Study Design 
Groups of at least 5 patients were treated with increasing activities of 188Re- 
HDD/Lipiodol, starting at 4.8 GBq. Escalation of the administered activity was 
implemented in increments of 1.1 (± 0.55) GBq, following an interval of 6 
weeks without the occurrence of an unacceptable event in at least 5 
consecutive patients. If a case of unacceptable toxicity was recorded in the first 
5 patients, a minimum of 10 patients had to be treated at this activity level 
without the occurrence of an additional unacceptable adverse event. However, 
if a second case of unacceptable toxicity was observed, the study was stopped 
at that activity level.  
An adverse event was considered unacceptable if it was grade 4 or 5 according 
to the CTC- scale (Common Terminology Criteria for Adverse Events, Version 
3.0. Cancer Therapy Evaluation Program. June 10, 2003. 
http://ctep.cancer.gov) and at least “probably related to the investigational 
agent”. However, grade 4 laboratory aberrations related to liver dysfunction 
could be considered acceptable depending on the baseline status of particular 
cases. On the other hand, grade 3 toxicity could be deemed unacceptable if it 
was prolonged or having a clear negative impact on the patient’s quality of life, 
compared to the baseline status. Any increase of more than 2 points on the 
Child-Pugh classification for liver dysfunction lasting until week 6 was regarded 
unacceptable, unless tumor progression occurred.  
Patients without evidence of disease progression on imaging were eligible for 
additional sessions with 12 week intervals. An individual patient always 
remained within the same activity level if the inclusion criteria were still met.  
 
Patient Selection  
The diagnosis of HCC had to be established by means of biopsy or conventional 
imaging techniques, such as Computed Tomography (CT)-scan, Magnetic 
Resonance Imaging (MRI) or arteriography, possably in conjunction with an 
elevated alpha-fetoprotein (AFP) level exceeding 400 ng/ml (6). For lesions 
smaller than 2 cm, a consensus had to be reached by two independent 
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 radiologists. Exclusion criteria were: eligibility for liver resection, pregnancy and 
breast feeding, age <18 years, Child B or C status according to the modified 
Child-Pugh score, poor general condition (Karnofsky <70%), white blood cell 
count <2. 10³/µl, forced expiratory volume in 1 second (FEV-1) or lung 
diffusion capacity for carbon monoxide (DLCO) <40% of the predicted value, 
abnormal baseline CT-scan of the chest, other active primary malignancy than 
HCC, symptomatic extra-hepatic metastasis, and potentially toxic anticancer 
treatment in the preceding 6 weeks (18). Additional contra-indications for the 
arteriography and isolation procedure were the following: serum creatinine level 
>2 mg/dl, prothrombin time <50 % of the normal value, platelet count <50. 
10³/µl, inability of self-care, encephalopathy and incontinence. The study was 
approved by the institutional ethics committee and an informed written consent 
was obtained from all patients. 
 
Administration 
Under local anesthesia, a 5 French catheter was inserted transfemorally and 
introduced into the arteria hepatica propria. After obtaining a diagnostic hepatic 
arteriogram, approximately 4 ml of 188Re-HDD/Lipiodol was injected slowly into 
the into the arteria hepatica propria under fluoroscopic control. Whenever an 
aberrant arterial supply was present, the radio-conjugate was injected 
selectively into the right and/or left hepatic artery separately. The volume of 4 
ml was divided over the different hepatic arteries proportional to the volume of 
liver parenchyma supplied by the respective artery. To reduce uptake of free 
perrhenate in the thyroid or gastric mucosa, patients received 1 gram sodium 
perchlorate for 3 days.  
 
Assessment of Urinary Elimination and Organ Dosimetry 
Following 188Re-HDD/Lipiodol administration patients were hospitalized in a 
dedicated radionuclide therapy room for 3 days. During the hospitalization, 
patients collected their urine. Urine samples were analyzed in a NaI(Tl) 
3”x3”gamma well counter calibrated for 188Re (Cobra II, Perkin Elmer, USA). 
Time-activity curves were generated and fitted mono-exponentially (SPSS 
software version 10.0, Chicago, USA).  
Whole body scintigraphies were acquired at (± SD) 3.7 ± 1.1, 24.5 ± 3.0 and 
49.9 ± 3.5 hours post-administration using a double or triple headed gamma 
camera (respectively AXIS® and IRIX®, Philips, Eindhoven, The Netherlands) 
equipped with medium energy parallel hole collimators. Scan speed varied from 
30 to 10 cm/minute depending upon the time elapsed since administration. The 
imaging window was set at 155 keV (20%). For quantification purposes a 
syringe containing a known activity of 188Re (mean activity ± SD: 16.0 ± 3.0 
MBq) was included in the whole body scan. Regions of interests (ROI) were 
drawn around the syringe, the total body, the liver (including tumor), the lungs 
and a background region on the first scan. The background corrected geometric 
mean of the total counts in the ROIs was used to calculate the total amount of 
activity in these regions, using the known activity in the syringe and 
experimental factors determined on an anthropomorphic phantom (Alderson 
Heart/Thorax SPECT phantom) for the conversion of the syringe activity into 
organ activity. In the latter conversion factors, the attenuation and scatter 
51  
 effects in this standard phantom were taken into account. The overall 
uncertainty using this methodology for the activity calculation was less than 
18%. 
Mono-exponential time activity curves were generated for the total body, the 
liver and lungs using SPSS 10.0 software. Source organ residence times were 
determined from integration of the time activity curves. Absorbed doses to the 
various organs were calculated according to the Medical Internal Radiation Dose 
(MIRD) formalism, using the MIRDDOSE© 3.1 (Oak Ridge Associated 
Universities, USA) software package (19,20). The patient’s dose rate was 
regularly measured at one meter distance of the liver region using a survey 
meter.  
 
Toxicity and Response Assessment 
Laboratory testing of red and white blood cell counts, platelets, liver function 
and renal function were performed shortly before treatment, following 48 hours 
and 2 and 6 weeks post-injection. Clinical evaluation of toxicity was performed 
daily during hospitalisation and 2 and 6 weeks later. Lung function testing was 
performed before treatment and 6 weeks later. Toxicity measurements were 
scored by means of the CTC-scale. Laboratory findings were compared by 
means of Friedman and Wilcoxon statistical testing and the significance level 
was set at P <0.05 (SPSS version 10.0). Radiological response was assessed by 
means of the RECIST (Response Evaluation Criteria in Solid Tumours) response 
criteria on CT-scans or MRI images acquired 6 weeks following treatment (21). 
AFP levels were measured at baseline, week 2 and week 6. 
 
 
RESULTS 
 
Between January 2004 and February 2005, 28 patients agreed to participate in 
the presented study. Nine patients underwent 14 treatment sessions with 4.8 
GBq 188Re-HDD/Lipiodol. In 1 patient his second administration was performed 
with only half of the planned activity due to a technical problem during the 
radiolabeling procedure. Eleven administrations with 5.9 GBq of the 
radioconjugate were carried out in 9 patients and 10 patients underwent a 
single treatment session with 7.0 GBq 188Re-HDD/Lipiodol. Radiochemical purity 
was in all cases higher than 95%. The total radiochemical yield (n=34) was 
49% ± 5.4 %.  
All patients but 2 were Belgian. The mean age was 69 years (range 48-82 
years). The sex-ratio was 22 males versus and 7 females. Among the 28 
patients, only 5 patients had undergone previous anti-cancer treatment. Patient 
characteristics are summarized in Table 1. Okuda and Cancer of the Liver 
Italian Program (CLIP) scores are prognostic staging systems for HCC. 
Prognosis worsens with increasing scores (22,23). Five patients presented with 
a thrombosis of the portal vein, which is a negative prognostic factor. 
The radio-conjugate was injected in the into the arteria hepatica propria, both 
right and left branch and only the right branch in respectively 15, 11 and 2 
patients. In the latter 2 cases only the right lobe was affected and treatment of 
the left lobe was not feasible due to an aberrant vascular anatomy. 
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 TABLE 1: Patient characteristics 
Etiology: chronic hepatitis B infection (HBV), chronic hepatitis C infection (HCV).  
 
 
 
 Number of patients 
Etiology 
      alcohol 
      HBV 
      HCV 
      idiopathic 
      hemochromatosis 
      auto-immune 
 
10 
4 
10 
2 
1 
1 
Child-Pugh score 
      no cirrhosis 
      5 points 
      6 points 
 
1 
23 
4 
Okuda score 
      class I 
      class II 
      class III 
 
27 
1 
0 
CLIP score 
      0 points 
      1 points 
      2 points 
      3 points 
      4 points 
 
7 
12 
6 
2 
1 
Karnofsky-index 
      100% 
      90% 
      80% 
 
17 
8 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Urinary Elimination and Organ Dosimetry 
Urinary excretion was assessable during hospitalization in 25 treatments. A 
mean of 41.7 % (± 9.7 SD, range: 20.1-56.1) of the administered activity was 
excreted within 46 hours (± 9.6 SD, range: 20-57) following administration. On 
whole body scintigraphy uptake in the liver, lungs and bladder was seen. 
Occasional gastro-intestinal or thyroid activity was very faint. The organ 
absorbed doses as well as the whole body dose were calculated in 12 sessions 
with 4.6 GBq, 8 sessions with 5.8 GBq and 7 sessions with 6.8 GBq and 
estimates are summarized in Table 2. 
The dose rate at one meter dropped below 20µSv/h within the first 48 hours 
following administration in all patients.  
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 TABLE 2: Normal organ dosimetry 
Mean absorbed dose estimations after treatment with 4.6 ± 0.3, 5.8 ± 0.3 and 
6.8 ± 0.2 GBq 188Re-HDD/Lipiodol respectively. LLI (lower large intestine), ULI 
(upper large intestine) 
 
Absorbed Dose (Gy) 
4.6 ± 0.3 GBq 
 188Re-HDD/Lipiodol 
 
(n=12) 
5.8 ± 0.3 GBq 
 188Re-HDD/Lipiodol  
 
(n=8) 
6.8 ± 0.2 GBq  
188Re-HDD/Lipiodol  
 
(n=7) 
Target 
Organ 
Mean SD Range Mean SD Range Mean SD Range 
Liver 7.6 2.2 4.6 – 10.4 9.8 4.9 5.6 – 14.9 15.2 4.9 12.3 – 21.8 
Lungs 5.3 2.9 2.0 – 10.3 6.8 3.1 3.8 – 8.9 8.9 4.5 5.6 – 14.7 
ULI Wall 0.3 0.1 0.2 – 0.7 0.4 0.2 0.3 – 0.6 0.4 0.2 0.3 – 0.7 
Kidneys 0.4 0.2 0.2 – 0.9 0.5 0.1 0.3 – 0.9 0.5 0.2 0.4 – 1.1 
Stomach 0.3 0.1 0.2 – 0.4 0.4 0.1 0.3 – 0.5 0.5 0.2 0.3 – 0.6 
LLI Wall 0.3 0.1 0.2 – 0.4 0.4 0.1 0.3 – 0.5 0.4 0.1 0.3 – 0.5 
Thyroid 0.3 0.1 0.2 – 0.5 0.4 0.2 0.3 – 0.7 0.5 0.1 0.4 – 0.6 
Red Marrow 0.3 0.1 0.2 – 0.4 0.4 0.1 0.3 – 0.5 0.4 0.1 0.3 –0.6 
Whole body 0.6 0.1 0.4 – 0.7 0.7 0.2 0.5 – 0.9 0.9 0.3 0.6 – 1.2 
 
Toxicity 
Toxicity was assessable in 33 treatment sessions. One patient was lost of 
follow-up because he moved to another country and another patient was 
transplanted before assessment was complete. One additional patient was 
excluded from the statistical analysis since he was treated with only half of the 
planned activity 188Re-HDD/Lipiodol due to a technical problem. In Table 3 the 
adverse events are scored according to the CTC-scale. Only the clinical events 
assumed to have at least a possible causal relation to the procedure and 
reflecting a worsening compared to the baseline values are tabulated.  
Haematology. A small but statistically significant decrease in white blood 
cell counts was observed at week 6. Further analysis pointed out this was 
limited to the patients who underwent treatment with 5.9 and 7.0 GBq (P-
values respectively 0.014 and 0.032). At these activity levels, respectively 4 and 
1 patients developed grade 2 leukopenia at some time point following 
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 treatment. Platelet counts did not change significantly. Values for white blood 
cells and platelets before therapy and on week 2 and 6 are depicted in Figure 1. 
Liver Function. No clinical liver toxicity was encountered. In 8 sessions 
the Child-Pugh score was increased with a single point 6 weeks later. In half of 
these cases it concerned patients treated at the highest activity level. In one 
case an increase with 2 points was noticed but this patient suffered a rapidly 
rising AFP and an increase of the dimensions of his tumour. At discharge 
statistically significant increases in bilirubin and AST levels were recorded for all 
activity levels. Overall, an increase in bilirubin and AST of one CTC-grade was 
observed in respectively 12 and 6 therapies and these events did not occur 
more frequently at higher activity levels. Changes in liver parameters for the 
various activity levels are depicted in Figure 2.  
Lung Function. No acute pulmonary symptoms were reported during the 
hospitalisation. Two patients developed pulmonary symptoms 2 to 5 weeks 
following the administration. One patient suffered a transient cough without 
fever 2 weeks following his second treatment session with 5.9 GBq. No 
deterioration of the lung function was seen 7 weeks later, nor abnormalities on 
high resolution CT-scan of the chest. The second case concerned a patient 
treated at the lowest activity level, who suffered an exacerbation of a pre-
existing dyspnea and cough. This was definitely more severe after the second 
treatment compared to the first one and the second time it was accompanied 
by prolonged fever. Again, high resolution CT-scan of the lungs failed to show 
fibrotic changes. After oral steroid treatment, symptomatic relief was achieved 
but the recovery was complicated by an episode of gastro-intestinal bleeding. 
Lung function testing was regarded to be of limited value in this case because 
cooperation was not satisfying due to the abdominal discomfort. The relation to 
the investigational agent remains unclear since the patient had a history of 
episodes of unexplained fever and was known with chronic obstructive 
pulmonary disease. Statistical analysis by means of Wilcoxon testing (n=23 
therapies) did not reveal any significant changes at week 6 compared to 
baseline pulmonary function, exception for the DLCO and pulmonary transfer 
factor for carbon monoxide (KCO) (P-values respectively 0.048 and 0.028, with 
a reduction of the overall mean of respectively 13 and 11%). However, 2 
patients treated at the lowest activity level were unable to fully cooperate due 
to a recent gastro-intestinal bleeding and after exclusion of these cases, no 
statistically significant changes were observed. Changes in FEV-1, FVC (forced 
vital capacity), DLCO and KCO are illustrated in Figure 2. 
Other. Three patients were admitted to hospital for gastro-intestinal 
bleeding (grade 3). Scintigraphy did not reveal extra-hepatic uptake of the 
radio-conjugate in these patients. CT-scans performed without contrast 2 weeks 
following treatment, did not show extra-hepatic Lipiodol. Taking into account 
their individual histories of variceal bleeding, the cause of these events was not 
considered to be likely related to the radionuclide therapy.  
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 TABLE 3: Adverse events 
Clinical adverse events are scored according to the CTC-scale version 3.0.  
 
 
Time 
point 
Adverse event Grade 
pre→post 
therapy 
Number 
of 
therapies
Comment  
fever 0 → 1 3  Week 1 
rash  0 → 1 3 related to contrast agent 
fatigue 0 → 1 2  
pain (tumor) 0 → 2 2 rising AFP 
infection 0 → 1 3 without leukopenia 
cough 0 → 1 1 causal relationship 
unclear, no signs of 
infection, normal CT-scan 
of chest and lung function 
test 
Week 2 
 
cough, dyspnea, fever  0 → 2 2 twice in  same patient, 
symptomatic relief with 
corticosteroids 
fatigue 0 → 1 4  
arthritis and 
hyperuricemia 
0 → 1 1 history of gout 
hemorrhage  
(esophagus/stomach) 
 
0 → 3 
 
 
2 
 
 
ethyl abusus (1), 
corticosteroid treatment 
(1), history of variceal 
bleeding (2) 
Week 6 
hemorrhage (stomach)  
 
0 → 1 1 administered activity too 
low, history of variceal 
bleeding  
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 FIGURE 1: White blood cell counts (A-C) and platelets (D-F) before therapy and 
at week 2 and week 6. Bilirubin (G-I) and AST (J-L) levels before therapy, at 
discharge, week 2 and week 6. 4.8 GBq (left), 5.9 GBq (middle) and 7.0 GBq 
(right) 188Re-HDD/Lipiodol. 
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 FIGURE 2: Changes in FEV-1 (A-C), FVC (D-F), DLCO (G-I) and KCO (J-L) 
before therapy and at week 6 for 4.8 GBq (left), 5.9 GBq (middle) and 7.0 GBq 
(right) 188Re-HDD/Lipiodol. The measurements are expressed as percentage of 
the predicted value for that patient. The dotted lines represent patients who 
could not fully cooperate at the moment of lung function testing. 
Forced expiratory volume in 1 second (FEV-1), lung diffusion capacity for 
carbon monoxide (DLCO), forced expiratory vital capacity (FVC), pulmonary 
transfer factor for carbon monoxide (KCO) 
 
 
 
Response  
Twenty five patients (31 treatment sessions) were assessable according to the 
RECIST-criteria. Two patients underwent a liver transplantation before response 
assessment was performed, 1 patient did not attend follow-up visits and in 1 
case RECIST-criteria could not be applied. Overall, partial response, stable 
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 disease and disease progression were observed in respectively 1, 28 and 2 
treatments. The partial response was obtained in a 81 year old patient with 
underlying HBV-induced cirrhosis, treated with a single session of 4.8 GBq 
188Re-HDD/Lipiodol (Fig. 3). This patient had an unexpected low tumoral uptake 
of Lipiodol according to a CT-scan performed 2 weeks following his treatment. 
The response on imaging was accompanied by a steep decrease in AFP over 6 
weeks (from 451 to 77 ng/ml). 
One case of disease progression occurred in the patient whose second 
administration consisted of only half of the planned activity due to a 
problematic radiolabeling procedure. 
In 8 out of 17 treatment sessions with an initially elevated AFP a reduction 
(median 47%, range 19-97% reduction) was observed 6 weeks later. Three 
patients had stable tumor markers whereas a rise in AFP (median 63%, 31-
2012% increase) was documented in 6 therapies.  
 
FIGURE 3: Whole body scintigraphy performed 24 hours post-administration of 
4.8 GBq 188Re-HDD/Lipiodol. Anterior (A) and posterior (B) image. 
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 DISCUSSION  
 
In the present study increasing activities of 188Re-HDD/Lipiodol were 
administered. If it was technically feasible, we aimed at treating the entire liver 
since there is a high risk of developing metachronous HCC in the non-treated 
segments (24). Targeting the whole liver was technically feasible in all patients 
but 2. Concerning the labeling procedure, no major technical problems were 
encountered up to 7.0 GBq except in one treatment.  
 
Instant thin-layer chromatography showed that the activity in the urinary 
samples was perrhenate (14). If compared to our earlier experiences, the use 
of increasing activities from 3.6 up to 7.0 GBq 188Re-HDD/Lipiodol did not yield 
an altered relative urinary excretion (P-value: 0.30). If the shorter physical half-
life of 188Re is taken into account, the urinary excretion compares favorably with 
the observations using 131I-Lipiodol (25,26). For all activity levels, organ dose 
estimates were well below the threshold levels for adverse radiation induced 
effects. 
 
In the initial clinical experiences, Sundram et al. used 1.8-9.8 GBq 188Re-
HDD/Lipiodol, depending on the dose estimations following the administration 
of a scout dose and the activity was administered as close to the tumor feeding 
artery as possible. In this study, about 35 out of 70 patients did not experience 
any adverse event. The most frequent adverse events consisted of mild 
anorexia, right hypochondrial discomfort and low grade fever (13). Although we 
aimed at treating the whole liver, we had a similar observation. Irrespective of 
the relation with the radionuclide therapy, in 19 out of 32 assessable treatment 
sessions a symptom was reported by the patient. In 5 additional treatments, 
only laboratory changes were recorded. In 8 sessions, no changes compared to 
baseline were observed. Sundram et al. reported 2 cases of pleural effusion and 
these were attributed to radiation induced pneumonitis (13). In the present 
study, one patient suffered cough and dyspnea which exacerbated following her 
second treatment and required oral corticosteroid treatment. Similarities with a 
case previously described in the pilot study conducted earlier at our institution, 
are striking. The absorbed cumulative lung doses for both patients were 
estimated to be 10.4 and 11.5 Gy, hence too low to explain this evolution. 
Although is was not clear whether the occurrence of pulmonary symptoms was 
related to the 188Re-HDD/Lipiodol therapy, we advocate that in the future 
particular attention is paid to patients developing pulmonary complaints.  
 
The preliminary response rates point out that the vast majority of patients had 
stable disease according to the RECIST-criteria. However, these results are 
difficult to interpret since most patients were treated early after diagnosis and 
hence, no evidence of rapidly progressive disease could be established at 
inclusion. Moreover, extensive tumor necrosis may not be always be paralleled 
by a reduction in diameter of the lesion (6). In 2 out of 4 subsequently 
transplanted patients in this series over 99% of tumour necrosis was present in 
the explanted liver although assessment by imaging suggested disease 
stabilization. 
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Due to the relatively long half-life and high energy of the gamma-emission of 
131I, 131I-Lipiodol treatment is associated with a hospital stay for up to 7 days in 
certain European countries. Besides the psychological burden for the patient, 
this isolation procedure is an extra cost. The need for rigorous radioprotective 
measures has been a major drawback for the administration of 131I-Lipiodol 
activities exceeding 2.2 GBq. Moreover, for patients listed for liver 
transplantation, prior treatment with 131I-Lipiodol excludes them from the 
waiting list for several weeks (27). In the present study, the patient’s dose rate 
measured at 1 meter dropped below the local limit of 20 µSv/h within 48 hours 
following administration of 188Re-HDD/Lipiodol, allowing a significant shorter 
hospitalization. Subsequent transplantation was allowed for after an interval of 
only 1 week. The shorter stay in the shielded therapy room and the use of on-
site 188W/188Re- generator improved the flexibility in treatment planning.  
 
The labeling yield of 188Re-HDD ranges between 50 and 70% and hence, the 
synthesis of activities exceeding 7.0 GBq routinely, poses a problem. A number 
of authors have focused on the development of new derivatives that may be 
produced at higher yields. These include bis-(diethyldithiocarbamato) nitrido 
188Re Lipiodol (188ReN-DEDC) and 188Re-(S2CPh)(S3CPh)2 Lipiodol (188Re-SSS 
Lipiodol). For intra-arterial 188ReN-DEDC treatment, either alone or in 
combination with trans-arterial chemo-embolization, feasibility was shown in a 
series of 9 patients. However, some unexplained spleen and bone marrow 
uptake was observed 20 hours post-injection and 1 patient suffered grade 4 
myelosuppression. Data on 188Re-SSS Lipiodol in HCC patients are currently 
lacking (28,29). 
 
Future work should focus on the optimization of the radiolabeling procedure of 
188Re-HDD/Lipiodol. Attempts should be made to elucidate various issues 
concerning the long term effects of cumulative treatment on the liver and lung 
tissue. In addition, efforts should be made in these studies to perform SPECT-
tumor dosimetry. 
 
 
CONCLUSION 
 
Activities ranging from 4.8 up to 7.0 GBq 188Re-HDD/Lipiodol were administered 
to 28 patients in 35 treatment sessions. Urinary excretion eliminated 41.7% (± 
9.7) of the injected activity within 46 hours (± 9.6) after administration and did 
not differ significantly between the activity levels. The mean absorbed dose to 
the liver including the tumor was 7.6, 9.8 and 15.2 Gy for the 4.8, the 5.9 and 
the 7.0 GBq patient group respectively, whereas the mean lung doses resulted 
in 5.3, 6.8 and 8.9 Gy. The mean whole body doses for the different activity 
levels resulted in 0.6, 0.7 and 0.9 Gy. Treatment was well tolerated at all 
activity levels, without the occurrence of unacceptable adverse events. Further 
escalation of the administered activities was limited by technical reasons related 
to the radiolabeling procedure.  
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ABSTRACT  
 
This study aimed to investigate the feasibility of the intra-arterial administration 
of 3.7 GBq 188Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-
decanethiol/Lipiodol (188Re-HDD/Lipiodol) for treatment of hepatocellular 
carcinoma (HCC) in patients with moderately advanced cirrhosis. Methods: 
Patients with HCC and underlying cirrhosis classified as Child-Pugh B in terms of 
severity were eligible. Whole body scintigraphies were performed at 4 time 
points post-injection. Absorbed doses to the various organs were calculated 
according to the MIRD-formalism. Urine was collected for 52 hours following 
injection. Toxicity was assessed until 6 weeks post-administration by means of 
the Common Toxicity Criteria for Adverse Events version 3.0 scale. Responses 
were evaluated on MRI and by alpha-fetoprotein (AFP) monitoring. Results: A 
mean activity (±SD) of 3.7 ± 0.2 GBq 188Re-HDD/Lipiodol was administered in 
the hepatic artery to 12 patients. 36.2% ± 5.7 of the activity was excreted in 
the urine 52 hours post-injection. The mean absorbed dose to the liver, lungs, 
kidney and thyroid was respectively 7.6 ± 2.9 Gy, 4.8 ± 2.6 Gy, 0.8 ± 0.7 Gy 
and 0.2 ± 0.1 Gy. Two weeks following administration 6 out of 12 patients 
suffered from adverse events consisting of aggravations of pre-existing 
laboratory changes (3 patients), fatigue (2), vomiting (1), fever (1), 
encephalopathy (1) and ascites (1). Toxicity assessment at week 6 revealed 
single cases of worsening of hyperbilirubinaemia, pleural effusion, 
thrombocytopenia and dyspnea. Three patients dropped out because of 
deterioration of their general condition. The response was assessable by MRI in 
8 patients: one case of partial response and 7 cases of stable disease were 
reported. Nine patients with an initially elevated AFP were evaluated. Stable 
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 AFP was recorded in one patient and 3 showed a reduction, whereas a 
considerable increase was observed in 5 patients. Conclusion: Following the 
administration of 3.7 GBq 188Re-HDD/Lipiodol, half of the Child-Pugh B patients 
in the present study suffered a worsening of their general condition or 
aggravation of pre-existing symptoms. This was associated with a rise in AFP in 
a considerable number of patients. In the future, administration of the 
radiopharmaceutical as close to the tumor feeding arteries as possible, might 
avoid further deterioration of the liver function and show enhanced antitumoral 
activity.  
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 INTRODUCTION  
 
Hepatocellular carcinoma (HCC) is a malignant epithelial tumor arising from 
parenchymatous liver cells (1). It is one of the world’s most common 
malignancies, causing almost one million deaths annually (2). The major risk 
factor for HCC is cirrhosis. All types of cirrhosis predispose to HCC, but the 
incidence is particularly high in persistent infection with hepatitis B and hepatitis 
C, and in alcoholic liver disease (3). Only a minority of patients presenting with 
HCC fulfill the eligibility criteria for curative surgery, either partial liver resection 
or liver transplantation. Local ablative therapies such as Percutaneous Ethanol 
Injection (PEI), Radio Frequency Ablation (RFA), and Trans Arterial Chemo 
Embolization (TACE) have proven to be useful in selected patients and are 
mainly applied to offer palliation or as bridging strategies in patients awaiting 
liver transplantation (4,5).  
 
Lipiodol is a mixture of iodized ethyl esters of the fatty acids of poppyseed oil. 
Injection of Lipiodol in the hepatic artery of HCC patients results in a selective 
and prolonged retention within the tumor. While Lipiodol alone does not appear 
to have any significant anti-cancer effect in hepatoma cells, radiolabeled 
Lipiodol has proven to be toxic for hepatoma cells (6). To date Lipiodol has 
been radiolabeled and clinically evaluated for the treatment of HCC respectively 
with Iodine-131 (131I) and Rhenium-188 (188Re). When compared to 131I, 188Re 
presents several advantages for radionuclide therapy. 131I has a long physical 
half-life of 8.03 days and emits a high energetic gamma-ray of 364 keV, with an 
abundance of 82% necessitating delayed hospitalization for radioprotection 
purposes. 188Re emits a gamma ray of 155 keV at an abundance of 15%, which 
allows for imaging and limits radiation protection problems. The maximum β-
energy of 131I is only 606 keV, whereas in 188Re β-particles are emitted with a 
maximal energy of 2.1 MeV. As a result, the maximum range of the high-energy 
188Re β-emission is about 3 times longer compared to 131I (maximum range in 
water: 2.9 and 10 mm for 131I and 188Re respectively) (7). Furthermore, the 
radionuclide is eluted from a 188W/188Re-generator, which has a long useful 
shelf-life of several months and provides a good yield of carrier-free 188Re 
routinely (8).  
 
The first clinical results using 188Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-
1,10-decanethiol/Lipiodol (188Re-HDD/Lipiodol) were reported by Sundram et al. 
(9,10). The radiopharmaceutical was administered as close to the tumor 
feeding artery as possible and the administered activity was defined individually 
according to the findings following a scout dose administration. Tolerance was 
excellent. In a pilot trial conducted by Lambert et al. a fixed activity of 3.6 GBq 
188Re-HDD/Lipiodol was used and in patients with well compensated cirrhosis a 
further escalation of the activity seemed feasible (11). To date no studies have 
been conducted to define the tolerance of 188Re-HDD/Lipiodol in patients 
suffering HCC with a moderately advanced underlying cirrhosis. The aim of the 
present study was to investigate the feasibility of 188Re-HDD/Lipiodol treatment 
for patients suffering a Child-Pugh B degree of liver cirrhosis. A secondary end 
point was response assessment.  
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 MATERIALS AND METHODS 
 
Synthesis and Quality Control of the Radio-conjugate 
188W/188Re-generators were purchased from the Oak Ridge National Laboratory, 
(Tennessee, USA) and the IRE (Institut des Radio-Eléments, Fleurus, Belgium). 
Lyophilised kits containing a HDD-chelator (4-hexadecyl-1-2,9,9-tetramethyl-
4,7-diaza-1,10-decanethiol) were provided by the Seoul National University 
Hospital and 188Re- HDD/Lipiodol was synthesized as described earlier (12). 
Briefly, the concentrated eluate (6 mL) from a commercially available 
188W/188Re-generator containing 11.1 GBq, was heated with the HDD/SnCl2 kit 
at 100°C for 1 hour to produce 188Re-HDD complex (13). 3 mL of Lipiodol was 
added and mixed on a vortex to extract the 188Re-HDD into the Lipiodol. After 
centrifugation at 4000g the 188Re-HDD/Lipiodol fraction was separated. Finally, 
the 188Re-HDD/Lipiodol layer was washed with a 0.9% NaCl solution. Quality 
control was performed according to the method described by Jeong et al. by 
ITLC (ITLC-SG plates, Gelman Sciences, mobile phase: 0.9% NaCl and Acetone) 
(14). The total radiochemical yield was 50% ± 9 %. Radiochemical purity was 
in all cases higher than 95%.  
 
Patient Selection  
The diagnosis of HCC was established by means of biopsy or conventional 
imaging techniques such as Computed Tomography (CT)-scan, Magnetic 
Resonance Imaging (MRI) and arteriography, eventually in conjunction with a 
serum alpha-fetoprotein (AFP) level exceeding 400 ng/ml (5). For lesions 
smaller than 2 cm, 2 radiologists had to reach a consensus on the diagnosis of 
HCC. The severity of the underlying cirrhosis was assessed by clinical 
examination and laboratory testing one week before treatment. Only patients 
with a Child-Pugh B status according to the Child-Pugh scoring for cirrhosis 
were included in this study (Table 1) (15). The modified Child-Pugh 
classification system has been widely used in both alcoholic and nonalcoholic 
cirrhosis for assessment of severity of liver impairment and one-year mortality 
based on the degree of ascites and encephalopathy, serum concentration of 
bilirubin, albumin and prothrombin time. Child-Pugh grade A cirrhosis is 
considered as well-compensated disease whereas a Child-Pugh B score reflects 
a significant functional compromise. Patients suffering Child-Pugh C cirrhosis 
have decompensated disease with a median survival less than one year (16).  
 
Exclusion criteria were: eligibility for liver resection, pregnancy and breast 
feeding, age <18 years, poor general condition (Karnofsky <70%), white blood 
cell count <1500/µl and potentially toxic anticancer treatment in the preceding 
6 weeks. Contra-indications for the arteriography consisted of: serum creatinine 
level >2 mg/dl, prothrombin time <50 % of the normal value or platelet count 
<50 000/µl. In order to comply with the radioprotective guidelines, inability of 
self-care and incontinence were additional contra-indications. The study was 
approved by the institutional ethics committee and an informed written consent 
was obtained from all patients. 
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 TABLE 1: Child-Pugh classification 
5-6 points is scored as Child-Pugh A cirrhosis, 7-9 points is scored as Child-Pugh 
B and 10-15 as Child-Pugh C degree of cirrhosis.  
 
 1 point 2 points 3 points 
Bilirubin (mg/dL) <2 2-3 >3 
Albumin (g/dL) >3.5 2.8-3.5 <2.8 
Ascites no slight moderate 
Encefalopathy no grade I- II grade III-IV 
Protrombin Time 
% 
INR 
 
>60 
<1.7 
 
40-60 
1.7-2.3 
 
<40 
>2.3 
 
Administration 
Under local anesthesia, a 5 French diagnostic Cobra catheter was inserted 
transfemorally by Seldinger technique. First the portal vein was evaluated by 
catheterization of the superior mesenteric artery performing a 
mesentericoportography. Then a diagnostic hepatic arteriogram was obtained 
by catheterization of the coeliac trunc and common hepatic artery. Afterwards 
the diagnostic catheter or a microcatheter was introduced in the proper hepatic 
artery, and approximately 4 ml of 188Re-HDD/Lipiodol was injected slowly under 
fluoroscopic control. Whenever aberrant arterial supply was present, the radio-
conjugate was injected selectively into the right and left hepatic artery 
separately. The volume of 4 ml was divided over the different hepatic arteries 
proportional to the volume of liver parenchyma supplied by the respective 
artery. To reduce uptake of free perrhenate in the thyroid or gastric mucosa, 
patients received 0.5 gram sodium perchlorate orally prior 188Re-HDD/Lipiodol 
administration followed by 1 gram daily until discharge.  
 
Pharmacokinetic and Dosimetric Study 
Following 188Re-HDD/Lipiodol administration, patients were hospitalized in a 
dedicated radionuclide therapy room for 3 to 4 days. Four whole body 
scintigraphies (±SD) were acquired at 2.1 ± 1.7, 22.7 ± 1.2, 28.9 ± 2.1 and 60.1 
± 8.2 hours after administration, using a double or triple headed gamma 
camera (AXIS® respectively IRIX®, Philips, Eindhoven, The Netherlands) 
equipped with medium energy parallel hole collimators. The imaging window 
was set at 155 keV (± 20%). Scan speed varied from 30 to 10 cm/minute 
depending upon the time elapsed since administration. Regions of interests 
(ROIs) were drawn around the total body, the liver (including tumor), the 
lungs, a background region and a syringe containing a known activity of 188Re 
(mean activity ± SD: 16.0 ± 1.9 MBq). The background corrected geometric 
mean of the total counts in the ROIs was used to calculate the total amount of 
activity in these regions, using the known activity in the syringe and 
experimental factors determined on an antropomorphic phantom (Alderson 
Heart/Thorax SPECT phantom) for the conversion of the syringe activity into 
organ activity (Figure 1). In the latter conversion factors, the attenuation and 
scatter effects in this standard phantom were taken into account. The overall 
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 uncertainty using this methodology for the activity calculation was less than 
18%. Mono-exponential time activity curves were generated for the total body, 
the liver and lungs using SPSS 10.0 software and source organ residence times 
were determined. Absorbed doses to the various organs were calculated 
according to the Medical Internal Radiation Dose (MIRD) formalism (17).  
Urine was collected for 52 hours and samples were analyzed in a NaI(Tl) 
3”x3”gamma well counter calibrated for 188Re (Cobra II, Perkin Elmer, USA). 
The patient’s dose rate was regularly measured at 1 meter distance of the liver 
region using a survey meter.  
 
FIGURE 1: Anterior (A) and posterior (B) view of a whole body scintigraphy 
(patient number 12) 28 hours following administration of 3.7 GBq 188Re-
HDD/Lipiodol. Part (C) illustrates the ROI-definitions on the geometric mean 
combination of the posterior and anterior view: liver (1), lungs (2), whole body 
(3), background to the liver (4), background to the lungs (5). 
 
 
 
Toxicity and Response Assessment 
Laboratory testing of red and white blood cells and platelets, liver function, 
renal function and serum AFP were performed one week before treatment, at 
discharge and 2 and 6 weeks post-injection. Laboratory findings were compared 
by means of Friedman statistical testing and the significance level was set at P 
<0.05 (SPSS version 10.0). Clinical evaluation of toxicity was performed daily 
during hospitalization and 2 and 6 weeks later. Toxicity was scored by means of 
the Common Toxicity Criteria (Common Toxicity Criteria for Adverse Events, 
Version 3.0. Cancer Therapy Evaluation Program.). Radiological response was 
assessed by means of the RECIST response criteria on MRI images acquired 6 
weeks following treatment (18). Patients without evidence of progressive 
disease were eligible for repetitive treatment sessions with a 12 week interval.  
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 RESULTS 
 
Twelve patients underwent a single treatment session. The mean administered 
activity per session was 3.7 ± 0.2 GBq (± SD). Patient characteristics are 
summarized in Table 2. The mean age was 63 years and the sex ratio was 9 
males versus 3 females. Four patients presented with portal vein thrombosis 
(PVT) on arteriography. Okuda and Cancer of the Liver Italian Program (CLIP) 
scores are prognostic staging systems for HCC. Prognosis worsens with 
increasing scores (19,20).  
 
Pharmacokinetic and Dosimetric Study 
Urinary excretion was measured in all patients and 36.2% ± 5.7 (±SD) of the 
administered activity was excreted within 52 hours post-injection. Due to 
technical problems, data sets for calculation of the absorbed doses to the 
organs were complete in 6 out of 12 patients (Table 3). Effective half-lives for 
whole body, liver and lungs were respectively 15.1 ± 1.2 h, 16.2 ± 0.3 h and 
16.4 ± 0.2 h. In all patients, the dose rate at 1 meter dropped below 20 µSv/h 
within the first 24 hours following administration and did not exceed 5µSv/h on 
day 2.  
 
TABLE 2: Patient characteristics 
Risk factors: chronic hepatitis C infection (HCV), alcohol (ALC), 
hemochromatosis (HC), none (NO). Recent previous treatment: none (NO), 
radionuclide therapy by means of 131I-Lipiodol (I131) or 188Re-HDD/Lipiodol 
(Re188), trans-arterial chemo-embolization (TACE). * Patients included in initial 
phase I study (11) 
 
Nr Age 
(years) 
Sex Risk 
Factor 
Child-
Pugh 
score
Okuda 
score 
(I-III) 
CLIP 
score  
(0-6) 
PVT Previous     
treatment 
(interval in 
weeks) 
1*  70 M HCV B9 II 2 NO NO 
2*  71 M ALC B9 II 3 NO I131 (16 w) 
3  60 M NO B7 I 2 NO chemotherapy 
IV (22 w) 
4  61 F HCV B9 II 3 NO Resection 
(56 w) 
5  48 M ALC B7 I 3 NO tamoxifen 
6  77 M NO B7 II 2 YES NO 
7 75 M ALC B8 II 3 YES NO 
8 59 F HCV B7 II 2 NO NO 
9  54 M HC, ALC B9 II 4 YES NO 
10  68 F ALC B7 I 4 YES I131 (12 w) 
11  44 M HCV B7 II 2 NO TACE (22 w) 
12* 72 M HCV B7 I 1 NO Re188 (18 w) 
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 TABLE 3: Mean absorbed dose estimations of 6 patients after treatment with 
3.6 ± 0.2 GBq 188Re-HDD/Lipiodol. 
ULI (upper large intestine) LLI (lower large intestine) 
 
 
Absorbed Dose (Gy) Target Organ 
Mean SD Range 
Liver 7.6 2.9 4.6– 11.8 
Lungs 4.8 2.6 1.7 – 10.4 
ULI Wall 0.6 0.4 0.2 – 1.4 
Kidneys 0.8 0.7 0.2 – 1.6 
Stomach 0.3 0.1 0.1 – 0.4 
LLI Wall 0.3 0.1 0.1 – 0.4 
Thyroid 0.2 0.1 0.1 – 0.4 
Red Marrow 0.3 0.1 0.1 – 0.4 
Whole body 0.6 0.1 0.5 – 0.7 
 
 
 
Toxicity  
Table 4 summarizes the adverse events according to the Common Toxicity 
Criteria version 3.0. Only the events reflecting a worsening compared to the 
baseline values are tabulated. Four patients dropped out for response 
assessment 6 weeks following treatment: patient number 2 received a liver 
transplantation at week 5 and patients number 5, 7 and 10 did not attend 
follow-up visits at week 6 due to a worsening of their general condition. Seven 
patients experienced a severe adverse event, consisting of a grade 3 or 4 
event. In three cases this event was associated with a rising tumor marker and 
thus the relation to the radiopharmaceutical remains unclear. Two patients 
suffered a severe aggravation of their jaundice. Patient number 10 developed 
rapidly progressive ascites at week 2. She could not attend further follow-up 
visits and died 8 weeks following treatment. Patient number 12 suffered mild 
dyspnea and coughing following his first treatment with 188Re-HDD/Lipiodol, 
which was performed in the framework of a phase I pilot trial conducted earlier 
at our institution. After 18 weeks his tumor marker was rising and his cirrhosis 
had worsened to a Child-Pugh B degree, whereas he initially presented with a 
Child-Pugh A cirrhosis. A second treatment was performed in the framework of 
the present study and his pulmonary symptoms reoccurred. A complete relief of 
the symptoms was achieved with oral steroid treatment. However, the patient 
discontinued the medication and relapsed.  
The most common adverse event during hospitalization consisted of a rise in 
aspartate amino transferase (AST) or alanine amino transferase (ALT). The 
early onset of this phenomenon suggests a relation with the radionuclide 
administration. Friedman statistical testing over the various time points however 
did not reach the level of significance (P <0.05) for any of the tested 
parameters (ALT, AST, gamma-glutamyl transferase, red blood cells, white 
blood cells, platelets, prothrombin time, albumin, total bilirubin and creatinine). 
Values for white blood cells, platelets, bilirubin, ALT and AST at baseline, 
discharge, week 2 and week 6 are depicted in Figure 2. 
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 TABLE 4: Adverse events and changes in AFP level 
Not applicable (NA) 
Patient Adverse event Grade 
pre→ 
post 
therapy 
Attribution 
to investiga-
tional agent 
Change in 
AFP  
1 none   NA 
fatigue (day 2) 0 → 2 possibly 
increase in bilirubin (week 2) 3 → 4 possibly 
2 
increase in AST  
(day 2-week 2) 
1 → 2 possibly 
+30% (week 
2); drop-out 
(week 6: 
transplanted) 
fever (day 2-3) 0 → 1 probably 
fatigue (week 2) 1 → 2 possibly 
increase in bilirubin (week 2) 2 → 3 possibly 
3 
increase in bilirubin (week 6) 2 → 4 possibly 
NA 
vomiting (day 0) 0 → 1 probably 
fever (day 0) 0 → 1 probably 
AST elevation (day 2) 2 → 3 probably 
hypoalbuminmia  
(day 2-week 2) 
1 → 2 possibly 
4 
ascites (week 6) 0 → 1 possibly 
+68%  
(week 6) 
5 AST elevation  
(day 2-week 2) 
3 → 4 possibly NA 
drop-out 
(week 6: 
worsening 
general 
condition) 
6 none   +69% (week 
6) 
7 encephalopathy (day 1) 0 → 2 possibly +25% (week 
2); drop-out 
(week 6: liver 
failure) 
8 pleural effusion (week 6) 2 → 3 unlikely -43% (week 6)
ALT elevation (day 2-week 6) 1 → 2 possibly 
AST elevation (day 2) 1 → 3 possibly 
AST elevation  
(week 2-week 6) 
1 → 2 possibly 
9 
increase in bilirubin (week 2) 1 → 2 possibly 
+37%  
(week 6) 
10 ascites (week 2) 0 → 3 possibly stable (week 
2); drop-out 
(week 6: liver 
failure) 
11 increase in bilirubin (week 6) 1 → 2 possibly -63% (week 6)
leukopenia (week 2-week 6) 0 → 1 probably 
thrombocytopenia (week 6) 1 → 3 probably 
cough, dyspnea,  
pulmonary fibrosis (week 6) 
1 → 2 possibly 
12 
reduced carbon monoxide  
diffusion capacity  
2 → 3 possibly 
-23% (week 6)
75  
 FIGURE 2: Changes in white blood cells (A), platelets (B), bilirubin (C), AST (D) 
and ALT (E) over time. 
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 Response  
     Response on MRI. Four patients dropped out for response assessment. 
One patient (patient number 8) presented with 2 small tumors measuring 1.9 
and 1.8 cm on MRI. On arteriography hypervascular blushes were obvious but 
CT-scan two weeks following Lipiodol administration failed to show prolonged 
uptake of Lipiodol in the lesions. In this patient a partial response was obtained 
with no evidence of HCC lesions on subsequent imaging. AFP dropped from 45 
to 26 ng/ml. This patient underwent a liver transplantation 12 weeks following 
radionuclide therapy and no neoplastic lesions were found in the explant liver. 
The remaining 7 patients had stable disease.  
  Response on AFP. Changes in tumor marker are listed in Table 3. In 9 
patients AFP levels were elevated prior to treatment. In 3 out of 9 treatment 
sessions a reduction in tumor marker (range 23-63%) was recorded 6 weeks 
later, but this was not observed in patients with baseline AFP-levels exceeding 
400 ng/ml. Five patients showed a considerable rise in their tumor marker at 
follow-up visits 2 or 6 weeks following therapy. 
 
 
DISCUSSION  
 
Available literature concerning radionuclide therapy for HCC comprise reports of 
mixed patient populations of mainly Child-Pugh A and B patients and do not 
allow for conclusions focusing on Child-Pugh B patients in particular 
(9,10,21,22). Available data concerning other locoregional treatment strategies 
for HCC as well are limited to patients with a well compensated liver cirrhosis. 
In a meta-analysis conducted by Llovet et al. TACE with cisplatin or doxorubicin 
was reported to improve 2-year survival. (23) This publication confirmed TACE 
in its role of standard treatment for inoperable HCC. However, the randomized 
controlled trials taken into account in this meta-analysis consisted of 70 up to 
100% Child-Pugh class A patients. Hence, its conclusions should be interpreted 
with caution if patients with advanced underlying liver dysfunction are 
considered. Best results were obtained in patients that underwent repeated 
TACE. Llovet and coworkers suggested that repeated treatment sessions are 
often only feasible in patients with a well preserved liver function, in whom the 
anti-tumoral effects are not offset by its toxic effects on the liver parenchyma. 
Although the present study design allowed for repeated 188Re-HDD/Lipiodol 
administrations with 12 week intervals, the majority of the patients were not 
eligible for repeated treatment, due to a worsening of their general condition. 
These findings probably reflect a poor tolerance or lack of anti-tumoral effect in 
this patient group.  
 
Sundram et al. reported 2 cases of pleural effusion and these were attributed to 
radiation induced pneumonitis (10). In our study patient number 12 developed 
grade 3 lung toxicity. The absorbed cumulative lung dose of was estimated to 
be 10.4 Gy, hence too low to explain this evolution. The timing of the 
occurrence of his symptoms and the associated bone marrow depression are 
suggestive for an increased sensitivity to ionizing radiation in this patient (11). 
Although a causal relationship is not clear, it is recommended that patients 
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 developing pulmonary complaints following 188Re-HDD/Lipiodol therapy are not 
eligible for repeated treatment sessions. Other adverse events in this series 
were related to underlying liver dysfunction and considering the features of this 
specific patient population, it is difficult to assess the cause of these adverse 
events: progressive underlying cirrhosis, tumor growth as well as toxicity due to 
the treatment may explain further liver decompensation. Even in patients with a 
rise in AFP, other factors than tumor progression might explain the occurrence 
of adverse events. A transient increase in AFP was documented following 
radiotherapy for HCC by Zeng and coworkers and was thought to reflect tumor 
repopulation. On the other hand, liver regeneration is a well known cause of an 
unspecific rise in AFP (24).  
 
Urinary excretion in the present study was comparable with earlier findings in a 
group of patients with well compensated cirrhosis. ITLC analysis showed that 
the activity in the urinary samples was perrhenate (11). The absorbed doses to 
liver, lungs and thyroid were compared with the dose estimates obtained in a 
group of 14 Child-Pugh A patients treated with the same activity at our 
institution. No significant difference in dose estimates between Child-Pugh A 
and B patients were found (Mann-Whitney statistical test, SPSS version 10.0, P 
<0.05) and hence, it is unlikely that the occurrence of adverse events was 
related to different distribution or elimination in Child-Pugh B patients.  
In contrast to the initial experiences in patients with a well preserved liver 
function, the present findings concerning patients suffering moderately 
advanced cirrhosis do not support further evaluation of administration of 3.7 
GBq 188Re-HDD/Lipiodol in the proper hepatic artery or both left and right 
branch. A hyperselective approach, consisting of injecting the 
radiopharmaceutical as close to the tumor feeding artery as possible, might 
avoid further liver decompensation and induce an enhanced antitumoral effect. 
As the case for local ablative techniques like PEI and RFA, development of HCC 
lesions in untreated segments remains a risk in such a strategy (23). Therefore 
part of the activity could be given in the proper hepatic artery and the rest of 
the activity could be administered as hyperselective as possible. Future research 
should elucidate whether modified administration protocols yield better results.  
 
 
CONCLUSION 
 
Following the administration of 3.7 GBq 188Re-HDD/Lipiodol in 12 patients 
suffering moderately advanced cirrhosis, 36.2% ± 5.7 of the injected activity 
was renally excreted within 52 hours post injection. The mean absorbed dose to 
the liver, lungs, kidney and thyroid was respectively 7.6 ± 2.9 Gy, 4.8 ± 2.6 Gy, 
0.8 ± 0.7 Gy and 0.2 ± 0.1 Gy. 
Treatment was well tolerated in 5 out of 12 patients. Seven patients suffered a 
worsening of their general condition, an aggravation of pre-existing symptoms 
or severe laboratory abnormalities. This was associated with a rise in AFP in a 
considerable number of patients. The results of the present feasibility study do 
not support further evaluation of the administration of 3.7 GBq 188Re-
HDD/Lipiodol in the proper hepatic artery or both right and left hepatic artery. 
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 In the future, administration of the radiopharmaceutical as close to the tumor 
feeding arteries as possible, might avoid further deterioration of the liver 
function and show enhanced antitumoral activity.  
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ABSTRACT 
 
Background: Liver transplantation has become an important curative treatment 
option for hepatocellular carcinoma (HCC). Criteria for transplantation are strict 
and therefore it is crucial that patients awaiting transplantation do not suffer 
disease progression. One of the therapeutic options to achieve disease 
stabilization is neoadjuvant radiolabeled Lipiodol treatment. The present study 
aimed to document the drop-out rate on the waiting list, the pathological 
findings on the explant livers and the long term outcome of patients treated 
with radionuclide therapy while awaiting transplantation. Methods: Patients 
eligible for transplantation were treated with 2.1 GBq 131I-Lipiodol or 4.1 GBq 
188Re-HDD/Lipiodol by transfemoral catheterisation of the hepatic arteries. 
Tumor necrosis was assessed in the explant livers and follow-up data such as 
drop-out from the waiting list, recurrence and survival following transplantation 
were retrospectively documented. Results: In 5 out of 22 explants necrosis 
exceeded 90%. Two patients died while on the waiting list (10%) and 4 out of 
20 transplanted patients (20%) suffered recurrent disease. The overall 
recurrence free survival was 19.7 months (range 1.75-56) with a mean follow-
up of  20.1 months. Conclusion: Our data support the evaluation on larger 
patient numbers to confirm the benefit of radiolabeled Lipiodol in candidates for 
liver transplantation suffering HCC. 
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 INTRODUCTION 
 
Hepatocellular carcinoma (HCC) is the most prevalent malignant primary liver 
tumor. It constitutes the third cause of cancer related deaths, responsible for 
more than 500 000 deaths worldwide annually (1). At present the mainstay of 
potentially curative strategy for HCC consists of hepatectomy, either a partial 
liver resection or a total removal of the liver, followed by cadaver organ 
transplantation or by living related liver donation. Three major criteria should be 
met, in case partial liver resection is considered: the absence of metastatic 
spread, no bilobar disease, and an adequate liver function afterwards (2). The 
two latter criteria are not essential in case transplantation is an option (3). As 
HCC typically presents late in its natural course, the vast majority of patients 
are not suitable for liver resection.  
Theoretically, liver transplantation is the optimum therapy for HCC, as it 
provides removal of the primary tumor, as well as the cirrhotic parenchyma, 
which is a seed-bed for development of HCC. For advanced disease stages of 
HCC, retrospective analyses have shown poor outcomes after transplantation, 
yielding unacceptable recurrence rates (3). Therefore, strict criteria concerning 
the dimensions and numbers of tumors were advocated and in well selected 
patients survival rates equalled those obtained in patients transplanted because 
of benign liver pathology (4-6). Since tumor size is a very important variable in 
predicting recurrence, it is essential that patients are transplanted before 
progression occurs. The waiting time for a classic liver transplantation in the 
Western world may cause a delay which can allow the tumour to grow to 
stages that contraindicate transplantation and therefore several neoadjuvant 
strategies have been proposed (7,8). 
Chemo-embolization is the most common neoadjuvant treatment but no 
randomized controlled studies have been reported so far to show an effect on 
the outcome (8,9). Using a non-selective arterial instillation, 131I-Lipiodol has 
been found to be equally effective in tumor control but far better tolerated than 
the classical chemo-embolization by cisplatinum, Lipiodol and gelatin-sponge 
fragments in a group of inoperable, palliative patients (10). The initial studies 
using 131I-Lipiodol in a neoadjuvant setting were conducted by Brans et al. and 
by Raoul et al. (11,12). 
The present study aims to report our experiences using radiolabeled Lipiodol for 
disease stabilization in patients awaiting liver transplantation. The drop-out rate 
of patients on the waiting list despite neoadjuvant treatment was calculated. 
Pathological examination of the explant livers was performed in order to 
document anti-tumoral effects of therapy. Clinical follow-up data of the 
transplant patients were retrospectively collected and recurrence rates were 
estimated.  
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 MATERIALS AND METHODS 
 
Patient selection 
The diagnosis of HCC was established on histological examination of biopsy 
specimens or on the radiological appearance of the lesions on imaging, 
eventually in combination with a rise in serum alpha-fetoprotein level. Patients 
were judged unresectable because of co-existing decompensated liver cirrhosis 
and/or multinodular HCC. Before listing for transplantation, metastatic spread 
was ruled out by bone scan, computed tomography scan of the chest and brain. 
Patients undergoing radiolabeled Lipiodol treatment gave written informed 
consent. Patients suffering Child C cirrhosis were not eligible for radionuclide 
treatment. Patients who had other anticancer treatment than radiolabeled 
Lipiodol in their history were excluded from the analysis. 
 
Neoadjuvant treatment 
The 131I-labeled Lipiodol (LipiocisTM) was purchased at CIS bio international (Gif-
sur-Yvette, France) and since 2002, 188Re-HDD/Lipiodol was used. Lyophilized 
kits containing a HDD-chelator (4-hexadecyl-1-2, 9, 9-tetramethyl-4, 7-diaza-
1,10-decanethiol) were provided by the Seoul National University Hospital and 
188Re-HDD/Lipiodol was synthesized as described earlier by Lee et al. (13). After 
selective hepatic catheterisation, a mean activity of 2.1 GBq 131I or 4.1 GBq 
188Re in a total volume of 2-4 ml Lipiodol was instilled in the proper hepatic 
artery or in its right and/or left branches. 
 
Pathology of the explanted livers 
Total hepatectomy specimens were transected in 1 cm thick slices and 
examined by a senior pathologist. Macroscopically, sampling from the explanted 
liver was focused on nodules corresponding to a tumor localization on MRI and, 
routinely of larger sized regenerative nodules in the other segments. Diagnosis 
of HCC was made on histology, depending on lightmicroscopical characteristics 
of cellular growth pattern and nuclear atypia. The number of HCC lesions and 
their size, differentiation, percent of necrosis and presence of microvascular 
invasion was noted.  
 
Assessment of long term outcome  
Follow-up after transplantation was made by control of tumor markers and 
imaging every three months. Survival was calculated from the day of 
transplantation until the date of the last follow-up visit or until death.  
 
 
RESULTS 
 
Between June 1999 and June 2004 37 patients, with biopsy proven HCC or 
lesions suspect for HCC on radiology, were awaiting liver transplantation and 
received neoadjuvant radiolabeled Lipiodol treatment at the Ghent University 
Hospital (Figure1). Nine patients who received other anti-cancer treatment 
modalities prior to radionuclide therapy, were excluded from further analysis. 
Twenty-eight transplant candidates were exclusively pretreated by radiolabeled 
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 Lipiodol. The mean age was 62 (range 24-72) years and the group consisted of 
24 males versus 4 females. The vast majority suffered underlying viral hepatitis, 
and to a lesser extend alcohol induced cirrhosis. Three and 21 patients 
underwent one single administration of respectively 188Re-HDD/Lipiodol and 
131I-Lipiodol. Two patients underwent 2 sessions of 131I-Lipiodol and two 
patients received 3 131I-Lipiodol administrations. In 18 patients both lobes were 
treated independent from lesion localisation and in 10 patients only the affected 
lobe was treated. The median interval between the last radiolabeled Lipiodol 
administration and the transplantation was 101 days (range 32-320). 
 
Drop-out ratio on the waiting list for transplantation  
Two patients underwent a cadaveric transplantation without being listed 
according to the classic eligibility criteria (so called “special request” cadaveric 
transplantations) and 6 patients received a split liver from an adult living donor 
and therefore the number of patients at risk to drop out for transplantation was 
20. The average waiting time for classic cadaveric transplantation was 5.8 
months. Two out of 20 patients on the waiting list did not undergo liver 
transplantation because of death caused by non-oncologic reasons and thus the 
drop-out ratio was 10% overall or 1.7 % per month in the subgroup exclusively 
pretreated by radiolabeled Lipiodol.  
 
Pathological examination of the explanted livers 
The diagnosis of HCC was confirmed by histological examination of the explant 
in 22 out of 26 cases. In 4 explants the diagnosis of HCC could not be 
confirmed since no lesions suspect for neoplastic disease were found. In these 
4 cases the diagnosis of HCC was based on the presence of hypervascular 
lesions on imaging which did not exceed the critical diameter of two 
centimetres and hence, the diagnosis is debatable and these patients were 
excluded from further analysis. Lightmicroscopical findings in 22 assessable 
explants are summarized in Table 1. 
 
TABLE 1: Findings on pathology in explants with unequivocal diagnosis of HCC.  
 
Mean number of tumors (range) 2.0 (1-7) 
Mean diameter of largest tumor (range) 3.0 cm (0.6-8.0) 
Tumor cell differentiation according to 
Edmondson’s grading 
I 
II 
III 
IV 
Not assessable 
1 
8 
7 
4 
2 
Necrosis (%) in largest lesion  0-50% 
>50-90% 
>90-100% 
13 
4 
5 
Presence of microvascular invasion 6/22 
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 Long term follow-up 
Two patients died in the peri-operative phase due to surgical complications. 
Four out of 20 patients with histological diagnosis of HCC (20%), suffered 
recurrent disease after a mean disease free interval of 6.9 months (range 1.75-
16). One patient suffered recurrent intrahepatic disease. Two patients 
developed pulmonary metastasis several months following transplantation and 
one patient was diagnosed with cutaneous metastasis. The overall recurrence 
free survival was 19.7 months (range 1.75-56) with a mean follow-up of  20.1 
months. The estimated risk for recurrence was 11.9% per patient year. Six 
patients received a liver transplantation although their tumor load exceeded the 
criteria concerning size and number of the tumors described by Mazzaferro et 
al. and among these patients only one case of recurrent disease was observed 
(4). 
 
FIGURE 1: Flowchart depicting the evolution of 37 patients treated by means of 
radiolabeled Lipiodol while awaiting liver transplantation (Tx). 
 
28 patients exclusively pretreated by 
means of radiolabeled Lipiodol; 
 
(20 patients listed for  classic 
cadaveric Tx ) 
2 patients died while on
the waiting list 
26 patients underwent Tx: 
18 classic cadaveric Tx in listed patients,  
2 special request cadaveric Tx,  
6 living related liver donations  
4 explant livers without 
confirmed diagnosis of HCC  
22 explant livers with 
confirmed diagnosis of HCC  
2 deaths post-operatively 20 patients assessable for 
long term outcome  
4 patients suffered recurrent disease  
9 patients excluded due to other 
treatment modalities prior to 
radiolabeled Lipiodol treatment  
37 patients pretreated by means of radiolabeled Lipiodol
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 DISCUSSION  
 
Encouraging survival data on liver transplantation for treatment of early HCC 
have emerged the last decade. However, the shortage of donor organs and the 
increasing demands cause waiting times of more than 6 months in some parts 
of Europe and the USA. Several authors have shown that waiting times 
exceeding 6 months are associated with more than 15% rate of drop-out from 
the waiting list, and drop-out rates may reach 50% if expanded criteria are 
applied (14). In general, the risk for drop-out while awaiting liver 
transplantation is assumed to be about 4% per month (15). Even after 
correction for the 4 cases without histological diagnosis of HCC, a  considerably 
lower drop-out ratio (2.2% per month or 12.5% over 5.8 months) was obtained 
in the present series.  
 
Four out of 26 assessable explants (15%) did not reveal any neoplastic nor 
completely necrotic lesion. In these patients the pre-operative findings did not 
fulfil the classic diagnostic criteria of HCC, hence the diagnosis of HCC remains 
questionable. Earlier explant assessment reports have shown that false positive 
diagnosis despite state of the art imaging occurs in 9 up to 31% of transplant 
candidates depending on the tumor stage (16). It is unclear whether a complete 
response following radionuclide therapy occurred in our series or whether the 
exposition to ionizing irradiation should have been avoided. In 22 explants with 
clear evidence of HCC, at least 90% of the tumor was necrotic in 23% of the 
explants. This compares favorably with the findings in a historical control group, 
consisting of 19 patients transplanted at our institution with  HCC without pre-
treatment (n=12) or with an incidental finding of a HCC in the explant (n=7). 
Although these patients had comparable tumor characteristics, none showed 
90% or more tumor necrosis. 
 
The mean follow-time of  20.1 months is acceptable since most recurrences are 
expected to occur within the first year following surgery, and to a lesser extend 
the second year (17).  
It is difficult to compare our series in terms of recurrence rates and survival 
with other reports since most series vary in patient characteristics and some 
series comprise incidental HCC, which is thought to have a better prognosis 
whilst others have focussed on more advanced disease stages (6,12,14). 
Reports dating from the early nineties often comprise patients with advanced 
disease stages and recurrence rates following transplantation were as high as 
54%. More recent data suggest recurrence rates of 4-16% following 
transplantation, applying restrictive selection criteria (17). In our series less 
stringent criteria for transplantation were used and this is probably reflected in 
the recurrence rate of 20%. An additional important drawback for assessing the 
impact of strategies for patients awaiting liver transplantation, is the lack of 
controlled studies (18). Moreover, the long term results should be based on an 
intention-to-treat analysis and the true role of neoadjuvant treatment may be 
preventing drop-out in those patients who wait for long periods until 
transplantation (8). 
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 No firm evidence for improved long term outcome to date is available for any 
adjuvant or neoadjuvant treatment strategy (18). Some evidence was 
established for the use of polyprenoic acid and 131I-Lipiodol following partial 
liver resection in prospective randomized trials (19,20). In transplant patients, 
no firm evidence is provided yet and future research should attempt to 
elucidate the role of local, locoregional and systemic modalities. It is assumed 
that tumor cells are present in blood in microscopic quantities and therefore it 
seems reasonable to add systemic treatment during the immediate post-
operative phase. Systemic treatment with limited toxicity, such as polyprenoic 
acid, are probably useful to test in a transplant patients at risk to relapse within 
the first year following surgery. Combined with aggressive local or locoregional 
treatment modalities whilst on the waiting list, this may yield an improved long 
term outcome if based on an intention-to-treat analysis. 
Following 131I-Lipiodol treatment patients were not eligible for surgery for 4 
weeks because of radioprotection issues related to the relatively long physical 
half-life of 131I (8 days). In patients with aggressive tumors, repeated 
radionuclide therapies were indicated and this lead to unacceptable long 
intervals during which the patients were not eligible for curative treatment. 
Because of the high energy of the gamma ray emission of 131I (365 keV) and its 
physical half-life of 8 days, a hospitalization up to 7 days is indicated according 
to the local radioprotective legislation. Considering the limited success of 131I-
Lipiodol for treatment of relatively large tumors, the switch towards 188Re, a 
radionuclide with a higher energy of the beta-emission (2120 keV and 1960 keV 
for 188Re versus 606 keV for 131I) might yield improved response rates. Since 
November 2002, we switched to 188Re-HDD/Lipiodol and the use of 188Re, with 
its physical half-life of 17 hours, avoids most of the radioprotection problems 
and allows a shorter hospitalization as well as further dose escalations (21). 
Following 188Re-HDD/Lipiodol treatment, patients were eligible for 
transplantation after an interval of only one week.  
 
CONCLUSIONS 
 
The drop-out ratio in this patient group exclusively pretreated by means of 
radiolabeled Lipiodol, was 10% and after correction for cases without 
unequivocal diagnosis of HCC on the explant liver,  a drop-out ratio from the 
waiting list of 12.5% or 2.2% per month was calculated.  
On pathology nearly complete or complete necrosis was observed in 23 % of 
assessable explants. Four out of 20 patients (20%) suffered recurrent disease. 
The overall recurrence free survival was 19.7 months (range 1.75-56) with a 
mean follow-up of  20.1 months. Our data support the evaluation on larger 
patient numbers to confirm the benefit of radiolabeled Lipiodol in candidates for 
liver transplantation suffering HCC. 
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ABSTRACT  
 
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the 
world. A wide variety of treatment modalities are available for palliative therapy 
of HCC, although there is no strong evidence that these treatments can have a 
significant impact on survival. The aim of this work was to screen cytotoxic 
drugs, relevant in the treatment of HCC, for enhancement of the effect of 
irradiation in an in vitro model. As the majority of patients presenting with HCC 
suffer a reduced liver function, attention was paid to low dose effects of the 
cytotoxic drugs tested.  
Multicellular tumor aggregates or “spheroids” of HepG2-cells were cultured and 
exposed to gamma irradiation in combination with cisplatin, gemcitabine or 5-
fluorouracil. Toxicity was evaluated by means of comparative growth curves, an 
outgrowth assay and histology. Supra-additive effects lasting for 4 weeks were 
observed for all drugs tested in combination with a gamma irradiation of 10 Gy.  
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  INTRODUCTION 
 
Hepatocellular Carcinoma (HCC) is the most frequently occurring malignant 
tumor in the liver. It is the fifth most common malignancy in men, and the 
eighth most common in women worldwide (1). The high incidence of this 
malignancy in sub Sahara Africa and Southeast Asia can be explained by the 
hepatitis B virus being endemic in these regions. In North America and Europe, 
the main risk factors are chronic Hepatitis C infection and alcohol intake. Over 
80% of patients presenting with HCC suffer from cirrhosis and the reduced liver 
reserve restricts treatment options in this patient group (2). A cure can be 
achieved through partial liver resection or transplantation, although the former 
is only feasible in less than 30% of patients and the latter is restricted by a 
shortage of donor organs (3). A wide variety of locoregional or systemic 
treatment modalities are available in a palliative setting, but there has been 
little evidence of a significant impact on survival (4). As HCC is a chemo- and 
radioresistant tumor, occurring often in patients that already have a reduced 
liver function, a combination of treatment modalities might improve outcome 
and minimize toxicity (5) . 
Locoregional radionuclide therapy by means of intra-arterial injection of 
Lipiocis™ (Schering, Gif sur Yvette, France), a fatty acid mixture labeled with 
Iodine-131 (E β max: 606 keV, E γ: 364 keV, T1/2 phys: 8 days), has yielded 
promising results (6). Phase I clinical studies are being conducted to investigate 
the benefit of adding systemic to locoregional irradiation by Lipiocis™. Cisplatin 
has radiosensitizing capacities and has been shown to have cytotoxic effects in 
monotherapy for HCC (7).  
The objective of this study was to determine whether cytotoxic drugs used for 
the treatment of HCC could enhance the effect of irradiation in vitro. The 
majority of patients that present with HCC suffer a reduced liver function, so 
particular attention was paid to low dose effects of the cytotoxic drugs tested. 
To reflect the in vivo situation, multicellular tumor aggregates or “spheroids” 
were cultured. Spheroids consist of different subregions, varying in the 
availability of oxygen, nutrients, pH, lactate and other substances. These 
factors influence the metabolic and proliferative status of the cells, resulting in 
a viable rim with proliferating cells and less mitotic activity in the deeper layers. 
Sutherland et al. reported that in general most of the proliferating cells are 
located in the outer three to five cell layers (75 µm) whilst quiescent cells are 
located more centrally at a depth of 100-220 µm (8). These often prove viable 
when removed from the deprived environment. Cells at a depth exceeding 160 
µm may become necrotic. As spheroids consist of cell populations with 
variations in their degree of radio-resistance and cell cycle status, this model 
reflects the in vivo situation, such as micrometastasis or microregions within a 
vascularized tumor, more accurately than monolayers (9). 
 
 
MATERIALS AND METHODS 
 
A human cell line, HepG2, derived from a HCC was used to culture the 
spheroids (Bioreliance Ltd., Stirling, Scotland.) After trypsinisation of a 
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 monolayer, spheroids were cultured by continuous gyratory shaking at 70 rpm ( 
Heidolph Instruments, Schwabach, Germany) of a single HepG2-cell suspension 
in DMEM medium supplemented with 10% fetal bovine serum (Gibco, 
Invitrogen Corporation, Merelbeke, Belgium) and 5% CO2 at 37°C in PETG-
flasks (Gosselin, Haezebrouck, France). After 7 to 10 days of shaking the 
spheroids attained a mean diameter of 189 ± 51 µm. 
The spheroids were irradiated at 37°C with Cobalt 60 at a dose rate of 1 Gy per 
minute. Between 10 and 30 Gy were delivered. Three cytotoxic drugs were 
used at several concentrations: cisplatin at 0.1, 0.5 and 1 µg/ml (Platosin, 
Pharmachemie, Haarlem, The Netherlands), gemcitabine at 3 and 30 ng/ml 
(Gemzar, Eli Lilly, Fegersheim, France) and 5-fluorouracil at 50 and 100 µg/ml 
(Fluracedyl, Pharmachemie, Haarlem, The Netherlands). For combined modality 
experimental conditions, a fixed dose of 10 Gy was chosen.  
The induced toxicity was evaluated by measuring the outgrowth potential of 
individual spheroids over 4 weeks. Within 24 hours of treatment, individually 
selected spheroids were placed in 24 well plates coated for cell culture (Becton 
Dickinson Biosciences, Erembodegem, Belgium). The longest diameter and its 
perpendicular are measured using a calibrated ocular micrometer and light 
microscopy. After some days a monolayer, varying in surface area and density, 
is formed by motile and clonogenic cells that surround the original spheroid. 
The longest diameter of the confluent outgrowth surface and its perpendicular 
are measured at 7 day intervals for one month and the outgrowth ratio is 
calculated by dividing the average diameter by the average diameter measured 
on the day of plating. The outgrowth ratios of treated spheroids are compared 
with controls and those exposed to combined treatment to those treated by 
monotherapy using Mann-Whitney statistics. In the case of severe damage to 
the spheroid caused by the experimental conditions, no adherence or a reduced 
monolayer surface or so-called outgrowth surface was observed. An outgrowth 
ratio of one signifies a lack of adherence and a reduced outgrowth potential 
reflects diminished cell motility and clonogenicity (10).  
Growth was also assessed in a three-dimensional model, in which spheroids are 
individually transferred to an elisa-plate (Kima, Piove Di Sacco, Italy). As these 
plates do not permit adherence of the HepG2-spheroid, the growth pattern 
remains spherical in three dimensions. The longest diameter and its 
perpendicular are measured the day of plating and for one week thereafter. 
Some spheroids were selected after three days for histology and morphology 
was assessed by means of hematoxyllin and eosin staining. 
 
 
RESULTS 
 
Sensitivity of HepG2-spheroids to gamma irradiation 
Absorbed doses of 10, 20 and 30 Gy were delivered to the spheroids with 
Cobalt 60-gamma irradiation. A dose of 10 Gy initially induced a reduction in 
the outgrowth of 55% relative to control spheroids but outgrowth fully 
recovered within 4 weeks. Absorbed doses of 20 Gy and 30 Gy caused the 
outgrowth to be only 27% and 1% respectively of that seen in the controls at 
week 4. In Figure1 the median outgrowth ratios are represented over time. 
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FIGURE 1: Median outgrowth ratios following gamma-irradiation (10, 20 and 30 
Gy) represented as a function of time. 
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For cisplatin, a steep dose response curve was observed. Exposure to 0.1 µg/ml 
cisplatin (0.33 µM) over 4 hours induced a slightly reduced growth (P <0.05) on 
the first and second week although the outgrowth subsequently recovered. A 
concentration of 0.5 µg/ml (1.67 µM) cisplatin reduced the outgrowth capacity 
to about one fifth of the normal value (P <0.05), without recovery. After a 4 
hour exposure to 1 µg/ml (3.33 µM) cisplatin, no outgrowth surface was formed 
surrounding the spheroids.  
 
In the case of gemcitabin, concentrations of 3 ng/ml (10 nM) and 30 ng/ml 
(100 nM) were used during a 4 or 24 hour exposure. Only transient and minor 
effects were observed after a 4 or 24 hour exposure to 3 ng/ml gemcitabin. 
However, following a 4 hour exposure to 30 ng/ml gemcitabin the outgrowth 
was reduced significantly during the first three weeks, although the spheroids 
were able to recover at week 4. This was not the case for a prolonged exposure 
of 24 hours to 30 ng/ml of gemcitabine (P <0.05).  
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 Spheroids exposed to 50 µg/ml 5-fluorouracil (0.38 mM) for 4 hours initially had 
a significant outgrowth reduction of 22 to 45% of the normal outgrowth (P 
<0.05) although recovery was seen at week 4. No major addition in toxicity was 
observed after doubling the concentration (0.77 mM) of 5-fluorouracil. 
 
Screening for supra-additive effects of cytotoxic drugs and gamma-
irradiation in HepG2-spheroids  
The addition of concomitant irradiation (10 Gy) to the 0.1 µg/ml cisplatin 
exposure yielded a further reduction of the outgrowth potential on week 2. This 
was observed as a significant supra-additive effect (P <0.05). At later time 
points the outgrowth recovered partially to 44 and 59% at weeks 3 and 4 
respectively (P >0.05). Combined with 0.5 µg/ml cisplatin, the irradiation 
inhibited the outgrowth completely (P <0.05). As a 4 hour exposure to 1 µg/ml 
cisplatin already impeded the formation of an outgrowth surface, no synergy 
could be demonstrated by adding 10 Gy (Figure 2).  
 
FIGURE 2: Median outgrowth ratios following a 4 hour exposure to cisplatin 
with or without concomitant irradiation. Control spheroids (1), 10 Gy (2), 0.1 
µg/ml cisplatin (3), 0.1 µg/ml cisplatin and 10 Gy (4), 0.5 µg/ml cisplatin (5), 
0.5 µg/ml cisplatin and 10 Gy (6), 1 µg/ml cisplatin (7), 1 µg/ml cisplatin and 10 
Gy (8). 
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Hematoxyllin and eosin staining in histological samples of the spheroids 
confirmed the outgrowth assay: changes in the intercellular contacts were 
observed after exposure to 0.1 µg/ml of cisplatin with or without irradiation but 
higher concentrations induced necrosis and significant alterations in 
morphology. Two days after a 4 hour incubation with 1 µg/ml cisplatin, a large 
fraction of the cells became necrotic. As illustrated in Figure 3, the cell density 
was decreased in spheroids exposed to 0.5 µg/ ml cisplatin. Furthermore, 
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 pycnotic nuclei, an increased vacuolization of the cells and a degradation of the 
intercellular contacts were observed. The addition of irradiation generated more 
pronounced changes. 
 
FIGURE 3: Spheroids following various treatments. Control spheroids (A), 
irradiation with 10 Gy (B), exposure to 0.5 µg/ml cisplatin for 4 hours (C) and 
exposure to 0.5 µg/ml cisplatin for 4 hours with concomitant irradiation of 10 
Gy (D). 
 
104  
  
The addition of 10 Gy after a 4 hour incubation with gemcitabin (3 ng/ml) 
induced only a supra-additive effect for the first week (P <0.05). Recuperation 
occurred over the following weeks and was complete at week 4. However, a 
prolonged incubation time of 24 hours at the same low concentration reduced 
the outgrowth to about one third without any recuperation (P <0.05). When the 
concentration of gemcitabin was increased to 30 ng/ml, the irradiated spheroids 
lost their outgrowth potential completely. In this case only 10 % of the normal 
outgrowth occurred during the first week and less than 1 % of the normal 
outgrowth was seen at week 4. Moreover, in the case of exposure to 30 ng/ml 
gemcitabin, the incubation time did not affect the irradiated groups (Figure 4). 
 
FIGURE 4: Exposure to gemcitabin for 4 or 24 hours with or without 
subsequent irradiation. 
Median outgrowth ratios are represented as a function of time. The curves 
shown are for control spheroids (1), irradiation with 10 Gy (2), exposure to 3 
ng/ml gemcitabin for 4h (9), 3 ng/ml gemcitabin for 4h and irradiation with 10 
Gy (10), 3 ng/ml gemcitabin for 24h (11), 3 ng/ml gemcitabin for 24h and 
irradiation with 10 Gy (12), 30 ng/ml gemcitabin for 4h (13), 30 ng/ml 
gemcitabin for 4h and irradiation with 10 Gy (14), 30 ng/ml gemcitabin for 24h 
(15), 30 ng/ml gemcitabin for 24h and irradiation with 10 Gy (16). 
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Irradiation of spheroids after incubation with 50 µg/ml 5-fluorouracil for 4 hours 
induced significant supra-additive effects, lasting until the fourth week. 71% of 
normal outgrowth was achieved in spheroids exposed to chemo alone whereas 
only 18% of normal outgrowth was observed if irradiation was added (P 
<0.05). Similar results are obtained with a concentration of 100 µg/ml (Figure 
5). 
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 FIGURE 5: Exposure to 5-fluorouracil (4 hours) with or without subsequent 
irradiation. 
Median outgrowth ratios are represented as a function of time. Control 
spheroids (1), 10 Gy (2), 50 µg/ml 5-fluorouracil (17), 50 µg/ml 5-fluorouracil 
and 10 Gy subsequent (18), 100 µg/ml 5-fluorouracil (19), 100 µg/ml 5-
fluorouracil and 10 Gy subsequent (20). 
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Spheroids with a reduced outgrowth capacity often expressed morphological 
changes. Qualitative changes after exposure to 100 µg/ml 5-fluorouracil such as 
loose cellular contacts, irregular architecture and a reduced density of the 
surrounding cellular surface are illustrated in Figure 6. 
 
FIGURE 6: Microscopic view (10 x 20) one week after plating in a 24 well plate. 
Control spheroids (A), 10 Gy (B), 100 µg/ml 5-fluorouracil (4 hours) (C), 100 
µg/ml 5-fluorouracil (4 hours) with subsequent irradiation of 10 Gy (D). 
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 Three-dimensional growth results obtained within the first week after plating in 
an elisa-plate did not completely match the outgrowth assay. The irregular 
growth pattern is illustrated in Figure 7 for a series of spheroids exposed to 0.1 
or 0.5 µg/ml cisplatin with or without concomitant irradiation. 
 
FIGURE  7: The mean diameter of the spheroids, plated in an elisa-plate 
expressed as a function of time. Control spheroids (1), 10 Gy (2), 0.1 µg/ml 
cisplatin during 4 hours (3) and 0.1 µg/ml cisplatin for 4 hours with concomitant 
irradiation of 10 Gy (4), 0.5 µg/ml cisplatin for 4 hours (5) and 0.5 µg/ml 
cisplatin for 4 hours with concomitant irradiation of 10 Gy (6). 
 
200
300
400
500
600
700
start day 2 day 3 day 5 day 7
di
am
et
er
 (µ
m
)
1
2
3
4
5
6
 
 
 
DISCUSSION  
 
The three tested drugs are known radiosensitizers, and cisplatin and 5-
fluorouracil are among the most effective agents in the treatment of 
hepatocellular carcinoma. However, objective response rates after systemic 
single-agent chemotherapy remain poor (11). In most instances response rates 
do not exceed 20% and a median survival of only 4 months is achieved (12). 
Gemcitabin has so far only been used for the treatment of HCC in phase II 
clinical trials, but its use in monotherapy is not recommended (13). More 
encouraging response rates of up to 50% were obtained after intra-arterial 
administration of single-agent chemotherapy (14). For sustained locoregional 
drug delivery the chemotherapeutic agent may be mixed in Lipiodol, a fatty acid 
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 mixture retained in malignant hepatocellular cells. This treatment modality has 
yielded promising results (15), but the clinical use of so-called chemo-
embolization is still under debate as considerable toxicity has been reported 
(16).  
 
An alternative treatment modality consists of the intra-arterial administration of 
Lipiocis™ (Schering, Gif sur Yvette, France), Lipiodol labeled with Iodine-131 
(6,17). In a randomized trial conducted by Raoul and coworkers Iodine-131 
labeled Lipiodol and chemoembolization (70 mg cisplatin mixed in Lipiodol) 
appeared equally effective in terms of patient survival and tumor response, but 
tolerance to 131I-labeled Lipiodol was significantly better (16).  
Although overall long-term survival remains poor, a combination of treatment 
modalities could result in improvement of outcome without induction of severe 
toxicity (5). Phase I clinical studies are being conducted to investigate the 
benefit of adding systemic cisplatin to locoregional irradiation by Lipiocis™ (7) 
and 5-fluorouracil and cisplatin were used with concurrent external beam 
irradiation (18). Of particular interest at present are Lipiodolized emulsions that 
remain in the tumor for long periods and release drugs in a sustained pattern. A 
wide variety of cytostatic drugs have been mixed successfully in Lipiodol which 
can also be radiolabeled with Iodine-131 or Rhenium-188, radionuclides that 
are routinely used in targeted radionuclide therapy (19-21).  
 
The radiosensitizing capabilities of the tested agents are clearly demonstrated 
in the outgrowth assay for a 4 hour incubation with 0.5 µg/ml cisplatin, a 24 
hour incubation with 3 ng/ml gemcitabine, a 4 hour incubation with 30 ng/ml 
and for 50 and 100 µg/ml exposure to 5-fluorouracil. For cisplatin and 
gemcitabin in particular, these doses are low compared to the safe plasma 
concentrations of these drugs in human use. The effect of 0.1 µg/ml cisplatin 
did not yield a sustained enhanced response to irradiation, whereas the effect 
of 1 µg/ml was too toxic to allow demonstration of an additive or supra-additive 
effect. In the case of gemcitabin, the incubation time played a crucial role in the 
outgrowth capacity. Similar observations have already been reported for other 
cell lines (22). In contrary to the two other drugs tested, there was no 
significant increase in toxicity after increasing the concentration of 5-fluorouracil 
as previously demonstrated for Hep G2 cells by Chenouffi et al (23).  
The results of the three-dimensional growth curves are not completely 
consistent with the outgrowth assay. This can partly be explained by the poor 
prediction of normal growth patterns of multicellular tumor spheroids using 
traditional continuous growth models (24) and by the results of histological 
examinations, showing a reduced cell density in heavily exposed spheroids.  
The follow-up period of one week is possibly too short to assess recovery from 
growth inhibition and longer observation periods are essential to discover 
significant differences between groups. However, extending the follow-up time 
of the three-dimensional growth experiments is not feasible because of the risk 
of fragmentation of control spheroids as they continue to grow. This is not the 
case in the outgrowth assay, in which a two-dimensional growth pattern is 
assessed. It was found that if the medium was refreshed weekly an excellent 
quality of the cultures could be maintained for 4 to 6 weeks. 
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 Further research is warranted to evaluate the radiosensitizing capabilities of low 
doses of cisplatin and gemcitabin in combination with low dose rate irradiation, 
as is the case for radionuclide therapy with Iodine-131 labeled Lipiodol.  
 
CONCLUSION 
 
It is feasible to use HepG2- tumor spheroids as in vitro model for hepatocellular 
carcinoma to screen drugs in various combinations with irradiation. Analysis of 
the outgrowth ratios of spheroids cultured in 24-well plates for 4 weeks shows 
enhancement of the effect of gamma irradiation if pretreated with 
chemotherapy. The most toxic combinations with the 10 Gy gamma irradiation 
were found in exposures to 0.5 µg/ml cisplatin for 4 hours and 30 ng/ml 
gemcitabin for 4 or 24 hours.  
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ABSTRACT  
 
Aim: The aim of this work was to screen cytotoxic drugs, relevant in the 
treatment of HCC, for enhancement of the effects of low dose rate (LDR) 
irradiation in an in vitro model for HCC. For comparison, all drugs were as well 
tested in combination with high dose rate (HDR) γ-irradiation. Methods: 
Multicellular tumor aggregates or “spheroids” of HepG2-cells were cultured and 
exposed to HDR or LDR irradiation by means of respectively external beam 
Cobalt-60 (60Co) or Rhenium-188 (188Re) dissolved in the culture medium for 24 
h. Secondly, exposure to irradiation (10 Gy, by means of 60Co or 188Re) was 
combined concomitantly with a 24 h incubation with 5-fluorouracil (5 µg/ml), 
topotecan (0.1 µg/ml) or gemcitabine (30 ng/ml). Toxicity was evaluated by 
means of a quantitative spheroid outgrowth assay. Outgrowth for the various 
combinations was compared on each week till week 4 by means of Mann-
Whitney statistical testing. Results: Absorbed doses of 10, 20 and 30 Gy 
following exposure to 188Re, did not yield significant outgrowth differences 
compared to HDR irradiation exposures. For 5-fluorouracil, supra-additive 
effects lasting for 4 weeks were observed in combination with a HDR 
irradiation. For combination with 188Re, the supra-additive toxicity was evident 
till week 3 but did not last till the fourth week. For topotecan and 188Re, no 
supra-additive effects were seen whereas the addition of HDR irradiation at the 
end of the topotecan exposure yielded lasting supra-additive effects on the 
outgrowth. However, this was not the case if the HDR irradiation was 
performed at the start of the 24 h topotecan exposure. For gemcitabine, 
synergy with 188Re was evident and lasted till week 4. Exposure to HDR 
irradiation at the end of the incubation with gemcitabine induced an even 
stronger synergic toxic effect on the spheroid outgrowth. No supra-additive 
effects were observed if HDR irradiation was added at the start of the 
incubation with gemcitabine. Conclusion: For all drugs tested, supra-additive 
effects were observed with HDR γ-irradiation if the timing of the irradiation was 
appropriate. For 188Re, supra-additive effects were less pronounced and only 
evident with 5-fluorouracil and gemcitabine but not with concomitant exposure 
to topotecan.  
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 INTRODUCTION 
 
Hepatocellular Carcinoma (HCC) is the most frequently occurring malignant 
tumor in the liver. It is the fifth most common malignancy in men, and the 
eighth most common in women worldwide (1). Over 80% of patients presenting 
with HCC suffer from cirrhosis and the reduced liver reserve restricts treatment 
options in this patient group (2). A cure can be achieved through partial liver 
resection or transplantation, although the former is only feasible in less than 
30% of patients and the latter is restricted by a shortage of donor organs (3). 
Patients presenting with HCC often have advanced disease with an underlying 
reduced liver function and thus a combination of treatment modalities might 
improve outcome and minimize toxicity in this vulnerable patient population (4). 
Radionuclide therapy by means of intra-arterial injection of radiolabeled 
Lipiodol, a fatty acid mixture labeled with Iodine-131 (131I) or Rhenium-188 
(188Re) has yielded promising results (5,6). Phase I clinical studies are being 
conducted to investigate the benefit of adding chemotherapy to locoregional 
irradiation by means of radiolabeled Lipidol (7,8).  
The objective of this study was to determine whether cytotoxic drugs used for 
the treatment of HCC could enhance the effect of low dose rate (LDR) 
irradiation in vitro. To reflect the in vivo situation, multicellular tumor 
aggregates or “spheroids” were cultured. Spheroids consist of different 
subregions, varying in the availability of oxygen, nutrients, pH, lactate and 
other substances. These factors influence the metabolic and proliferative status 
of the cells, resulting in a viable rim with proliferating cells and less mitotic 
activity in the deeper layers. Sutherland et al. reported that in general most of 
the proliferating cells are located in the outer three to five cell layers (75 µm) 
whilst quiescent cells are located more centrally. These cells often prove viable 
when removed from the deprived environment. Cells at a depth exceeding 160 
µm may become necrotic (9). As spheroids consist of cell populations with 
variations in their degree of radio-resistance and cell cycle status, this model 
reflects the in vivo situation, such as micrometastasis or microregions within a 
vascularized tumor, more accurately than monolayers (10). 
 
 
MATERIALS AND METHODS 
 
A human cell line, HepG2, derived from a HCC was used to culture the 
spheroids (Bioreliance Ltd., Stirling, Scotland). After trypsinisation of a 
monolayer, spheroids were cultured by continuous gyratory shaking at 70 rpm 
(Heidolph Instruments, Schwabach, Germany) of a single HepG2-cell 
suspension in DMEM medium supplemented with 10% fetal bovine serum 
(Gibco, Invitrogen Corporation, Merelbeke, Belgium) and 5% CO2 at 37°C in 
PETG-flasks (Gosselin, Haezebrouck, France). After 4 to 10 days of shaking, the 
spheroids attained a mean (±SD) diameter of 205 ± 49 µm. 
For exposure to LDR irradiation, the spheroids were incubated at 37°C with 
188Re (E β max 2.2 MeV, E γ 155 keV with an abundancy of 15%, physical half-
life of 16.9 h) for 24 h. 188Re was eluted from a 188W/188Re-generator, 
purchased from the Oak Ridge National Laboratory (Tennessee, USA), and the 
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 IRE (Institut des Radio-Eléments, Fleurus, Belgium). For comparison, all 
experiments included a high dose rate (HDR) γ-irradiation by means of Cobalt 
60 (60Co) at a dose rate of 1 Gy per minute. Doses of 10, 20 and 30 Gy were 
delivered. Three cytotoxic drugs were used: 5 µg/ml 5-fluorouracil (Fluracedyl, 
Pharmachemie, Haarlem, The Netherlands), 0.1 µg/ml topotecan (Hycamtin, 
Glaxo-SmithKline, Middlesex, UK) and 30 ng/ml gemcitabine (Gemzar, Eli Lilly, 
Fegersheim, France). All cytotoxic drugs were incubated with the spheroids for 
24 h. For combined modality experimental conditions, a fixed dose of 10 Gy 
was chosen. Irradiation was given concomitantly with the exposure to the 
cytotoxic drugs. For LDR irradiation, 188Re was added to the culture medium in 
which the cytotoxic drug was dissolved and spheroids were washed after 24 h. 
Exposure to 60Co was scheduled at 1 h following the start or 1 h before the end 
of the incubation with gemcitabine or topotecan. In case of 5-fluorouracil, 60Co-
irradiation was performed between 8 and 14 hours following the start of 
incubation with the cytotoxic drug.  
The induced toxicity was evaluated by measuring the outgrowth potential of 
individual spheroids over 4 weeks (11). Within 24 h of treatment, individually 
selected spheroids were placed in 24 well plates coated for cell culture (Becton 
Dickinson Biosciences, Erembodegem, Belgium). The longest diameter and its 
perpendicular are measured using a calibrated ocular micrometer and light 
microscopy. After some days a monolayer, varying in surface area and density, 
is formed by motile and clonogenic cells that surround the original spheroid. 
The longest diameter of the confluent outgrowth surface and its perpendicular 
are measured at 7 day intervals for one month and the outgrowth ratio is 
calculated by dividing the average diameter by the average diameter measured 
on the day of plating. The outgrowth ratios of treated spheroids are compared 
with controls and those exposed to combined treatment to those treated by 
monotherapy using Mann-Whitney statistics (SPSS10.0-software package, 
Chicago, USA). The P-level of significance was set at 0.05. In the case of severe 
damage to the spheroid caused by the experimental conditions, no adherence 
or a reduced monolayer surface or so-called outgrowth surface was observed. 
An outgrowth ratio of 1 signifies a lack of adherence and a reduced outgrowth 
potential reflects diminished cell motility and clonogenicity (12). All series 
consisted of a minimum of 14 spheroids and all experiments were performed at 
least in duplicate.  
 
 
RESULTS 
 
Sensitivity of HepG2-spheroids to LDR versus HDR irradiation 
Absorbed doses of 10, 20 and 30 Gy were delivered to the spheroids with 188Re 
and 60Co-irradiation. Independently from the applied dose rate, a dose of 10 Gy 
did not affect the outgrowth of the spheroids significantly compared to control 
spheroids (Figure 1). Exposure to 20 Gy and 30 Gy by means of 60Co-irradiation 
yielded a significantly reduced outgrowth ratio compared to control spheroids of 
respectively 59% ± 47 SD and 4% ± 10 SD on week 4. For neither of the 
doses, a significant difference was observed in function of the applied dose 
rate. In Figure 2 the mean outgrowth ratios are represented over time. 
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FIGURE 1: Outgrowth surface showing complete recovery at week 4. Control 
spheroids (A), spheroids exposed to HDR irradiation (10 Gy) (B) and spheroids 
exposed to LDR irradiation (10 Gy) (C). 
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 FIGURE 2: Mean outgrowth ratios following HDR- and LDR-irradiation (10, 20 
and 30 Gy) represented as a function of time. 
 
 
 
Sensitivity of HepG2-spheroids to the cytotoxic drugs 
Spheroids exposed to 5 µg/ml 5-fluorouracil (38 µM) for 24 h had a small but 
statistically significant decreased outgrowth (85% ± 52 SD) at week 4. A similar 
observation was recorded for 30 ng/ml (100 nM) gemcitabine, whereas a full 
recovery of the outgrowth was seen following exposure to 0.1 µg/ml (0.22 µM ) 
topotecan. The effects of the various drugs on the outgrowth ratios are 
depicted in Figure 3. 
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 FIGURE 3: Mean outgrowth ratios following incubation for 24 h with 5 µg/ml 5-
fluorouracil (5FU), 0.1 µg/ml topotecan (Topo) and 30 ng/ml gemcitabine 
(Gem) represented as a function of time.  
 
 
Screening for supra-additive effects of cytotoxic drugs and LDR or 
HDR irradiation  
Irradiation of spheroids by means of 60Co whilst incubated with 5 µg/ml 5-
fluorouracil for 24 h induced significant supra-additive effects, lasting until the 
fourth week. The first week the outgrowth was reduced to 10% (± 9 SD) of the 
outgrowth of control spheroids and on week 4 no recuperation had occurred 
(20% ± 24 SD). For concomitant exposure to 5-fluorouracil and 188Re for 24 h, 
supra-additive effects were seen on week 1 (20% ± 19 SD) till week 3 (41% ± 
26 SD) but on the fourth week no significant difference was observed in 
comparison to exposure to 5-fluorouracil alone. On all time points, the observed 
toxic effects were significantly stronger following the addition of HDR radiation 
to 5-fluorouracil compared to LDR radiation (Figure 4A).  
Exposure of spheroids to 0.1 µg/ml topotecan for 24 h and concomitant HDR 
irradiation at the start of the incubation did not yield a significant decreased 
outgrowth compared to topotecan alone. However, if the 60Co-exposure was 
scheduled at the end of the incubation with topotecan, a synergistic effect was 
seen. The first week the outgrowth was reduced to 19% ± 30 SD and at week 
4 no recovery occurred (31% ± 30 SD). Adding 188Re to the topotecan-
exposure did not induce synergistic effects (Figure 4B).  
The addition of 10 Gy HDR irradiation at the beginning of a 24 hr incubation 
with gemcitabin (30 ng/ml) induced a temporary additive effect on the 
outgrowth ratio. In the last 2 weeks, no statistical significant effect was 
observed in comparison to gemcitabine alone. If the exposure to 60Co was 
planned at the end of the incubation with gemcitabine, a strong and lasting 
synergistic effect was evident (24% ± 27 SD at week 4). Similar observations, 
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 although less pronounced (61% ± 48 SD at week 4), were obtained following 
the addition of LDR irradiation to the gemcitabine-exposure (Figure 4C).  
In figure 5 a summary is given for all experimental conditions. 
 
FIGURE 4 : Mean outgrowth ratios represented over time 
A: following incubation for 24 h with 5 µg/ml 5-fluorouracil (5FU) with or 
without concomitant irradiation by means of 60Co (10 Gy HDR, after 8-12 h of 
incubation with 5-fluorouracil) or 188Re (10 Gy LDR). B: following incubation for 
24 h with 0.1 µg/ml topotecan (Topo) with or without concomitant irradiation 
by means of 60Co (10 Gy HDR, at the start or at the end of incubation with 
topotecan) or 188Re (10 Gy LDR). C: following incubation for 24 h with 30 ng/ml 
gemcitabine (Gem) with or without concomitant irradiation by means of 60Co 
(10 Gy HDR, at the start or at the end of incubation with gemcitabine) or 188Re 
(10 Gy LDR).  
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 FIGURE 5: Relative outgrowth ratios at week 4 of spheroids following various 
treatments. All outgrowth ratios were normalized to the outgrowth of the 
control spheroids. Experimental conditions yielding significant (P <0.05) supra-
additive effects lasting till week 4 are indicated (*).  
 
 
 
DISCUSSION  
 
The 3 tested drugs have been used in monotherapy for  treatment of advanced 
HCC. However, objective response rates after systemic single-agent 
chemotherapy remain poor (13-17). More encouraging response rates of up to 
50% were obtained after intra-arterial administration of single-agent 
chemotherapy (18). Chemotherapeutic agents may be mixed in Lipiodol, a fatty 
acid mixture retained in malignant hepatocellular cells, and injected in the 
hepatic artery with or without subsequent occlusion of the arterial supply of the 
tumor. This treatment modality has yielded promising results, but the clinical 
use of so-called chemo-embolization is still under debate and considerable 
toxicity has been reported (19-21). An alternative treatment modality consists 
of the intra-arterial administration of Lipiodol labeled with Iodine-131 (131I ) or 
188Re (5,6,22). In a randomized trial conducted by Raoul and coworkers 131I 
labeled Lipiodol and chemo-embolization (70 mg cisplatin mixed in Lipiodol) 
appeared equally effective in terms of patient survival and tumor response, but 
tolerance to 131I-labeled Lipiodol was significantly better (21). A combination of 
treatment modalities could result in improvement of outcome without induction 
of severe toxicity (4). Phase I clinical studies are being conducted to investigate 
the benefit of adding systemic cisplatin to locoregional irradiation by 131I labeled 
Lipiodol and 5-fluorouracil and cisplatin were used with concurrent external 
beam irradiation (7,23). Of particular interest at present are lipiodolized 
emulsions that remain in the tumor for long periods and release drugs in a 
sustained pattern. A wide variety of cytostatic drugs have been mixed 
successfully in Lipiodol which can also be radiolabeled with 131I or 188Re (24-
26).  
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In the first part of the present study a comparison was made between HDR and 
LDR irradiation by exposure of HepG2-spheroids to 60Co (at a fixed dose rate of 
1 Gy/minute) and 188Re (at a mean dose rate of 6 mGy/minute over 24 h). In 
contrast to LDR irradiation, HDR exposure will deliver the absorbed dose before 
the cell can mobilize a significant reparative response (27). In accordance with 
the linear quadratic model employed in radiobiology, we expected that the 
biological effects of incubation with 188Re would be less pronounced since 
intermittent repair of single strand DNA breaks was thought to occur. This 
would reduce the yield of double strand breaks induced by multiple DNA-hits 
(the quadratic term) (28). In our experiments a trend towards a stronger effect 
of HDR irradiation with increasing doses was found, although no statistically 
significant differences in outgrowth were detected between HDR and LDR 
irradiation for all absorbed doses tested (10 Gy up to 30 Gy). This finding 
suggests the relative overweight of the double strand DNA breaks induced by a 
single electron (linear term) in this experimental model. In a second part of our 
study, a number of drugs were screened for exhibiting synergistic effects when 
applied with HDR or LDR irradiation. 
 
Enhancement of the effects of ionizing radiation by chemotherapy, is assumed 
to be related to (1) direct enhancement of the initial radiation damage by 
incorporating drugs into DNA, (2) inhibiting cellular repair, (3) accumulating 
cells in a radiosensitive phase or eliminating radioresistant phase cells, (4) 
eliminating hypoxic cells, (5) inhibiting the accelerated repopulation of tumor 
cells (29). 
The tested drugs in the present study are known radiosensitizers. Gemcitabine 
and 5-flourouracil are pyrimidine analogues. Radiosensitizing effects are 
thought to be related to the perturbing effects on the deoxynucleotide 
metabolism. Nucleoside analogues act as DNA synthesis inhibitors and have the 
potential to inhibit the repair of genomic damage induced by ionizing radiation. 
Nucleoside analogues may also act as DNA chain terminators, and trigger an 
apoptotic response. Since DNA damage is induced in all phases of the cell cycle 
by radiation, this mechanism offers the prospect of extending the cytotoxicity of 
these analogues to non-S-phase cells. 
Topotecan acts as an inhibitor of topoisomerase I, an enzyme essential for DNA 
replication, RNA transcription, chromosomal condensation and chromatid 
separation during mitosis (30). Topoisomerase I inhibitors are known to cause 
redistribution to the S-phase of the cell cycle.  
 
The enhancement of the effects of ionizing radiation by these drugs depends on 
the applied drug concentration, the incubation time, the timing with the 
irradiation and the tested cell line (31-33). Animal studies with a murine 
hepatoma tumor model have shown the importance of administration of 
gemcitabine and 5-fluorouracil prior to HDR irradiation rather than post-
irradiation. However, in this animal study supra-additive effects were only 
observed with gemcitabine and not with cisplatin, paclitaxel, adriamycin or 5-
fluorouracil (33). Data concerning radiosensitizing effects of these cytostatic 
drugs combined with LDR irradiation are scarce and data focusing on HCC in 
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 particular are lacking for gemcitabine. In vitro tests using a rat hepatoma cell 
line did not yield encouraging results for topotecan and 60Co-irradiation. But in a 
rat model for HCC, increased therapeutic efficacy was described using a 
topoisomerase inhibitor dissolved in Lipiodol and 131I based 
radioimmunotherapy (34). For 5-fluorouracil, no synergism with 131I could be 
demonstrated in HepG2-monolayer experiments (35). In the present study, 
radiosensitizing capabilities are clearly demonstrated in the outgrowth assay 
following incubation with 5 µg/ml 5-fluorouracil, 30 ng/ml gemcitabine or 0.1 
µg/ml topotecan and HDR irradiation if the timing between both modalities was 
appropriate. For LDR irradiation however, supra-additive effects that persisted 
until the fourth week following exposure to 188Re were only evident with 
gemcitabine. 
 
 
CONCLUSION 
 
For palliative treatment of HCC, encouraging clinical data have been reported 
for locoregional chemotherapy mixed in Lipiodol as well as for 131I or 188Re 
labeled Lipiodol. The present study aimed to investigate whether the addition of 
5-fluorouracil, gemcitabine or topotecan could enhance the anticancer effects of 
188Re labeled Lipiodol therapy in an in vitro model for HCC. A dose of 10 Gy did 
not affect the outgrowth of the spheroids significantly compared to control 
spheroids whereas doses of 20 Gy and 30 Gy yielded a significantly reduced 
outgrowth ratio. For neither of the doses, a significant difference was observed 
in function of the applied dose rate. Following the addition of 5-fluorouracil, 
gemcitabine or topotecan, supra-additive effects were observed with HDR γ-
irradiation if the timing of the irradiation was appropriate. For 188Re, supra-
additive effects were less pronounced and only evident with 5-fluorouracil and 
gemcitabine but not with concomitant exposure to topotecan. Only in case of 
gemcitabine the supra-additive effects with LDR irradiation lasted till week 4. 
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 Discussion 
 
Current status of locoregional radionuclide therapy for palliative treatment 
of HCC 
 
A considerable number of patients suffering HCC present with advanced 
intrahepatic disease and thus curative treatments options such as partial liver 
resection or transplantation are not an option. Local ablative techniques such as 
PEI and RFA have yielded good long term results in retrospective series but are 
as well mainly applicable to patients with a limited number of lesions and 
tumoral diameters not exceeding 5 cm. Therefore, for many patients TACE 
remains as sole treatment modality that is widely available and for which 
evidence is available concerning its benefit in terms of patient survival (1). A 
meta-analysis conducted by Llovet and coworkers confirmed TACE in its role of 
standard treatment for HCC in this setting. However, several authors have 
pointed out that the conclusions of Llovet et al. are not that firm and mainly 
apply on well selected patients, suffering a Child-Pugh A degree of cirrhosis 
(2,3). In addition, a randomized study conducted by Raoul and coworkers 
showed a markedly better tolerance for 131I-Lipiodol than for TACE with equal 
long term outcome and encouraged various research groups to continue the 
search for improved radionuclide treatment for HCC (4). 
Optimization strategies consisted mainly of using radionuclides that are more 
‘user friendly’ in terms of radioprotection and allow for administering higher 
activities, and thus aiming at delivering higher tumor doses. Attempts that have 
reached the stage of clinical trials consist mainly of 90Y labeled microspheres 
and 188Re-labeled Lipiodol. In the following section, the current status and 
future prospects of the various locoregional radionuclide therapies for HCC are 
discussed.  
 
131I-Lipiodol  
 
Most published papers dealing with radionuclide therapy for HCC in a palliative 
setting concern the use of 131I-Lipiodol, which is commercially available as 
LipiocisTM (CIS Bio International, Gif sur Yvette, France) (5-7). Most reports 
using 131I-Lipiodol agree on its good tolerance. Undesirable effects that are 
observed fairly frequently consist of moderate and temporary fever (29%), 
moderate and temporary disturbances of the biological liver tests (20%) and 
pain on injection (12.5%). Moderate and reversible leukopenia (7%) and 
serious diffuse infiltrative pneumopathies (2%) are observed more rarely. These 
diffuse infiltrative pneumopathies appear about 1 month after the injection of 
LipiocisTM , most frequently after the second injection. They are clinically 
manifested by the appearance of dyspnea that is sometimes associated with dry 
cough and bilateral crepitations. The CT-scan shows infiltrates with the 
appearance of frosted glass, bilateral, surrounded by septal thickenings and 
sometimes evolving into fibrosis with some honeycomb-like images. This is a 
serious complication with a high mortality rate (Cis Bio International, personal 
communication). 
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 Using either a drop on AFP levels or a reduction in tumor size as response 
criterion, reported response rates varied from 17 to 92% (5-7). Palliative 
treatment with 131I-Lipiodol (n=65 patients) was compared to chemo-
embolization (n=64 patients) in a prospective, randomized trial and survival 
after 6 months, 1, 2, 3 and 4 years were respectively 69%, 38%, 22%, 14% 
and 10% for the 131I-Lipiodol arm versus 66%, 42%, 22%, 3% and 0% in the 
chemo-embolization arm (4). Importantly, treatment tolerance was much better 
in the 131I-Lipiodol arm with only 3 reported serious side-effects versus 29 in 
the chemo-embolization arm and these results are in line with an earlier report 
by Bhattacharya et al. (8). While no survival benefit could be demonstrated for 
the whole group of palliative HCC patients, when focusing on HCC patients 
presenting with portal vein thrombosis a significant benefit in survival following 
131I-Lipiodol treatment versus tamoxifen, 5-fluorouracil or anti-inflammatory 
medication was however documented in a prospective randomized study by 
Raoul and coworkers (9). However, de Baere et al. did not confirm this benefit 
in patients with portal vein thrombosis in a non-controlled trial (10).  
 
A dosimetry study was carried out at our institution in 15 patients who received 
a mean activity of 1.9 GBq (±0.2 SD) 131I-Lipiodol. Patient dosimetry was 
performed based on 2 bi-planar total body scans using Monte Carlo simulation 
techniques. CT images of each patient were used to determine liver and tumor 
volume and position. Based on the data from the total body scans, the mean 
decay-corrected percentage of 131I uptake in the total body at 7 days after 
administration was 72.8% (± 13.6 SD). At the same time the uptake in the 
normal liver, the tumor and the lungs was, respectively, 26.1% (± 8.3% SD), 
17.2% (±7.5% SD) and 11.7% (± 5.4% SD). The percentage uptake in the 
total body two weeks following therapy had decreased to 53.1% (±  13.8% 
SD). The percentage uptake for the normal liver, the tumor and the lungs at 
the time of the second scan was 14.4% (± 4.3% SD), 14.5% (± 6.4% SD) and 
7.4% (±  4.1% SD), respectively. The following mean absorbed doses were 
obtained: normal liver 7.8 Gy (range 4.0-11.8), tumor 129.5 Gy (range 68-246) 
and lungs 6.8 Gy (range 2.2-11.3). Eight patients received thyroid blocking by 
100 mg potassium iodide daily and the absorbed dose to the thyroid was 
significantly lower for patients who received potassium iodide (7.2 Gy, range 
3.4-10.7) than for the other patients (mean 13.8 Gy, range 8.0-21.9). For the 
total body dose, a mean value of 0.95 Gy (range 0.58-1.18) was obtained (11).  
Despite the good tolerance and the absorbed doses for the normal organs 
being far below the tolerance limits, an escalation in activity was not performed 
because the subsequent isolation of the patient for radioprotection concerns, 
would exceed 7 days and this is an important psychological drawback for the 
patient as well a significant extra cost.  
 
Despite the numerous clinical reports, it remains unclear what the precise 
exclusion criteria for 131I-Lipiodol treatment should be. Although never 
published as such, most centers exclude patients suffering an underlying 
cirrhosis with more than 7 points according to the Child-Pugh classification (12). 
According to Raoul et al. portal vein thrombosis does not imply unacceptable 
toxicity, whereas de Baere et al. do not recommend the use of 131I-Lipiodol for 
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 patients with portal vein thrombosis due to the occurrence of considerable 
toxicity in their experience (9,10). According to the recent guidelines provided 
by Cis Bio International, a radiography of the chest should be performed to 
document the baseline status in order to diagnose interstitial pneumopathy if 
symptoms would occur. However, maybe lung function testing should be added 
at baseline so that more discrete changes could be documented, allowing 
careful patient selection for the planning of repeated treatment sessions. 
 
188Re-labeled Lipiodol 
 
Lee et al. developed a long-chain alkyl diaminedithiol derivative, abbreviated as 
188Re-HDD/Lipiodol, with satisfactory uptake and retention in an animal model 
(13). In a multi-center study sponsored by the International Atomic Energy 
Agency (IAEA) the safety and efficacy of this radioconjugate was assessed for 
treatment of inoperable HCC. Sixteen patients were treated in a pilot study with 
administered activities ranging from 1.8 GBq up to 7.7 GBq (14). The level of 
radioconjugate activity was based on radiation absorbed dose to critical organs, 
calculated following a ‘scout-dose’ of radioconjugate. The normal organs at 
greatest risk for toxicity were the normal liver and the lungs. In a subsequent 
study a further 54 patients were treated. The mean administered activity in this 
group was 4.6 GBq.  
 
In this IAEA sponsored studies only a faint visualization of the kidneys was 
described, suggesting minimal renal elimination. However, the urinary excretion 
was not quantified (14). According to our measurements a mean of 44.1% of 
the administered 188Re was excreted in the urine within 76 hours (15). ITLC 
analysis showed that the activity in the urinary samples was perrhenate. If the 
shorter physical half-life of 188Re is taken into account, the value of 44.1% for 
188Re-HDD/Lipiodol compares favorably with the observations of Raoul et al. 
and Nakajo et al. using 131I-Lipiodol (16,17). No visualization of the gastro-
intestinal tract was described in the biodistribution studies using 131I-Lipiodol 
nor in the initial reports on 188Re-HDD/Lipiodol (14,16-19). In a minority of our 
patients faint and transient uptake in the small or large bowel was seen but 
fecal elimination was negligible compared to the renal excretion (15). In the 
animal study conducted by Lee et al. intestinal uptake was observed following 
intravenous administration of 188Re labeled diaminedithiol derivatives in mice 
and the intestinal activity was thought to be result of bile excretion (13). In our 
study the uptake pattern and its transient character suggested biliary excretion 
rather than gastro-intestinal wall uptake. 
Besides the liver, the lungs were the organs with considerable uptake in the 
majority of patients (14,15,19). We calculated a biologic half-life in the lungs for 
188Re of 8.7 (± 4.9 SD) days and this result is in line with earlier reports on the 
biologic half-life in the lungs following 131I-Lipiodol therapy of 10.3 (± 5.2 SD) 
days (11,15). The relatively long biologic half-life in the lungs in both cases 
suggests that the activity in the lungs is present under a stable formulation 
from which diffusion to blood is minimal.  
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 In the experience of Sundram et al. comprising about 70 patients, half of the 
patients reported mild and transient side effects, mainly consisting of low grade 
fever and right hypochondrial discomfort (19). In our experiences, 188Re-
HDD/Lipiodol is excellently tolerated in patients with well compensated 
cirrhosis. In this subset of patients, activities up to 7.0 GBq can be administered 
without the occurrence of unacceptable adverse events. For patients suffering 
underlying Child-Pugh B cirrhosis, the administration of 3.7 GBq in the arteria 
hepatica propria was accompanied by a considerable aggravation of pre-
existing symptoms and laboratory aberrations. However, it remained unclear 
whether this was related to tumor progression rather than to the radionuclide 
therapy.  
Sundram et al. adapted the administered activity of 188Re-HDD/Lipiodol in 
function of a dosimetric analysis following the administration of a ‘scout dose’ of 
the radio-conjugate. The total administered activity was such that the liver, 
lung and bone marrow dose would not exceed respectively 30, 12 and 1.5 Gy. 
However, 2 cases of pleural effusion were reported by Sundram and coworkers 
and these were attributed to radiation induced pneumonitis (19). In our 
experience, 2 patients suffered prolonged coughing and dyspnea which 
exacerbated following the second treatment and required oral corticosteroid 
treatment. High resolution CT-scan of the lungs did not reveal stigmata of 
interstitial pneumopathy. The absorbed cumulative lung doses for both patients 
were estimated to be 10.4 and 11.5 Gy, hence too low to explain this evolution, 
although an increased sensitivity to ionizing radiation in these patients can not 
be excluded. An underlying allergy to components of the radio-conjugate could 
explain why exacerbation occurred in both cases following the second 
administration. Although it was not clear whether the occurrence of pulmonary 
symptoms was related to the 188Re-HDD/Lipiodol therapy, we advocate that in 
the future, as is the case for 131I-Lipiodol, particular attention is paid to patients 
developing pulmonary complaints.  
 
According to the reports of the IAEA-trials, 13 patients had a partial response, 
34 patients had stable disease and 23 patients suffered disease progression 
according to imaging. In our experience, 3 partial responses and 3 cases of 
progression were observed overall according to imaging whereas stable disease 
was recorded in the 46 remaining treatments. Unfortunately there were 
insufficient data about disease progression as measured by repeated imaging 
prior to treatment.  
In the Western population, AFP-monitoring is only useful for the assessment of 
response in a limited number of patients since only 50% of patients present 
with a level of AFP that exceeds the critical limit of 400 ng/ml. Among our 
patients, 8 cases with rapidly increasing AFP prior to treatment were included. 
In 4 cases the tumor marker continued to rise 6 weeks later, in 2 cases it 
stabilized and in the 2 remaining patients the AFP was reduced by more than 
90%.  
Imaging by means of ultrasound, CT and MRI as well as by positron emission 
tomography (PET) using Fluoro-18 deoxyglucose (18FDG) does not always 
reflect the true tumor load. Small lesions are easily missed and viability of 
tumor tissue is not well assessed (20). At our institution, 2 patients underwent 
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 a liver transplantation which revealed over 99% of necrosis in their tumor 
although this had been reported as stable disease according to MRI. Further 
treatment of a larger numbers of patients is required to assess the therapeutic 
efficacy of 188Re-HDD/Lipiodol and, in particular, long term outcome should be 
followed carefully rather than radiological response.  
 
At present, the most important shortcoming of 188Re-HDD/Lipiodol for 
treatment of HCC in patients with well compensated liver cirrhosis, consists of 
the labeling yield ranging between 50 and 70%. As pointed out in this work, the 
synthesis of activities exceeding 7.0 GBq routinely, poses a problem. A number 
of authors have focused on the development of new derivatives that may be 
produced at yields exceeding 95%. These include bis-(diethyldithiocarbamato) 
nitrido 188Re Lipiodol (188ReN-DEDC) and 188Re-(S2CPh)(S3CPh)2 Lipiodol (188Re-
SSS Lipiodol). While the 188ReN-DEDC version was shown to be safe when given 
via the hepatic artery, either alone or in combination with TACE, in a series of 9 
patients, data on 188Re-SSS Lipiodol in HCC patients are currently lacking 
(21,22) . 
For patients with Child-Pugh B cirrhosis, the administration of 3.7 GBq 188Re-
HDD/Lipiodol in the arteria hepatica propria did not yield encouraging results 
and possibly the treatment could be optimized by administering the 
radioconjugate as close to the tumor feeding arteries as possible. 
 
 
Table 1: Summary of the 3 clinical studies, conducted in the framework of the 
present thesis, reporting the feasibility of the use of 188Re-HDD/Lipiodol. 
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1.1.1. 11 
(9 Child-Pugh A,  
2 Child-Pugh B) 
16 3.7 GBq 44.1 ± 11.7% 
over 76 h 
PR: 1 
SD: 11 
PD: 1 
5/8 ↓  
(19-90%) 
1.1.2. 28 
(Child-Pugh A 
only) 
35 4.8-7.0 GBq 41.7 ± 9.7%  
over 46 h 
PR: 1 
SD: 28 
PD: 2 
8/17 ↓  
(19-97%) 
1.1.3. 12 
(Child-Pugh B 
only) 
12 3.7 GBq 36.2 ± 5.7% 
over 52 h 
PR: 1 
SD: 7 
PD: 0 
3/9 ↓  
(23-63%) 
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 Radiolabeled microspheres 
 
HCC are rich in vasculature and almost exclusively dependent on arterial blood 
supply while normal liver tissue receives most of its flow from the portal vein. 
Based on this difference in blood supply between HCC and normal liver tissue, 
microspheres with a diameter between 20 and 50 µm when injected into the 
hepatic artery, will selectively lodge in the vascular bed of HCC.  
 
90Y labeled microspheres  
 
Early experiences with 90Y labeled ceramic microspheres yielded disappointing 
results due to leaching of 90Y from the microspheres, leading to bone marrow 
toxicity. In the 1980s a 25 µm glass microsphere (TherasphereTM, MDS Nordion, 
Canada) and a 35 µm resin-based 90Y labeled microsphere (SirtexTM, Sirtex 
Medical Ltd, Australia) were developed and these vehicles proved stable (5). 
The initial experiences with both types yielded promising results and it was 
proven feasible to deliver high liver (including tumor) doses (50 up to 150 Gy) 
(5,23-27). In all recent studies the therapeutic approach consists of treating the 
affected liver lobe if the patient presents with unilobar disease. Patients with 
bilobar disease receive whole-liver treatment spread over 2 treatment sessions. 
For estimating the required activity for TherasphereTM treatment, the liver 
volume planned to treat is determined by CT or MRI, and an algorithm is used. 
Before treatment, a percutaneous catheter is inserted into the femoral artery 
for angiography and selective visceral catheterization and a 99mTc-
macroaggregated albumin (MAA) scan is performed to test for any 
gastrointestinal flow and to estimate the percentage of injected activity that 
might be shunted to the lungs. Lung doses exceeding 30 Gy following a single 
treatment or a cumulative dose exceeding 50 Gy should be avoided in order to 
prevent radiation pneumonitis (26). Although high activities are administered, 
no clinical significant bone marrow toxicity is observed. Severe toxicities mainly 
consist of hepatic failure and in rare occasions radiation pneumonitis, gastro-
intestinal bleeding or cholecystitis (25).  
 
It was shown by Goin et al. that 90 day mortality following TherasphereTM 
treatment could substantially be reduced by screening candidates for the 
presence of a number of risk factors such as infiltrative growth pattern, bulk 
disease, AST or ALT >5xULN, more than half of the liver volume replaced by 
tumor and albumin <3g/dL, bilirubin ≥2mg/dL (28). In low risk patients doses 
to the liver (including the tumor) as high as 150 Gy on a single administration 
and as high as 268 Gy on repeated administrations were well tolerated (29). 
The application of high activities (up to 13 GBq cumulatively) of 90Y-labeled 
resin microspheres was also shown to be feasible in patients suffering HCC 
(5,30). Following the occurrence of a limited number of cases with radiation 
pneumonitis, the use of a pre-treatment 99mTc-MAA scan was implemented and 
patients with lung shunting exceeding 13% should not be treated according to 
the experiences of Leung and coworkers (31). In a phase I/II study by the 
same group tumor regression studied in 18 inoperable HCC patients was found 
to be dose-related. Progression or static disease occurred in a higher proportion 
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 of patients whose tumor received <120 Gy. Also, in these patients survival was 
much poorer when compared to those whose tumor received >120 Gy ( 26.2 
weeks versus 55.9 weeks) (27). In an attempt to more accurately predict tumor 
response and lung toxicity, a simple mathematical model was developed using 
the MIRD-formulation based on 99mTc-MAA scans. Using a beta-probe at 
laparotomy the validity of the 99mTc-MAA scan-derived estimated doses was 
evaluated both in a pre-clinical and clinical setting (30).  
 
For both types of microspheres promising radiological response rates (27-38%) 
were claimed, but methodological differences make it impossible to compare 
results. A few cases of complete responses have been reported and survival 
compared favorably with historical controls (5,23,27).  
In contrast to TherasphereTM, no safety data are available concerning the use of 
SirtexTM in patients with impeded venous flow but considering the embolizing 
effects of Sirtex TM its use should be avoided in patients with portal vein 
thrombosis whereas TherasphereTM might have a role to play in this particular 
setting (32). 
 
In contrast to 131I, 90Y lacks the emission of gamma-rays and thus treatment 
with 90Y-labeled microspheres is feasible on an outpatient or 24 hour 
hospitalization basis (32). However, patients should be admitted twice to the 
hospital, since a prior angiography and 99mTc-MAA scan are recommended to 
avoid lung toxicity. If both lobes should be treated, in total 3 interventions 
should be performed. In addition, the cost price of 90Y labeled microspheres for 
a single administration to date is about 6 times higher than for LipiocisTM. 
 
32P labeled microspheres 
 
Besides 90Y labeled microspheres, some clinical experience was gained with 32P 
glass microspheres (33). In a comparative study, including 111 unresectable 
HCC patients, Liu et al. compared the therapeutic effect of intra-arterial 32P 
glass microspheres (n=30 patients), to intra-arterial 32P glass microspheres 
combined with half a dose of TACE (adriamycine 30 mg/m² + cis-diammine 
dichloroplatinum + iodized oil, n= 49 patients) and TACE alone (n=18). Results 
obtained using intra-arterial 32P glass microspheres closely approximated those 
obtained using TACE alone. In contrast, results obtained using intra-arterial 32P 
glass microspheres combined with half a dose of TACE were significantly better 
than those obtained using TACE alone.  
 
186/188Re labeled microspheres 
 
Wunderlich et al. developed an efficient method of radiolabeling biodegradable 
human serum albumin (HSA) microspheres with 188Re using a simple kit. One 
advantage of HSA microspheres compared to other labeled particles (e.g. 
human macro-albumin) is the uniformity of their size with a mean particle 
diameter of about 25 µm. Another advantage is the biocompatibility and in vivo 
degradability. The occlusion of blood vessels following intra-arterial application 
is only temporary (34). Clinical data on its use in patients suffering colorectal 
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 liver metastasis suggest a good in vivo stability. As reported for 90Y-labeled 
microspheres and in contrast to our experiences with radiolabeled Lipiodol, only 
minimal radioactivity is retrieved in the urine (35).  
For 186Re  and 188Re glass microspheres and 166Ho-AcAc PLA-microspheres a 
therapeutic effect in animal models was shown but clinical data so far are 
lacking (36-38).  
 
Radiolabeled microspheres versus Lipiodol 
 
In Table 2 the advantages and disadvantages of the use of various types of 
radiolabeled microspheres are summarized and compared with radiolabeled 
Lipiodol. 
 
TABLE 2: Comparison of the the various types of radiolabeled microspheres and 
Lipiodol derivatives. 
* according to Belgian guidelines. ** depends on the number of patients 
treated per purchased 188W/188Re-generator. 
 
 90Y-labeled glass 
microspheres 
Therasphere TM 
90Y-labeled 
resin 
microsphere 
Sirtex TM 
188Re-labeled 
HSA 
microspheres 
188Re-HDD/ 
Lipiodol 
131I-Lipiodol 
Lipiocis TM 
In vivo stability excellent excellent good 
(preliminary 
data) 
moderate moderate 
Need for 
hospitalization * 
day clinic day clinic not defined: 
24-48h? 
24-48h 5-7 days 
Applicable in case of 
portal vein 
thrombosis 
yes no no data 
available 
yes yes 
Visual control during 
and following 
administration by 
means of X-rays 
limited limited limited excellent excellent 
Visual control 
following 
administration by 
means of 
scintigraphy 
yes yes yes yes yes 
Commercially 
available in 
European 
Community 
no yes no no yes 
Cost of 
radiopharmaceutical 
per treatment 
8.000- 
12.000$ 
8.000- 
12.000 $ 
Low 
production 
cost** 
Low 
production 
cost** 
1.500-
2.000$ 
Clinical reports on 
treatment of HCC 
available 
++ 
uncontrolled 
trials 
+ 
uncontrolled 
trials 
- + 
uncontrolled 
trials 
+++ 
including 
randomized 
controlled 
trials 
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 Locoregional radionuclide therapy as part of a multimodality approach 
 
Surgery is the mainstay of curative treatment. No firm evidence for improved 
long term outcome to date is available for any adjuvant or neoadjuvant 
treatment strategy (39). Some evidence was established for the use of 
polyprenoic acid and 131I-Lipiodol following partial liver resection in prospective 
randomized trials (39,40).  
 
Locoregional radionuclide therapy as bridging strategy to 
transplantation 
 
Neo-adjuvant treatment in patients meeting transplant criteria aims at 
preventing patients to drop out from the waiting list or to prevent disease 
progression while a donor is sought for living organ donation. Results of neo-
adjuvant treatment strategies should be evaluated in terms of long term 
outcome, based on the number of patients intended to transplant. It is known 
that malignant cells have often spread to distant sites at the moment of 
transplantation and subsequent proliferation is enhanced by the 
immunosuppressed status of the patients post-transplantation. As a 
consequence, a multimodality approach combining local, locoregional and 
systemic treatment options seems to be essential in preventing recurrent 
disease. 
The locoregional component of the neo-adjuvant treatment should target the 
entire liver since the presence of more than 3 tumors is considered as a contra-
indication for transplantation is many centers. In that view intra-arterial 
radionuclide therapy or chemotherapy are appealing approaches. However the 
use of 131I-Lipiodol excludes patients from the waiting list for 6 weeks due to 
radioprotection issues. In case of 188Re, removal from the waiting list is 
recommended for only for one week due to its 17 hour physical half-life. This 
benefit is less pronounced for radionuclides with an intermediate physical half-
life such as 90Y (2.7 days).  
Besides eventual therapeutic benefits, radiolabeled Lipiodol treatment might 
have additional diagnostic value in the work-out of potential transplant 
candidates. Before administering the radioconjugate, a diagnostic hepatogram 
including an indirect mesentericoportography was performed, which has proven 
of important added value for the surgeons in some cases.  
 
Radionuclide therapy combined with cytostatic drugs 
 
A combination of treatment modalities could result in improvement of outcome 
without induction of severe toxicity. Phase I clinical studies are being conducted 
to investigate the benefit of adding chemotherapy to locoregional irradiation by 
131I, 188Re or 32P based radionuclide therapy and 5-fluorouracil and cisplatin 
were used with concurrent external beam irradiation (21,33,42,43). Of 
particular interest at present are Lipiodolized emulsions that remain in the 
tumor for long periods and release drugs in a sustained pattern. A wide variety 
of cytostatic drugs have been mixed successfully in Lipiodol which can also be 
radiolabeled with 131I or 188Re (44-46).   
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The tested drugs in the presented work are known radiosensitizers and the 
radiosensitizing capabilities were clearly demonstrated in the outgrowth assays 
with high dose rate irradiation. Data concerning radiosensitizing effects of 
cytostatic drugs combined with low dose rate irradiation are scarce in the 
literature and thus we focused at combined effects of cytostatic drugs and 188Re 
(low dose rate irradiation) in the second part of this thesis (47). With increasing 
doses, there was a trend towards stronger anti-tumoral effects if high dose rate 
irradiation was applied compared to low dose rate. It was expected that an 
absorbed dose delivered at low dose rate would not be as effective as if 
delivered at high dose rate. However, no statistically significant differences in 
therapeutic effect between high dose rate alone and low dose rate alone were 
observed. This was in contrast with the combined modality experiments, 
showing clearly that supra-additive effects of 188Re and cytostatic drugs were 
less pronounced than for combinations with external beam 60Co (high dose 
rate) irradiation. 
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 Future prospects for 188Re-based radionuclide therapies 
 
The use of an on-site 188W/188Re-generator provides a good yield of carrier-free 
188Re routinely for radionuclide therapy (48). The main advantages of 188Re are 
the relatively short physical half-life, the high energy of the β-particle emission 
and the γ-emission of 155 keV (15%) that allows imaging. The use of 188Re for 
radionuclide therapy generates less concerns over radiation protection 
compared to 131I. In addition, an on-site generator enables hospitals in remote 
areas or in regions with limited transport facilities to produce their own 
radiopharmaceuticals. This is particularly useful for less developed countries 
with a high prevalence of HCC since other commonly used therapeutic 
radiopharmaceuticals require a nuclear reactor for its production (131I, 90Y). 
 
Most publications so far have focused on the use of 188Re for bone pain 
palliation (49-51). Although encouraging results were reported, various aspects 
of this treatment modality remain unclear. Some authors prefer the use of low 
β-energy emitters for treatment of painful bone metastasis, because it is 
assumed that such radionuclides would exhibit less bone marrow toxicity. 
However, little evidence for such a strategy is available. 188Re-HEDP and 153Sm-
EDTMP, show similar pain palliation effects in patients suffering from breast and 
prostate cancer. There were no differences in bone marrow toxicity reported 
between the higher β-energy 188Re-HEDP and the lower β-energy 153Sm-EDTMP 
in a comparative study (52). Other authors suggest enhanced antitumoral 
effects if high energy β-emitters are used and propose aggressive treatment in 
an earlier disease stage in stead of using these radiopharmaceuticals only in 
end-stage patients suffering intractable bone pain. The electrons emitted by 
188Re have a range of 3 to 5 mm in osseous tissue and thus target tumor as 
well as surrounding bone trabeculae and periostium. This would lead to 
cytotoxic effects in the outer layers of the tumor and repeated treatment with 
short intervals would prevent new tumor growth and eradication of deeper 
tumor layers (53). Another approach consists of including other treatment 
modalities such as autologous stem cell rescue and chemotherapy to a 
radionuclide treatment scheme (54). Future research should focus on the 
potential antitumoral effects of such aggressive treatment strategies and their 
impact on quality of life as well as survival. 
So far, no studies with 188Re-HEDP were carried out in patients with 
compromised bone marrow or impaired renal function. However, in daily 
practice, a considerable number of patients presenting with bone pain would 
not meet the inclusion criteria of the published phase I studies. In addition, the 
efficacy of radionuclide therapy for bone metastasis of other malignancies than 
prostate and breast cancer should be investigated.  
 
Radioimmunotherapy for hematological malignancies is also an application 
where clinical results so far are very promising. However, it remains unclear 
what role 188Re will play in radioimmunotherapy for solid tumors. The use of 
high molecular weight IgG could have a negative impact on the tumoral uptake 
kinetics of the radiopharmaceutical. In the case of slower tumoral uptake, the 
physical half-life of 188Re of 16.9 hours would be relatively too short. On the 
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 other hand the use of antibody fragments bears the risk of radiation nephritis. 
It remains to be elucidated if cationic amino acid infusions are able to prevent 
excess renal uptake of the radiolabel in such a setting.  
Although various animal experiments on the subject were published several 
years ago, no recent clinical advances using 188Re-labeled somatostatin 
analogues or other peptides were reported (55-58). 
 
For treatment of liver tumors, important preclinical and clinical progresses were 
made in the last five years. Attempts to use 188Re for treating HCC as well as 
liver metastasis, consist of a number of radiolabeled Lipiodol based 
radiopharmaceuticals (13-15,19,21,22,59) as well as radiolabeled glass, 
polylactic acid and albumin microspheres (34-36). At present most clinical data 
are derived from phase I studies using 188Re-HDD/Lipiodol for palliative 
treatment of HCC. In the present work it was shown that patients with well 
compensated liver dysfunction, have an excellent tolerance and future research 
at our institution will focus on the long term outcome following repeated 
treatment with high activities. If phase II clinical trials confirm the encouraging 
results that were reported in the feasibility studies, 188Re-HDD/Lipiodol should 
be compared to the standard palliative treatment for HCC (TACE) in a 
randomized controlled trial. Subgroups of patients that did not benefit from the 
radionuclide therapy should be identified (role of underlying liver dysfunctions, 
general status, tumor dimensions, …).  
Research concerning various dosimetry and radiation protection matters is 
ongoing at our hospital, including patient-specific calculation of the tumor doses 
based on SPECT-scans and estimation of the radiation burden for staff and 
relatives of patients treated with 188Re-HDD/Lipiodol. 
In patients in whom local ablative techniques are applicable, combining RFA or 
PEI with locoregional radionuclide therapy might be of added value. Combining 
radionuclide therapy with systemic or locoregional chemotherapy could also 
enhance the antitumoral effects. In the present work, a number of cytostatic 
drugs that might have a role to play in management of HCC were tested in vitro 
for synergistic effects when combined with exposure to 188Re. Results so far 
using topotecan, 5-fluorouracil and gemcitabin were not encouraging since 
synergistic effects were lacking or markedly less pronounced than observed 
with external beam irradiation. Future experiments should elucidate whether 
other drugs such as taxanes and anthracyclines yield more promising results 
when combined with 188Re. 
 
In conclusion, a considerable number of clinical trials, directed to the 
application of 188Re in oncological as well as benign conditions, have 
demonstrated its feasibility. However, most clinical know-how remains limited 
to a number of expert centers in  Germany and Asia. In the future, efforts 
should be made to facilitate innovative research using a 188W/188Re-generator 
and the implementation of 188Re based therapies should be encouraged in other 
centers. 
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Summary 
 
Hepatocellular Carcinoma or HCC is the most prevalent primary liver cancer. It 
constitutes the third cause of cancer related deaths, responsible for more than 
500.000 deaths worldwide annually. Due to the underlying carcinogenic risk 
factors such as chronic viral hepatitis and alcohol intake, the vast majority of 
patients presenting with HCC, suffer from cirrhosis, a condition limiting the 
therapeutic possibilities. Surgery, either by means of hepatectomy or liver 
transplantation, is the mainstay of curative treatment. Overall, if the degree of 
liver dysfunction and the tumor load is taken into consideration, the vast 
majority of patients is not eligible for surgery.  
Amongst the non-surgical treatment modalities producing response rates 
exceeding 20% are the use of Lipiodol mixed with chemotherapeutic agents or 
radiolabeled with Iodine-131 (131I) without subsequent embolization. 
Encouraging results have been obtained using 131I-Lipiodol, but the use of 131I 
has hampered its routine clinical implementation. 131I has a physical half-life of 
8 days and emits a high energetic gamma(γ)-ray (364 keV, with an abundancy 
of 82%) necessitating prolonged hospitalization for radioprotection purposes. 
Although 131I-Lipiodol therapy is generally well tolerated, a ‘dose escalation’ 
study was not conducted so far as the administration of activities exceeding 
2.22 GBq is restricted by the above mentioned practical issues. Rhenium-188 
(188Re) has favorable characteristics for radionuclide therapy and considering 
the limited success of 131I-Lipiodol for treatment of relatively large tumors, the 
switch towards a radionuclide with a higher energy of the beta(β)-emission 
(2120 keV and 1960 keV for 188Re versus 606 keV for 131I) might yield improved 
response rates. 188Re emits a γ-ray of 155 keV at an abundancy of 15%, 
allowing γ-camera imaging and it has a relatively short physical half-life of 17 
hours, limiting radiation protection problems. Additionally, the radionuclide is 
eluted from a 188W/188Re-generator, which has a long useful shelf life of several 
months and provides a good yield of carrier-free 188Re routinely.  
 
In the present work we aimed at conducting a feasibility study in which the 
biodistribution and safety was investigated following the administration of 3.7 
GBq 188Re-4-hexadecyl-1-2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol 
(188Re-HDD/Lipiodol) in the hepatic artery. A fast blood clearance of the 
injected activity was observed with a calculated effective half-life of 7.6 (± 2.2 
SD) hours in blood. The predominant elimination of the activity was through 
urinary excretion with a mean renal clearance of 44.1 (± 11.7 SD) % of the 
injected activity within the 76 hours following administration. The absorbed 
dose to the liver (including the tumor), the lungs, the kidneys and the thyroid 
was 4.5 ± 1.9 Gy, 4.1 ± 1.2 Gy, 0.9 ± 0.7 Gy and 0.3 ± 0.1 Gy, respectively. The 
calculated whole body effective half-life was 14.3 (± 0.9 SD) hours. Treatment 
was well tolerated, in particular in patients with well compensated cirrhosis and 
according to the dosimetric estimations a further activity escalation seemed 
feasible.  
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 However, in patients suffering moderately advanced cirrhosis, the 
administration of 3.7 GBq 188Re-HDD/Lipiodol did not yield encouraging results 
and therefore, it was preferred to conduct the activity escalation study in the 
subset of patients with well compensated cirrhosis. Activities up to 7.0 GBq 
188Re-HDD/Lipiodol were administered without the occurrence of unacceptable 
adverse events. The most important drawback consisted of the limited 
efficiency of the radiolabeling procedure, which implicates careful planning to 
implement such high activities in routine practice. In addition, attention should 
be paid in the future to patients developing pulmonary symptoms, such as a 
cough or dyspnea. In our overall experience, 2 out of 39 assessable patients 
developed unexplained prolonged dyspnea requiring corticosteroid treatment. 
 
In the second part of our clinical research, a retrospective analysis of our 
experiences with radiolabeled Lipiodol for patients awaiting liver transplantation 
for HCC was performed. Two patients died while on the waiting list (10%) and 
4 out of 20 transplanted patients (20%) suffered recurrent disease. In 5 out of 
22 explants necrosis exceeded 90% and these results compare favorably with a 
historical control group from our hospital. The overall recurrence free survival 
was 19.7 months (range 1.75-56) with a mean follow-up of  20.1 months.  
These data support the evaluation on larger patient numbers to confirm the 
benefit of radiolabeled Lipiodol in candidates for liver transplantation suffering 
HCC. 
 
In the preclinical study, we aimed at developing a three dimensional in vitro 
model for HCC, which would be a helpful tool in our search for strategies to 
optimize radionuclide therapy for HCC. Multicellular tumor aggregates or 
“spheroids” of HepG2-cells were cultured and exposed to high dose rate γ-
irradiation in combination with cisplatin, gemcitabine or 5-fluorouracil. Toxicity 
was evaluated by means of comparative growth curves, an outgrowth assay 
and histology. Supra-additive effects lasting for 4 weeks were observed for all 
drugs tested in combination with 10 Gy. In a subsequent experiment, the 
effects of low dose rate irradiation (188Re) were compared with high dose rate 
γ-irradiation, with or without chemotherapy (gemcitabine, 5-fluorouracil or 
topotecan) added. For 188Re, supra-additive effects were less pronounced and 
only evident with 5-fluorouracil and gemcitabine but not with concomitant 
exposure to topotecan. Only in case of gemcitabine the supra-additive effects 
with low dose rate irradiation lasted till week 4.  
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 Samenvatting 
 
Het hepatocellulair carcinoom of HCC is de meest prevalente primaire 
kwaadaardige levertumor. Het is wereldwijd de derde meest frequente oorzaak 
van sterfte tengevolge van kanker, verantwoordelijk voor meer dan een half 
miljoen overlijdens per jaar. Chronische virale hepatitis en alcohol gebruik zijn 
belangrijke carcinogene risicofactoren. De meeste patiënten bij wie de diagnose 
van een HCC gesteld wordt, hebben dan ook een cirrotische lever. Dit 
onderliggend leverlijden betekent voor veel patiënten een ernstige beperking 
van de therapeutische mogelijkheden. Heelkunde, onder de vorm van een 
partiële leverresectie of een transplantatie, is de beste optie met het oog op 
definitieve genezing. Helaas is een heelkundige behandeling in de meerderheid 
van de patiënten niet aangewezen omdat de onderliggende cirrose te ernstig is 
of omdat de tumor te uitgebreid is.  
Er zijn verscheidene niet-heelkundige behandelingsmodaliteiten toepasbaar bij 
patiënten die niet in aanmerking komen voor chirurgie. Slechts een beperkt 
aantal van deze strategieën leidt echter tot een aanvaardbaar aantal (20%) 
goede responsen. Tot deze groep behoort de lokoregionale behandeling met 
Lipiodol gemengd met chemotherapeutica of radioactief gemerkt met Jodium-
131 (131I). Er werden bemoedigende resultaten bekomen met 131I-Lipiodol, 
maar helaas wordt deze behandeling niet wijd toegepast tengevolge van de 
radioprotectieve beperkingen verbonden aan het gebruik van 131I. 131I heeft een 
fysisch half leven van 8 dagen en zendt een hoog energetische gamma(γ)-
straal uit (364 keV, met een abundantie van 82%) waardoor een isolatie in een 
aangepaste radionuclidenkamer gedurende minstens vijf dagen noodzakelijk is. 
Ondanks de goede tolerantie van een behandeling met 131I-Lipiodol kon toch 
geen ‘dosis escalatie’ studie uitgevoerd worden: de toediening van activiteiten 
boven de 2.22 GBq zou gepaard gaan met een onaanvaardbaar lange opname 
in isolatie. Rhenium-188 (188Re) heeft geschikte fysische karakteristieken voor 
radionuclidentherapie. De hogere energie van de beta(β)-emissies (2120 keV en 
1960 keV voor 188Re versus 606 keV voor 131I) kan een voordeel betekenen in 
de behandeling van relatief grote tumoren. In deze subgroep van tumoren was 
het effect van behandeling met 131I-Lipiodol immers weinig succesvol. 188Re 
zendt eveneens een γ-straal van 155 keV uit met een abundantie van 15%, 
hetgeen beeldvorming aan de hand van scintigrafie mogelijk maakt. De lagere 
energie en abundantie van de γ-straling, alsook het relatief korte fysisch half 
leven van 17 uur, maken van 188Re een aantrekkelijk radionuclide op 
radioprotectief vlak. Bovendien wordt dit radionuclide bekomen via elutie van 
een 188W/188Re-generator. Deze generator kan gebruikt worden in het 
ziekenhuis en kan gedurende verscheidene maanden ‘carrier-vrij’ 188Re voorzien 
met het oog op therapeutische toepassingen.  
 
In het kader van dit proefschrift werd een fase I studie opgezet om de 
biodistributie en veiligheid van het gebruik van 3.7 GBq 188Re-4-hexadecyl-1-
2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol (188Re-HDD/Lipiodol) in 
kaart te brengen. Het radiofarmacon werd toegediend in de arteria hepatica 
propria. Een snelle klaring van de activiteit in het bloed werd waargenomen met 
een effectief half leven van 7.6 (± 2.2 SD) uur. De activiteit werd hoofdzakelijk 
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 uitgescheiden via de urine met een gemiddelde renale klaring van 44.1 (± 11.7 
SD) %, 76 uur na toediening. De geabsorbeerde dosis ter hoogte van de lever 
(inclusief de tumor), de longen, de nieren en de schildklier bedroeg 4.5 ± 1.9 
Gy, 4.1 ± 1.2 Gy, 0.9 ± 0.7 Gy en 0.3 ± 0.1 Gy, respectievelijk. Het effectief half 
leven voor het totale lichaam werd geschat op 14.3 (± 0.9 SD) uur. De 
behandeling werd uitstekend verdragen, in het bijzonder bij patiënten die een 
goed gecompenseerde leverdysfunctie (Child-Pugh A) hadden. In deze 
subgroep patiënten leek een verder opdrijven van de toegediende activiteit 
haalbaar. 
In een daaropvolgende studie werden activiteiten van 4.9 tot 7.0 GBq 188Re-
HDD/Lipiodol trapsgewijs toegepast bij patiënten met een goed 
gecompenseerde leverdysfunctie. Er werden geen onaanvaardbare bijwerkingen 
gedocumenteerd. Verder opdrijven van de toegediende activiteit werd beperkt 
door de relatief lage labelingsefficiëntie van de synthese van het radiofarmacon. 
Bij patiënten met ernstiger onderliggend leverlijden (Child-Pugh B), waren de 
resultaten na toediening van 3.7 GBq 188Re-HDD/Lipiodol echter niet 
bemoedigend en er werd dan ook afgezien van een verder opdrijven van de 
toegediende activiteiten in deze patiënten.  
Verder wensen wij erop te wijzen dat er in de toekomst aandacht dient besteed 
te worden aan patiënten die hoest of kortademigheid ontwikkelen na 
behandeling met 188Re-HDD/Lipiodol. In onze ervaring traden er longklachten 
op bij 2 op 39 patiënten en was behandeling met corticosteroïden aangewezen 
in deze gevallen. 
 
In het tweede deel van het klinisch onderzoek verricht in het kader van dit 
proefschrift, werd een retrospectieve analyse uitgevoerd van de patiënten die 
op onze afdeling behandeld werden met radioactief Lipiodol terwijl zij op de 
wachtlijst geregistreerd waren voor een lever transplantatie. Twee patiënten 
overleden op de wachtlijst (10%) en 4 van de 20 getransplanteerde patiënten 
(20%) heeft nadien een recidief in de donorlever of metastasen ontwikkeld. In 
5 van de 22 explanten overschreed het percentage necrose 90% van de tumor. 
Een dergelijke uitgebreide necrose werd niet waargenomen in een historische 
controle groep, bestaande uit niet-voorbehandelde patiënten die een 
levertransplantatie omwille van HCC ondergingen in ons ziekenhuis. In de groep 
patiënten behandeld met radioactief Lipiodol bedroeg de ziektevrije overleving 
gemiddeld 19.7 maanden (range 1.75-56, met een gemiddelde observatieduur 
van 20.1 maanden). Deze positieve bevindingen dienen echter nog verder 
bevestigd te worden door een groter aantal transplantkandidaten met een HCC 
te behandelen met radioactief gemerkt Lipiodol. 
 
In de preklinische studie, werd een drie dimensionaal in vitro model voor HCC, 
bestaande uit multicellulaire tumor aggregaten of “sferoïden” van HepG2-cellen, 
ontwikkeld. Een dergelijk model maakt het mogelijk om op eenvoudige wijze de 
efficiëntie van een aantal strategieën ter optimalisatie van radionuclidentherapie 
voor HCC te testen. De HepG2-sferoïden werden blootgesteld aan een γ-
bestraling met hoog dosistempo gecombineerd met cisplatinum, gemcitabine of 
5-fluorouracil. De toxiciteit werd geëvalueerd aan de hand van vergelijkende 
uitgroeicurves en histologie. Supra-additieve effecten die langer dan 4 weken 
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 aanhielden, werden geobserveerd voor alle geteste chemotherapeutica. In een 
daaropvolgend experiment, werden de effecten van bestraling met behulp van 
188Re (laag dosistempo) vergeleken met deze van de γ-bestraling aan hoog 
dosistempo, al dan niet gecombineerd met cytostatica (gemcitabine, 5-
fluorouracil of topotecan). Voor 188Re waren de supra-additieve effecten minder 
uitgesproken en enkel aantoonbaar voor 5-fluorouracil en gemcitabine. 
Concomitant gebruik van 188Re en topotecan induceerde geen supra-additief 
effect. Enkel in het geval van gemcitabine waren de supra-additieve effecten na 
bestraling met laag dosistempo nog aantoonbaar na vier weken. 
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 Résumé 
 
Le carcinome hépatocellulaire (CHC) est la forme de cancer hépatique ayant la 
plus forte prévalence. Mondialement responsable de plus de 500.000 décès 
annuels, il occupe la troisième place parmi les décès par maladies liées au 
cancer. En raison des risques carcinogènes sous-jacents, tels que l’hépatite 
virale chronique et la consommation d’alcool, la grande majorité des patients 
présentant un carcinome CHC souffre de cirrhose, ce qui limite les possibilités 
thérapeutiques. La chirurgie, hepatectomie ou transplantation, reste l’option 
préférée, assurant les meilleures conditions de guérison. Mais si le degré de 
dysfonctionnement du foie et la tumeur sont pris en compte, la grande majorité 
des patients ne subira pas d’acte chirurgical. 
 
Seul un nombre restreint de stratégies offre un taux satisfaisant de réussite, 
excédant 20%. Parmi celles-ci le Lipiodol, combiné à des substances 
chimiothérapeutiques ou radiomarqué avec de l’Iode-131 (131I). Des résultats 
encourageants furent obtenus avec le 131I-Lipiodol, mais la radioprotection 
nécessaire en restreint l’utilisation. En effet, 131I émet un fort rayonnement γ 
(364 keV; abondance 82 %) nécessitant la mise en quarantaine du patient en 
chambre radionuclide durant un minimum de 5 jours par mesure de sécurité. 
Malgré une bonne tolérance au traitement avec le 131I-Lipiodol, une étude ‘à 
dose progressive’ n’a pu être effectuée en raison de la quarantaine, 
inacceptable quant à la durée, pour une irradiation supérieure à 2.22 GBq. Le 
Rhenium-188 (188Re) présente des caractéristiques physiques adéquates pour 
une thérapie radionucléaire. Les énergies de rayonnement β plus élevées (2120 
keV et 1960 keV pour 188Re comparé à 606 keV pour 131I) sont notoirement plus 
efficaces dans le traitement de tumeurs relativement importantes. L’émission γ 
du Rhenium-188 (155 keV; abondance de 15 %) permet d’obtenir des images 
par scintigraphie. L’énergie moindre et l’abondance de rayons gammas, ainsi 
que la courte période (17 heures) font du 188Re un radionuclide intéressant au 
point de vue radioprotection. De plus, le radionuclide peut être élué de façon 
routinière avec un bon rendement à partir d’un générateur 188W/188Re. 
 
Cette étude présente d’abord une étude de faisabilité incluant la biodistribution 
de et la sureté du traitement après injection de 3.7 GBq 188Re-4-hexadecyl-1-
2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol (188Re-HDD/Lipiodol) dans 
l’Arteria hepatica propria. Une rapide clairance de l’activité sanguine fut 
observée dont la période calculée est de 7.6 (± 2.2 DS) heures. L’activité fut 
éliminée principalement par les reins. La clairance rénale est de 44.1 (±11,7 
DS)% , 76 heures après administration. La dose absorbée par le foie (tumeur 
incluse), par les poumons, les reins et la thyroïde est respectivement de 4.5 ± 
1.9 Gy, 4.1 ± 1.2 Gy, 0.9 ± 0.7 Gy et 0.3 ± 0.1 Gy. La période totale, calculée 
d’après les données mesurées, est de 14.3 (±0.9 DS) heures. Le traitement fut 
très bien supporté, en particulier par les patients souffrant d’un 
dysfonctionnement hépatique bien compensé (Child-Pugh A). Ce sous-groupe 
de patients semblerait bien tolérer une activité supérieure. 
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 L’administration de 3.7 GBq 188Re-HDD/Lipiodol aux patients atteints d’une 
cirrhose modérée n’a par contre pas fourni de résultats encourageants en 
conséquence de quoi nous avons préféré diriger notre recherche vers les 
patients atteints de cirrhose bien compensée. 
Des activités atteignant 7.0 GBq 188Re-HDD/Lipiodol furent administrées sans 
effets contraires notoires. Des expériences avec des activités supérieures furent 
limitées par la relative inefficacité du radiomarquage dans la synthèse de la 
substance radiothérapeutique. Par ailleurs, notre expérience nous a fait 
attacher une importance particulière aux patients développant des symptômes 
pulmonaires tels que la toux ou une dyspnée suite au traitement. Deux des 
trente-neuf patients ont développé une inexplicable dyspnée récalcitrante 
nécessitant un traitement corticoïde. 
 
Le second volet de notre recherche clinique traite de l’analyse des résultats de 
nos expériences avec le Lipiodol radiomarqué sur des patients souffrant de CHC 
et attendant une transplantation de foie. Deux patients (10%) sont décédés en 
attente d’une transplantation; 4 des 20 transplantés (20%) ont souffert d’une 
malignité récurrente. Dans cinq des vingt-deux foies la nécrose excédait 90% 
de la tumeur. Une nécrose aussi importante n’est pas retrouvée chez le groupe 
de contrôle historique, composé de patients de notre hôpital. La durée 
moyenne d’absence de rechute est de 19.7 mois (min. 1.75–max. 56); les suivi 
moyen est de 20.1 mois par patient. 
Ces données appellent une étude à plus grande échelle afin de confirmer l’effet 
bénéfique du Lipiodol radiomarqué chez les patients CHC attendant une 
transplantation.  
 
Lors de l’étude pré-clinique nous avons développé un modèle in-vitro 
tridimensionnel, pouvant offrir un outil à l’optimalisation de la thérapie 
radionuclide. Des ‘sphéroïdes’ ou agrégats multicellulaires tumoraux de cellules 
HepG2 furent mis en culture et exposés à une importante radiation γ combiné 
soit à du cisplatin, de la gemcitabine ou a du 5-fluorouracil. La toxicité a été 
évaluée en utilisant et les courbes comparatives de croissance en 3D, la mise 
en culture en 2D et l’histologie. Pour toutes les chimiothérapies combinées à 
une irradiation de 10 Gy (Cobalt 60), des effets supra-additifs furent observés 
durant plus de 4 semaines. Ensuite, nous avons comparé l’effet d’une 
irradiation à faible débit de dose avec le 188Re à l’effet d’une irradiation à un 
haut débit de dose (γ, Cobalt 60) en combinaison avec ou sans chimiothérapie 
(gemcitabine, 5-fluorouracil ou topotecan). En ce qui concerne le 188Re, les 
effets supra-additifs furent moins prononcés et uniquement détectable avec le 
5-fluorouracil et la gemcitabine. Utilisation concomitante de 188Re et topotecan 
n’a induit nul effet supra-additif. Avec la gemcitabine, les effets supra-additifs 
après radiation étaient manifestes après 4 semaines. 
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